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Patient-centeredness, patient empowerment, shared decision-making and self-management 
are fundamental elements of current health policy in the Netherlands [1-3]. The changing 
role of the healthcare consumer to a more active one, is part of a broader movement away 
from the classical welfare state towards a participation society in which citizens are required 
to take responsibility for their own life, including health [4]. One concrete example is that 
citizens are, since the introduction of the universal health insurance scheme with managed 
competition in 2006 [2, 5, 6], expected to critically assess the available health plans annually, 
and to switch to another insurer’s health plan if that better meets their preferences.
The changing role of the healthcare consumer does not only apply at the individual level 
(i.e. patient-physician and consumer-insurer relationship), but also at the collective level [1, 
7]: the involvement of consumers in health policy decision-making is also being encouraged 
more and more. For example, the World Health Organization published a global strategy 
that advocates a shift towards people-centred1 and integrated health services, in which 
more engagement is one of the core strategic directions [8]. Engagement is hereto defined 
as “People and communities being involved in the design, planning and delivery of health 
services, enabling them to make choices about care and treatment options or to participate 
in strategic decision-making on how, where and on what health resources should be spent”. 
Direct involvement of consumers in decision-making can be achieved by, for example, 
the participation of public or patient representatives in a decision committee during the 
health technology assessment process [9, 10]. Indirect involvement includes the elicitation 
of public perspectives by using, for example, focus group discussions and questionnaires 
[11]. By involving the public, health policies will better reflect public preferences [12]. 
Preferences can have an impact on the acceptance of and satisfaction with products, 
services or interventions, as well as on outcomes [13].
Although numerous research techniques are available to elicit public preferences for health-
related topics, this dissertation focuses specifically on the discrete choice experiment (DCE) 
methodology to quantify public preferences. The main advantage of this methodology over 
other techniques, such as standard gamble or time trade-off, is that the DCE task more 
closely resembles the nature of real-life decision-making between products, services, or 
interventions [14, 15]. 
In this introductory chapter, relevant concepts are introduced first; the objectives as well 
as the content of the following chapters of this dissertation will be presented subsequently.
1 People-centred care is not the same as patient-centred care [12]. The former reflects involvement of the 
public in all levels of health systems, including involvement in planning and developing of health services, 
while the latter relates to collaboration with the healthcare professional in individual clinical decision-making 
to ensure it reflects his/her own values and needs [50].
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THE DISCRETE CHOICE EXPERIMENT METHODOLOGY
How many choices have you made today? One choice that is obvious at this point: you made 
the choice to read this dissertation. All choices involve at least two alternatives that need 
to be evaluated before making a choice: an alternative to reading this dissertation is not to 
read this dissertation, or to read another dissertation. There might be a number of reasons, 
or underlying preferences, that explain your choice. For example, the cover that attracted 
your attention, the topic is of interest, or you are curious to see what I wrote as you know 
me, and one reason might be more important for your choice than another reason. The 
goal of choice modelling is to better understand how choices are made, by quantifying the 
strength of underlying preferences, and to forecast future choice responses [16].
A DCE is a survey-based stated-preference elicitation technique: respondents are asked 
to state their preference for a product, service, or intervention, in hypothetical choice 
situations. Stated-preferences represent a hypothetical choice, while revealed preferences 
can be observed through choice behaviour in real market situations [16]. The main 
advantage of studying stated-preferences over revealed preferences, is that preferences can 
be elicited in a controlled situation. The DCE technique is particularly useful for products, 
services or interventions for which no market exists (yet). A DCE survey typically consists 
of a series of hypothetical choice situations (called choice sets), each concerning a discrete 
choice between two or more alternatives. The word ‘discrete’ indicates that respondents 
can only choose one of the alternatives. The presented alternatives are decomposed into 
characteristics (called attributes) to describe the alternative. Alternatives are distinguished 
from one-another by the systematic variation in the values of the characteristics (called 
attribute levels). See Figure 1 for an example of a choice set.
DCEs originate from mathematical psychology [18], and are, since pioneering work of 
Louviere and colleagues [19], standard practice in the field of marketing, transportation 
and environmental economics. The first DCE in health economics was published in 1990 by 
Propper [20]. Ryan and colleagues further introduced the method in health economics later 
in the 1990’s [21-23]. Subsequently, the body of scientific literature is increasing rapidly 
(Figure 2). 
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Figure 1 | Example of a choice set concerning migraine treatment (adapted from [17]). 
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Figure 2 | Number of PubMed hits since 2001 [‘discrete choice experiment’ and equivalent terms], by year 
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THEORETICAL FOUNDATION OF DISCRETE CHOICE EXPERIMENTS
DCEs have their foundation in random utility theory (RUT)2, first described by Thurstone 
in 1927 [24], and extended on by Manski [25] and Nobel Prize winner McFadden [26, 27]. 
They are consistent with Lancaster’s economic theory of value, in which it is assumed that 
products, services, or interventions can be valued in terms of their constituent characteristics 
[28].
The true, but unobservable and therefore indirect, utility function U for alternative i of 
respondent n (Uin) consists of a systematic component that reflects the factors that are 
observable by the researcher (Vin), and a random component that reflects the factors that 
are not or cannot be observed by the researcher (εin) [16]:
[Equation 1]:  Uin = Vin + εin
RUT assumes that respondent n evaluates all available information, and will choose 
alternative i within a choice set that yields the highest utility (or lowest regret in the case of 
random regret modelling [29]). The actual distribution of the random component of utility 
(εin) in the population is unknown; estimation of utility is therefore based on probabilistic 
choice modelling. The probability that respondent n prefers alternative a over alternative b 
in a particular choice set is expressed as follows [30]:
[Equation 2]: Prob (Uan > Ubn ∀ b≠a) = 
  Prob (Van + εan > Vbn + εbn ∀ b≠a) = 
  Prob (Van - Vbn > εbn - εan ∀ b≠a)
The impact of the attributes on the systematic component of utility (Vin) is estimated based 
on the choices that respondents make in the DCE survey: 
[Equation 3]:  Vin = β Xin 
Where Xin is the vector of the attributes for alternative i for respondent n and β
3 is the vector 
of coefficients to be estimated. The β for a certain attribute represents the weight of that 
attribute to overall utility for that alternative, which is sometimes called part-worth utility. 
The larger the β for one attribute, compared to another attribute, the more important this 
attribute is for someone’s choice. The sign of the β reflects whether the effect on someone’s 
choice is positive or negative.
2 Utility is the level of happiness that an alternative yields to an individual [16].
3 The vectors of coefficients β are scaled with the variance of the unobserved factors (λ), and are therefore 
only comparable in absolute terms within one model, not between models.
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Based on these part-worth utilities, researchers can determine the relative importance of 
attributes, the trade-offs between attributes by calculating marginal rates of substitution 
(i.e. the degree to which respondents are willing to trade one attribute to the other), 
calculate total utility scores, and predict uptake rates.
HOW TO UNDERTAKE A DISCRETE CHOICE EXPERIMENT?
A number of guidelines have been written to support researchers when carrying out health-
related DCEs [31, 32], including guidelines that focus on specific aspects of DCEs [33-35], 
and a guideline that focuses on conducting DCEs in low income countries [36]. Figure 3 
presents a schematic overview of the scientific process of conducting a DCE. Each step is 
summarized briefly below. 
Figure 3 | Schematic overview of the scientific process of conducting a DCE. 
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The first step in a DCE is the selection of attributes and attributes levels. Attributes are 
usually identified through literature study and qualitative research, for example expert 
interviews and/or focus group discussions [37]. Attributes generally need to be relevant for 
respondents as well as for the policy environment. DCEs can include only a limited number 
of attributes. Next, appropriate levels need to be assigned to the selected attributes. To 
avoid ignorance because of too small differences in levels, specification of a sufficient wide 
range of levels is necessary. Levels can include possible future levels that are currently 
unavailable. A minimum number of three attribute levels needs to be specified if non-linear 
effects are expected.
The following step is to define the choice format. The researcher needs to decide on whether 
to use labelled or unlabelled alternatives [38], and on the number of alternatives that will be 
presented within a choice set [39, 40]. In addition, the researcher needs to decide on either 
a forced or an unforced choice format. An unforced choice format involves the inclusion of 
an opt-out option (i.e. choosing not to buy the product, or not to use the service), a neither 
option (i.e. choosing neither of the alternatives), and/or a status quo option (i.e. choosing 
your current alternative). 
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Based on the utility function one wants to estimate, an experimental design needs to be 
constructed next. The number of all possible combinations of attributes and levels is often 
too large to be used in practice; a subset of all possible choice sets is therefore generated, 
usually using statistical software (e.g. Ngene or SAS). The design should enable the researcher 
to estimate unbiased estimates for every parameter in the model.
Once the design is created, the survey instrument can be developed. The presentation 
of the attributes and levels within a choice set, such as attribute ordering [41], attribute 
framing [42], and the use of either words or graphics [43] might have unintended influences 
on the obtained estimates, and therefore needs to be thoroughly considered. The survey 
instrument could further include an introductory text, practice choice sets, and general 
questions on respondent characteristics, health attitudes and health beliefs. In addition, it 
needs to be decided how the DCE survey will be administered: via pen-and-paper (either 
completed on-site, or distributed via mail) or electronically (either on-site using a laptop, or 
distributed via Internet).
The final data-collection is usually preceded by a pilot study. Pilot testing is necessary to 
detect instrument errors, as well as to test for respondent understanding. In addition, the 
parameter estimates of a pilot can serve as priors to improve the experimental design. 
The required sample size to being able to answer the research question also needs to be 
determined [35, 44].
Once the data is collected, econometric modelling techniques are used to estimate the part-
worth utilities as described above. Several aspects determine which model is appropriate to 
analyse the DCE data: 1) the distributional assumption of the random component of utility 
(εin), 2) the choice set format (binary or multiple alternatives), 3) whether or not panel data 
was used (one respondent answering a number of choice sets), and 4) whether or not the 
analyst is interested in preference heterogeneity.
OBJECTIVES OF THIS DISSERTATION
This dissertation aims to contribute to the growing field of health-related stated-preference 
research by addressing research questions that relate to the past, the present and the future 
of the DCE methodology. 
Part I: The past - review of the literature
1. What are recent practices and trends, including progress in methodology, in applications 
of health-related DCEs?
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Part II: The present - three state of the art applications
2a. Stay healthy: What are preferences of European citizens for vaccination programmes 
during future pandemics? 
2b. Anticipate future health: What trade-offs do consumers make between basic health 
plan characteristics in the Dutch health insurance market?
2c. Manage health and sickness: What are personal health record preferences of potential 
users?
Part III: The future - methodological studies
3a. Does the inclusion of an “opt-out” instead of a “neither” alternative affect DCE results? 
Does the inclusion of a “status quo” alternative in addition to an “opt-out” alternative 
affect DCE results in markets where there is a status quo?
3b. Does the choice of DCE administration mode (paper versus online) affect the result of 
a DCE?
3c. How do respondents complete the choice sets in a DCE?
OUTLINE OF THIS DISSERTATION
This dissertation consists of nine studies that relate to these research questions. 
Part I of this dissertation (Chapter 2, research question 1) gives an overview of recent DCE 
practice, including progress in methodology, by systematically reviewing health-related DCEs 
published between 2009 and 2012. Having an overview of past DCE practices is important 
since this gives insights in methodological developments, and the current state of practice. 
In addition, such an overview provides directions for future research. Although systematic 
reviews of DCEs on specific health-related topics, for example health workforce policy [45] 
and pharmacy services [46], have been published recently, the latest general systematic 
review of health-related DCEs included studies published only up until 2008 [47-49]. A more 
recent general overview is lacking. 
Part II of this dissertation presents a focus group discussion study and four DCE studies. 
The first three chapters of this part (Chapters 3-5, research question 2a) describe studies 
that were carried out in the context of the FP 7 funded project ‘Effective Communication 
in Outbreak Management: development of an evidence-based tool for Europe (ECOM)’. 
Chapter 3 describes a qualitative exploration of public opinions and attitudes for pandemics 
and vaccinations across three European countries. Chapter 4 presents the results of the 
subsequently developed DCE on public preferences for vaccination programmes during 
pandemics in four European countries. Chapter 5 further explores within-country differences 
in preferences for pandemic vaccinations by studying the DCE data of one of the included 
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European countries (the Netherlands) in more detail. Chapter 6 concerns the second DCE 
application (research question 2b). It quantifies consumer trade-offs between health plan 
characteristics, and potential differences herein, according to age, health status and income, 
in the Dutch health insurance market with managed competition. The third DCE application 
is presented in Chapter 7, and focuses on potential user preferences for personal health 
records in the Netherlands (research question 2c). 
Part III presents three methodological DCE studies. Chapter 8 (research question 3a) focuses 
on the use of opt-out, neither and status quo alternatives in DCEs. The current guidelines 
do not request to assess the appropriate unforced choice format critically. If researchers do 
not select the unforced choice that best mimics the real market situation, welfare estimates 
could be biased. Evidence is needed to guide researchers in selecting the right unforced 
choice format in future DCEs. Chapter 9 (research question 3b) describes if and how the 
mode of DCE administration (either via pen-and-paper or online) affects the outcomes of the 
DCE. Studies show that the presentation of attributes and levels might influence the results, 
it can be questioned whether the mode of administration likewise affect DCE results. This is 
especially important, since it is increasingly common to collect DCE data electronically, and 
more particularly, online. Chapter 10 (research question 3c) describes an interview study 
that explores how respondents complete the choice sets of a DCE. In order to make valid 
inferences about individuals’ preferences, it is essential that researchers understand how 
participants complete the choice sets in a DCE.
This dissertation concludes with the general discussion (Chapter 11), in which the main 
findings of the previous chapters are integrated and further discussed. Directions for future 
research are formulated. The chapter concludes with recommendations for health policy 
and recommendations for DCE researchers.
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ABSTRACT
Background: Discrete choice experiments (DCEs) are increasingly used in health economics 
to address a wide range of health policy-related concerns.
Objective: Broadly adopting the methodology of an earlier systematic review of health-
related DCEs, which covered the period 2001-2008, we report whether earlier trends 
continued during 2009-2012.
Methods: This paper systematically reviews health-related DCEs published between 2009 
and 2012, using the same database as the earlier published review (PubMed) to obtain 
citations, and the same range of search terms.
Results: A total of 179 health-related DCEs for 2009-2012 met the inclusion criteria for the 
review. We found a continuing trend towards conducting DCEs across a broader range of 
countries. However, the trend towards including fewer attributes was reversed, whilst the 
trend towards interview-based DCEs reversed because of increased computer administration. 
The trend towards using more flexible econometric models, including mixed logit and latent 
class, has also continued. Reporting of monetary values has fallen compared with earlier 
periods, but the proportion of studies estimating trade-offs between health outcomes and 
experience factors, or valuing outcomes in terms of utility scores, has increased, although 
use of odds ratios and probabilities has declined. The reassuring trend towards the use of 
more flexible and appropriate DCE designs and econometric methods has been reinforced 
by the increased use of qualitative methods to inform DCE processes and results. However, 
qualitative research methods are being used less often to inform attribute selection, which 
may make DCEs more susceptible to omitted variable bias if the decision framework is not 
known prior to the research project.
Conclusions: The use of DCEs in healthcare continues to grow dramatically, as does the 
scope of applications across an expanding range of countries. There is increasing evidence 
that more sophisticated approaches to DCE design and analytical techniques are improving 
the quality of final outputs. That said, recent evidence that the use of qualitative methods 
to inform attribute selection has declined is of concern.
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1. INTRODUCTION
Discrete choice experiments (DCEs) are increasingly used in health economics to address 
a wide range of health policy-related concerns. The approach draws its microeconomic 
foundations from the characteristics theory of demand [1] and random utility theory 
(RUT) [2]. The characteristics theory of demand assumes that goods, services, or types of 
healthcare provision can be valued in terms of their constituent characteristics (otherwise 
known as attributes). DCEs involve respondents making a number of stated preference 
choices in response to DCE questions. According to RUT, respondents are assumed to act 
in a utility maximizing manner and make choices contingent upon the levels of attributes in 
DCE scenarios. Therefore, choice data obtained from respondents’ stated preferences can 
be analysed using econometric methods compatible with RUT. If the specified attributes 
are significantly related to respondent choices, findings from data analysis should confer 
information relating to how the average respondent’s utility (or willingness to pay) is 
affected by changes in the levels of attributes. RUT assumes that respondent utility can be 
decomposed into a systematic component, which is a function of attributes and their levels, 
and a random component, which is an error term in the regression equation related to 
unmeasured preference variation. Published DCEs in healthcare are usually compatible with 
RUT [3-5], in the sense that they adopt a methodology consistent with RUT.
Although reviews and commentaries have been published of healthcare-related DCEs 
for specific clinical contexts or health-related concerns [6-8], and conjoint analyses more 
broadly [9], the most comprehensive reviews of the healthcare DCE literature cover the 
periods 1990-2000 [4] and 2001-2008 [3]. This paper updates those earlier systematic 
reviews to cover the period 2009-2012, and considers how key aspects of the design and 
application of DCEs have changed across the three periods.
2. METHODS
This review builds upon the earlier systematic reviews [3, 4]. It focuses on the 2009-2012 
literature, and was derived from the literature in the sense that it replicates the methodology 
of the most recent review [3]. Although further checklists or commentaries on best practice 
[10-16] have been developed in recent years, these did not require fundamental changes 
to the approach to reviewing the DCE literature. Moreover, some of these checklists or 
commentaries [12-14] had already informed the development of the criteria deployed in the 
2001-2008 review, whilst others served to confirm that our review encompassed appropriate 
criteria [11, 15, 16]. However, we did feel that the range of information extracted in relation 
to preference heterogeneity models such as mixed logit could be improved upon, and so 
we also gathered additional information on the distributional assumptions deployed when 
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mixed logit was applied, and the number of Halton draws that were specified for replications. 
Searches were restricted to the PubMed search engine, replicating the approach of the most 
recent review [3], and used the same search terms, including ‘conjoint’, ‘conjoint analysis’, 
‘conjoint measurement’, ‘conjoint studies’, ‘conjoint choice experiment’, ‘part-worth 
utilities’, ‘functional measurement’, ‘paired comparisons’, ‘pairwise choices’, ‘discrete choice 
experiment’, ‘dce’, ‘discrete choice mode(l)ling’, ‘discrete choice conjoint experiment’, and 
‘stated preference’. Initial searches were conducted in September 2011, and then updated 
in March 2012 and August 2013 to ensure that all 2011 and 2012 papers were included. 
Moreover, for the period 2009-2012, we also allowed for the inclusion criteria to include a 
small number of best-worst scaling (BWS) DCEs/technical theoretical papers, as long as they 
generated health-related DCE results alongside BWS results. We included case 3 type BWS 
studies [17, 18] in the main review because, unlike case 1 and 2 BWS studies, these involve 
a comparison between two or more profiles [17]. This is despite the fact that case 3 BWS 
studies do differ from mainstream DCEs, because respondents choose the least attractive 
profile in addition to the most attractive one [17].
At the request of one of the peer reviewers, we also reviewed health-related adaptive 
conjoint analysis (ACA) and adaptive choice-based conjoint (ACBC) studies, and any menu-
based conjoint analyses that had been published between 1990 and 2012. Such analyses 
had been excluded from the previous reviews [3, 4].
3. SEARCH RESULTS
Following the PubMed searches using the aforementioned search terms, we sourced 12 
ACA/ACBC analyses for the period 2009-2012 [19-30]; 14 ACA/ACBC analyses for the period 
2001-2008 [31-44], and no analyses of these types for the period 1990-2000. However, 
we reviewed these separately and deposited the data in an additional file because these 
analyses adopt a fundamentally different approach to valuing attributes to mainstream DCE 
analyses, and we wanted to ensure that data in the main body of the paper were in step 
with inclusion criteria adopted for the previous reviews [3, 4], which had excluded such 
analyses.
Overall, 179 analyses were identified as meeting the inclusion criteria for the main review, 
i.e. health-related DCEs or case 3 BWS analyses published in the English language. Each 
paper was read carefully and key data extracted systematically in the sense of evaluating 
them against a checklist of pre-established criteria, which largely corresponded to those 
used in the most recent of the previous reviews [3]. The data are summarized in the 
following Sects. 3.1-7.2. In Table 1, we provide further information relating to the definitions 
and other details of analyses in each of the categories.
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Category A covers 25 separate analyses in 24 papers [45-67]; Category B includes 13 analyses 
in 13 papers [68-80]; Category C encompasses 81 analyses in 81 papers [81-162]; Category 
D relates to four analyses in four papers [163-166]; Category E covers 11 different analyses 
in eight papers [167-174]; Category F encompasses 24 analyses in 23 papers [47, 71, 72, 82, 
86, 107, 119, 161, 175-189]; Category G includes 24 analyses in 23 papers [53, 62, 70, 72, 
103, 122, 133, 139, 141, 143, 145, 190- 201]; and Category H relates to ‘other’ analyses, and 
there are 21 ‘other’ analyses in 21 papers [63, 90, 103, 137, 145, 158, 159, 197, 202-214]. 
In Sects. 3.1-7.2, key findings are summarized in graphs. In the following text, we highlight 
changes that are of a reasonable magnitude and may be regarded as of significance.
3.1 Number of Discrete Choice Experiment (DCE) Analyses per Year
Figure 1 summarizes the average number of DCEs published per year across the three review 
periods. The 2001-2008 review [3] noted that the number of published applications of DCEs 
in healthcare rose from a mean of 3 per year (1990-2000) to a mean of 14 per year (2001-
2008). Our review for 2009-2012 showed that the average number of analyses rose again to 
45 per year (2009-2012), a marked increase, and peaked at 74 in 2012.
Figure 1 | Average number of DCE studies/year.
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3.2 DCE Studies Country of Origin
Figure 2 indicates the proportion of analyses emanating from different countries during the 
three time periods. The 2001-2008 review noted that the UK remained the main source of 
DCEs in healthcare. However, UK dominance has been eroded considerably since then (see 
Fig. 2). The proportion of analyses emanating from the UK has continued to fall, from 59% in 
1990-2000 to 48% in 2001-2008, and to 22% during 2009-2012. Moreover, the proportion of 
analyses emanating from Australia (AUS) has fallen from 18% in 1990-2000 to 11% in 2001-
2008, and to 7% in 2009-2012.
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Figure 2 | Country of origin.
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Comparing 2001-2008 with 2009-2012, an increased proportion of analyses now originate 
in the USA, Canada (CAN), Denmark (DNK), the Netherlands (NLD), and Germany (DEU). 
There was also an increase in analyses coming from ‘other’ countries (11% in 2001-2008 
compared with 25% in 2009-2012), reflecting an increasing trend towards applying DCEs 
across a range of high-, middle-, and low-income countries4.
3.3 The Number of Attributes Included in DCE Studies
Figure 3 provides information on the number of attributes included in DCE analyses across 
the three time periods. The most noteworthy change includes the fact that the proportion 
of analyses with four or five attributes rose from 29% in 1990-2000 to 44% in 2001-2008, 
but fell back to 32% in 2009-2012. There was also an increase in the number of DCEs with 
between seven and nine attributes: 12% in 1990-2000, 13% in 2001-2008, increasing to 22% 
in 2009-2012. The proportion of analyses with more than ten attributes fell from 12% in 
1990-2000 to 2% in 2001-2008, and remained at that level in 2009-2012.
3.4 Domains of DCE Attributes
Figure 4 provides information on the proportion of DCEs encompassing different domains. 
The main noteworthy changes include the fact that the proportion of analyses with a domain 
related to time fluctuated; it was 74% in 1990-2000, in 2001-2008 it fell to 51%, before rising 
again to 65% in 2009-2012.
4 Lower income countries in 2009-2012 included Kenya, South Africa, Thailand, China, Ghana, Vietnam, 
Ethiopia, Peru, Ukraine, India, Cuba, Nepal, Turkey, and Burkina Faso.
30  |  Chapter 2
Figure 3 | Number of attributes.
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Figure 4 | Attribute domains.
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The proportion of DCEs including a measure of risk rose in the most recent period from 35% 
in 1990-2000 and 31% in 2001-2008, to 57% in 2009-2012.
The proportion of analyses with a healthcare (HC) domain also fluctuated: 82% in 1990-2000, 
falling to 69% during 2001-2008, and increasing to 72% in 2009-2012. At the same time, 
the proportion of analyses with attributes relating to ‘other’ domains, not encompassed 
by existing categories, increased from 9% in 1990-2000 to 15% in 2001-2008, and 47% in 
2009-2012. Additional categories in Fig. 4 include a monetary domain (Money) and a health 
status domain (HS).
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3.5 The Number of Questions Posed by DCEs
Figure 5 provides information on the number of choice tasks posed by DCEs. The main 
noteworthy trends are as follows. The proportion of DCE analyses posing eight or fewer 
choices (<9) was 38% in 1990-2000, 39% in 2001-2008, but fell back to 22% in 2009-2012. 
In contrast, the proportion of analyses with 9-16 choices was 53% in 1990-2000, falling to 
38% during 2001-2008, and rising to 62% during 2009-2012. The proportion of analyses with 
more than 16 choices (>16) rose initially and then stabilized (6% in 1990-2000, 18% in 2001-
2008, and 15% in 2009-2012).
Figure 5 | Number of choice tasks.
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3.6 DCE Survey Administration
Figure 6 provides information on the different modes of administering DCEs. Since 1990, 
there has been a trend away from self-completed pen/paper questionnaires. The proportion 
of analyses using self-completed questionnaires (Survey) was 79% in 1990-2000, falling to 
67% in 2001-2008, and then further to 48% in 2009-2012. The proportion of interviewer-
administered DCEs (Interview) was 9% in 1990-2000, rising to 19% in 2001-2008, and was 
17% in 2009-2012.
Overall, there has been a trend towards DCEs involving computerized administration 
(Computer), sometimes involving internet surveys, over the last 20 years. There have been 
improvements in computer technology, combined with the increased use of computers by 
the wider population. This has made accessing DCE respondent samples using computers 
easier. Moreover, the ease with which DCE samples can be accessed using computers and 
the internet partly explains the trend towards increased use of DCEs since 1990. During 
1990-2000, 9% of analyses involved computerized administration; the figure was 11% in 
2001-2008 and then rose sharply to 40% during 2009-2012. As depicted in Fig. 6, a small 
32  |  Chapter 2
proportion of analyses failed to report (Not reported) the form of survey administration in 
each period.
Figure 6 | Survey administration.
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4. DCE EXPERIMENTAL DESIGN AND CHOICE SET CONSTRUCTION
A good discussion of some of the relevant issues relating to DCE design is contained in the 
review by de Bekker-Grob et al. [3], so in the interests of brevity, we refer the reader to that 
paper and to another key citation [11].
4.1 Design Plan
Figure 7 depicts information on the different types of design plans. The most noteworthy 
trends are as follows. The proportion of analyses involving full factorial (Full fact.) DCE 
designs fell from 12% in 1990-2000 to 0% in 2001-2008, and then rose again to 6% during 
2009-2012. In the period 1990-2000, 74% of analyses adopted a fractional factorial design 
(Fractional fact.), a proportion that rose to 100% in 2001-2008, but then decreased to 88% in 
2009-2012. Overall, 15% of analyses did not clearly report their design type (Not reported) 
in 1990-2000, a proportion that fell to 0% in 2001-2008, but then rose again to 7% during 
2009-2012.
Overall in 1990-2000, 74% of DCE analyses involved a ‘main effects’ design (Main Eff.), and 
this proportion rose to 89% during 2001-2008, but then fell back to 54% in 2009-2012. 
Therefore, as with the baseline and 2001-2008 reviews, ‘main effects’ designs remain the 
dominant type of design in published DCE studies. In 1990-2000, 6% of analyses catered for 
interaction effects alongside main effects (Main & Int. Eff.); the proportion was 5% in 2001-
2008, and increased to 13% in 2009-2012. In some cases, a design plan was not applicable, 
whilst in others, it was not reported.
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Figure 7 | Design plan.
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
1990-2000 (N=34)
2001-2008 (N=114)
2009-2012 (N=179)
Abbreviations: fact. factorial; Eff. effects; Int. interaction
4.2 Use of Software Packages to Design DCEs
Figure 8 summarizes information on the use of different software packages for the design 
of the DCEs. The most noteworthy trends are that the use of a software package to design 
DCEs remained steady throughout the years (Fig. 9).
Figure 8 | Software packages.
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Figure 8 shows there seems to have been a general trend away from using SPEED over the 
period as new software has become available. In 1990-2000, 38% of analyses used SPEED; 
this proportion fell to 19% in 2001-2008, and to 4% in 2009-2012.
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The SAS package (which can provide D-efficient designs) has become increasingly popular. 
Recorded use rose from 0% in 1990-2000 to 12% in 2001-2008, and 21% in 2009-2012. 
Use of SPSS did not change that much. The use of Sawtooth software fluctuated; 6% of 
analyses used this software in 1990-2000, 4% used it in 2001-2008, and 13% used it in 2009-
2012. The use of ‘other’ software was also low (6% in 1990-2000, 0% in 2001-2008, and 
7% in 2009-20125), and only a small proportion of analyses in each period failed to provide 
information on type of software (No details).
4.3 Use of Design Catalogues, Websites, and Expert Advice to Design DCE Questionnaires
Figure 9 depicts information on the use of software, design catalogues, websites, and 
experts to inform DCE design and whether this was not reported. Figure 9 shows that there 
have not been any particularly large changes in the use of these over the three periods.
Figure 9 | Design source.
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4.4 Methods Used to Create Choice Sets
Figure 10 depicts information on the use of different methods to create choice sets. The 
most noteworthy trends are as follows. In 1990-2000, 9% of analyses reported designs 
that involved orthogonal arrays with single profiles, i.e. binary choices (Single profiles); the 
proportion was 11% in 2001-2008, but fell to 1% in 2009-2012. Use of orthogonal arrays 
with random pairing (RP) was more common, but has fallen over time; in 1990-2000 it was 
applied in 53% of analyses, falling to 17% in 2001-2008 and 10% in 2009-2012. 
5 ‘Other’ packages used included Gauss for two analyses; Ngene (a Bayesian efficient design) for four 
analyses; and the statistical design procedure Gosset for one analysis; a D-efficient design advocated by 
Rose and Bliemer for one analysis; STATA for one design; a design described as ‘‘an experimental design 
algorithm optimizing orthogonality, attribute balance, and efficiency’’ for one design; and Street and 
Burgess Software for one design.
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Figure 10 | Methods to create choice sets. 
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Analyses involving orthogonal arrays with pairing with a constant comparator constituted 
approximately one in five designs in earlier periods, 18% in 1990-2000 and 20% in 2001-2008, 
before falling to 3% in 2009-2012. In 1990-2000, none of the analyses involved orthogonal 
arrays with a foldover design, but this proportion rose to 10% in 2001-2008 and 17% in 
2009-2012. Very few analyses in each period used a foldover design with random pairing 
(Foldover RP), or pragmatically chosen designs. Similarly, there has been a general trend 
towards D-efficient designs (D-efficiency), rising from 0% in 1990-2000 to 12% of studies in 
2001-2008, and 30% of studies in 2009-2012. The proportion of analyses that did not clearly 
report (Not reported) the methods used to create choice sets rose from 9% in 1990-2000 
to 28% in 2001-2008 and stabilized at 26% in 2009-2012, whilst in one period (2009-2012), 
11% of analyses used ‘other’ methods to create choice sets.
5. ESTIMATION PROCEDURES
As there is a good explanation of RUT, alternative DCE econometric models, and the 
appropriateness of different models for different DCE applications in the earlier review 
paper, we refer readers to Sects. 5.1–5.3 of that paper in the interests of brevity [3]. Figure 
11 depicts information on the different estimation methods. The most noteworthy trends 
are described in the sections below. In Fig. 11 details of the econometric estimation methods 
used are depicted.
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Figure 11a | Estimation procedures.
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Figure 11b | Distributional assumptions.
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5.1 Use of Probit, Random Effects Probit, Logit, and Random Effects Logit
As previously reported, early DCE studies, i.e. those published in 1990-2000, seemed to 
focus upon applying either binary choice or ‘forced choice’ DCEs [4]. So, for example, in 
1990-2000, 18% of analyses used probit; this proportion fell to 7% in 2001-2008, and fell 
further to 2% in 2009-2012. Similarly, in 1990-2000, 53% of analyses used random effects 
probit (RE probit), falling to 41% in 2001-2008, and then further to 10% in 2009-2012. The 
proportion of logit analyses was 3% in 1990-2000, rising to 11% in 2001-2008, and was 10% 
in 2009-2012, and relatively few analyses used random effects logit (RE Logit) in each time 
period.
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5.2 Use of Multinomial Logit
The overall decline in the use of logit, probit and random effects probit reported above has 
been offset by an increased use of multinomial logit (MNL) analyses, which are sometimes 
otherwise known as conditional logit analyses. These analyses have the advantage that they 
can cater for more than two response options, and they can also allow respondents to ‘opt-
out’ from making a decision. Sometimes such models may also be associated with better 
‘goodness of fit’ than some other econometric models. During 1990-2000, 18% of studies 
used MNL, 22% used it during 2001-2008, rising to 44% during 2009-2012.
5.3 Use of Nested Logit
During the period 2001-2008, a small shift towards use of nested logit (NL), a technique that 
relaxes the independence of irrelevant alternatives (IIA), was observed [3]. It was applied in 
4% of studies during 2001-2008, up from 0% in 1990-2000. For the period 2009-2012, the 
proportion remained low at 2% of studies.
5.4 Models Applicable When There is Preference Heterogeneity
During 1990-2000, only 3% of studies used mixed logit/random parameters logit (MXL/RPL); 
by 2001-2008, 5% of analyses used MXL/RPL. During the period 2009-2012, there was a 
clear trend towards increased use of MXL/RPL, and 21% of analyses utilized the technique. 
All the analyses involving MXL/RPL found evidence of preference heterogeneity. Ideally, 
when MXL/RPL analyses are submitted for publication, details of the number of replications 
(sometimes described as ‘Halton draws’) should be provided, as results can be sensitive to 
the number of replications. This occurred in 0% of MXL/RPL analyses in 1990-2000, 67% in 
2001-2008, and 47% in 2009-2012.
Unlike latent class models (LCM), MXL/RPL analyses make distributional assumptions for 
random parameters (Fig. 11b). Not all MXL/RPL analyses indicate what these are. Indeed, 
in 1990-2000, 100% of analyses failed to indicate them. In 2001-2008, 17% failed to 
provide this information, and in 2009-2012, 47% failed to provide this information. When 
such information was provided, analyses usually indicated they had assumed normal 
distributions for random parameters: 0% in 1990-2000, 83% in 2001-2008, and 53% in 
2009-2012. However, in 17% of cases in 2001-2008, and 8% in 2009-2012, models assuming 
logarithmic distributions for random parameters were also reported alongside results from 
models assuming normal distributions for random parameters. Also, one study [115] used 
a mixed logit hierarchical Bayesian model (MLHB), an extension of mixed logit modelling. 
Another analysis used what it described as a Bayesian-like approach similar to mixed logit 
[80]. Sometimes hierarchical Bayesian analysis has also been used without mixed logit [48, 
70, 114, 204]. A small proportion of analyses did not report the estimation procedure used.
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During the early period (1990-2000), no study used LCM. During the period 2001-2008, 
one study (1%) used LCM, and the study also found evidence of preference heterogeneity 
[216]. During 2009-2012, five analyses (3%) [57, 61, 129, 168, 204] used LCM, and they all 
identified evidence of preference heterogeneity.
A few analyses used ‘other’ estimation procedures. In 1990-2000, this was the case for 3% 
of analyses; the proportion was 4% of analyses in 2001-2008 and 17% of analyses in 2009-
20126.
6. VALIDITY
6.1 Validity Checks
The proportions of studies that used different validity tests are depicted in Fig. 12. 
Figure 12 | Validity checks.
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6 ‘Other’ methods used in 2009-2012 included weighted probit [68]; OLS with a hetero-robust covariance 
matrix estimator [192]; a method described as ‘‘modelling including interaction effects’’ [45]; Cox’s 
proportional hazards model with time-dependent covariate [105]; weighted least squares regression to 
estimate utility weights [105]; multivariate ordered probit to estimate conjoint utility parameters [76]; mixed 
logit with hierarchical Bayesian modeling and ordered probit [115]; generalized estimated equations [109, 
125]; random parameter logit estimated using a hierarchical Bayesian algorithm [208]; conditional logit and 
parameter weighting functions [160]; a series of multivariate regressions [50, 65]; a method described as 
Bayesian-like for preference weights [80]; OLS [87]; hierarchical Bayesian analysis [48, 70, 114, 205, 212]; 
multinomial exploded logit [177]; Firth’s unbiased estimator [193]; combined conditional logit and ranked 
logit model [127]; multivariate multilevel logistic regression [46]; generalized multinomial logit [119]; mixed 
effect logistic regression [184], error components mixed logit analysis [63]; a combination of Bayes theorem, 
Monte Carlo Markov chain procedure and the Metropolis Hastings algorithm [182]; and logistic and probit 
regression using cluster-robust standard error (SE), random effects and GEE and multinomial logistic and 
probit regressions with cluster-robust SE and random effects multinomial logistic model and probit model 
with cluster-robust SE treating the choices from two stages as two correlated binary outcomes [94].
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The most noteworthy trends are as follows. Tests of external validity (External) are 
particularly valuable because stated preferences from DCEs can then be compared with 
revealed preferences. However, there is often little scope to conduct tests of external 
validity (particularly if DCEs are applied in the context of state funded healthcare provision). 
This may explain why none of the analyses contained a test for external validity during 1990-
2000. The proportion rose to 1/114 analyses (1%) in 2001-2008 as there was a study [217] 
that compared doctors’ prescribing decisions in relation to prescriptions for alcoholism with 
the preferences they expressed in a DCE. For the most recent period (2009-2011), only one 
[144] analysis (<1%) contained a test of external validity.
Most analyses included tests for internal theoretical validity (Theoretic). Overall, 65% of 
analyses in 1990-2000 included these tests, with the proportion falling to 56% in 2001-2008, 
and it was 60% in 2009-2012. Such tests involve an assessment of whether coefficients 
appear to move in line with prior expectations, and studies generally reported that this was 
the case.
Tests for non-satiation were less frequently reported. For the period 1990-2000, 44% of 
analyses contained such a test; the proportion was 49% in 2001-2008, before falling to 21% 
in 2009-2012. The decline in the use of such tests probably reflects concerns that they tend 
to be passed, so that they are a relatively weak test of validity. Also, in an influential paper 
[218], it has been argued that preferences that may appear to be ‘irrational’ may in reality 
be compatible with some form of rationality. Therefore, to delete such responses may be 
inappropriate, so the decline in the use of such tests may reflect good practice.
If tests of transitivity could readily be applied using DCEs, the information yielded might 
be more useful. However, they cannot always be readily applied, which is presumably why 
over the period 1990-2000 only 9% of analyses contained a transitivity test; in 2001-2008, 
4% of analyses contained such a test, and during 2009-2012, 1% of analyses contained a 
transitivity test. During 1990-2000, none of the analyses contained a test relating to Sen’s 
expansion and contraction properties (Sen’s exp. & contraction); the proportion was 2% of 
analyses during 2001-2008, and 1% of analyses during 2009-2012. Use of a test for internal 
compensatory decision-making (Compensatory) [3] was much more frequent. In 1990-2000, 
35% of analyses involved such a test; the value for 2001-2008 was 32% of analyses, but in 
2009-2012, this declined to 14% of analyses.
6.2 Use of Qualitative Methods to Enhance DCE Processes and Results
Information on the use of qualitative methods to enhance DCE processes and results is 
depicted in Fig. 13. In 1990-2000, 18% of analyses used qualitative methods to inform 
attribute selection (Attrib. selection), rising to 69% of analyses in 2001-2008, before 
declining to 51% of analyses in 2009-2012. This is potentially a worrying trend because if the 
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selection of attributes is not properly grounded in qualitative research, then inappropriate 
attributes may be specified and appropriate attributes may be omitted (triggering omitted 
variable bias). It would be of little concern, however, if the recent reduction in the use of 
qualitative methods to inform attribute selection was triggered by the wider use of DCEs 
in contexts in which the decision framework is already known (for example, if DCEs are 
conducted alongside clinical trials).
Figure 13 | Use of qualitative methods.
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In contrast, the use of qualitative methods to inform attribute level selection (Level selection) 
increased; the proportion was 18% of analyses in 1990-2000, increasing to 33% in 2001-
2008, before increasing again to 40% in 2009-2012. The use of a pre-testing questionnaire 
(Pre-testing) fluctuated over time; it was applied in 47% of analyses in 1990-2000, just 32% 
of analyses in 2001-2008, but was applied in 41% of analyses in 2009-2012. The use of 
debriefing choices (Debriefing) to help strengthen understanding increased from 0% of 
analyses in 1990-2000 to 4% of analyses in 2001-2008, and 8% of analyses during 2009-
2012.
7. AREAS OF APPLICATION AND OUTCOME MEASURES
7.1 Areas of Application
As indicated by de Bekker-Grob et al. [3], although DCEs had originally been introduced 
into health economics primarily in order to value patient experience [219], there was 
clear evidence that the application of DCEs had broadened considerably by 2000-2008 [3]. 
Moreover, this trend continued into 2009-2012. Figure 14 summarizes the relevant data (for 
the definitions of categories A, B, C, D, E, F, G, and H, refer to Table 1).
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Figure 14 | Areas of application.
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Notes: For the definitions of categories A, B, C, D, E, F, G, and H, refer to Table 1.
The main noteworthy trends are as follows. In 1990-2000, 35% of analyses had a main 
study objective that involved valuing experience factors (Category A). The proportion was 
the same in 2001-2008, as 35% of analyses had the same main study objective. However, 
during 2009-2012, this proportion fell to 12% of analyses. In contrast, the proportion of 
DCEs exploring trade-offs between health outcomes and experience factors has risen 
steadily (Category C). In 1990-2000, 41% of analyses had this as a primary objective; during 
2001-2008, the proportion was 33% of analyses, increasing further to 44% of analyses in 
2009-2012. This reflects a shift from examining patient experience factors (Category A) in 
isolation (down from 35% in 2001-2008 to 12% in 2009-2012) towards estimating trade-
offs between health outcomes and experience factors (Category C), which increased from 
33% of analyses in 2001-2008 to 41% in 2009-2012. The latter category (Category C) also 
includes the estimation of trade-offs for non-patient groups, whereas the former (Category 
A) is specific to patient respondents.
In 1990-2000, no analysis included a main objective of estimating utility weights within a 
quality-adjusted life year (QALY) framework (Category D). During 2001-2008, 2% of analyses 
had this as the main objective. These two analyses used DCEs as an alternative to standard 
gamble (SG) and time trade-off (TTO) to estimate utility weights within a QALY framework 
[220, 221]. More recently, there has been some further work in this area. In 2009-2012, 2% 
of analyses had this as their main objective, reflecting some interest in this research agenda. 
One of these analyses [165] looked at deriving distributional weights for QALYs using DCEs; 
another [164] used DCEs to quantify EQ-5D health states, whilst another [163] explored 
whether a DCE that resembles TTO exercises is able to estimate consistent values on the 
health utility scale for the EQ-5D. A further analysis compared case 3 BWS DCE analysis with 
WTP analysis [166].
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A small proportion of DCEs have had a primary objective of evaluating job choices, human 
resource policy (Category E), or developing priority setting frameworks (Category F), and 
values for these categories did not exhibit much change (see Fig. 14).
During 1990-2000, 3% of analyses had the main objective of establishing health professionals’ 
preferences (Category G); this rose to 15% in 2001-2008, before falling slightly to 12% in 
2009-2012. In 1990-2000, 0/34 analyses (0%) had an ‘other’ (Category H) main objective; 
this rose to 4% of analyses in 2001-2008, before rising again to 10% of analyses in 2009-
20127.
7.2 Outcome Measures
Information on trends relating to ‘main outputs’ is depicted in Fig. 15. In the past, DCEs 
often expressed outputs in terms of a primary outcome measure of ‘per WTP unit’ or ‘per 
time unit’. In 1990-2000, 29% of analyses used the ‘per WTP unit’ (WTP) outcome measure, 
increasing to 39% of analyses in 2001-2008; however, in 2009-2012, the proportion was 
only 31% of analyses. The use of ‘per unit of time’ (Time) as an outcome measure has also 
declined markedly over the period. During 1990-2000, 29% of analyses used this outcome 
measure; in 2001-2008, the proportion was 20% of analyses, and it declined further to 3% 
of analyses in 2009-2012.
The proportion of DCEs using ‘per risk unit’ (Risk) as a primary outcome is low, and this 
has fluctuated little over the period (see Fig. 15). Only a minority of analyses use monetary 
welfare measures (Money) as the primary outcome measure, and this proportion has fallen 
in proportionate terms over time. During 1990-2000, 15% of analyses involved a money 
welfare measure; during 2001-2008, the proportion was 12% of analyses; and during 2009-
2012, the proportion was 2% of analyses.
7 In 2009-2012, one study explored how changing the number of responses elicited from respondents might 
affect estimates of WTP [204]; another looked at parents’ preferences for management of attention-deficit 
hyperactivity disorder [206]; one study looked at general public preferences for long-term care [137]; another 
two studies looked at preferences for human papillomavirus vaccine, one case looking a societal preferences 
[207] and the other [63] looking at mothers’ preferences; another study looked at the valuation of diagnostic 
testing for idiopathic developmental disability by the general population [208]; another looked at various 
stakeholder groups’ preferences for coagulation factor concentrates to treat hemophilia [145]; one study 
looked at general public preferences for tele-endoscopy services [158]; another compared Dutch and German 
preferences for health insurance amongst their populations [214]; one paper looked at public and decision 
maker preferences for pharmaceutical subsidy decisions [215]; one study explored how individuals perceive 
various coronary heart disease factors [203], whilst another described the relative importance of major 
adverse cardiac and cerebrovascular events to be used when analyzing trials [212]. Two other DCEs were 
performed on the area of quality improvement; one investigated how to best disseminate evidence-based 
practices to addiction service providers and administrators [205], while the other was used to investigate 
which indicators had the greatest impact on the decisions of health service inspectors concerning the 
assessment of quality of mental health care [211]. Other applications included a study on preferences of 
health workers in Burkina Faso for health insurance payment mechanisms [209]; a study on how respondents 
valued mortality risk attributable to climate change reductions [210]; and a study on the preferences for 
reducing contaminated sites to reduce the risk for cancer [213].
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Figure 15 | Outcome measures.
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The use of utility scores (Utility) as the primary outcome measure is more common, and this 
has fluctuated over time. In 1990-2000, 24% of analyses had utility scores as the primary 
outcome measure. The proportion was 18% of analyses during 2001-2008, decreasing to 8% 
of analyses during 2009-2012.
There is also evidence that the use of odds ratios (Odds) has fluctuated. In 1990-2000, 
only 3% of analyses used odds ratios as the primary outcome measure. By 2001-2008, the 
proportion of had more than tripled to 11% of analyses; the proportion was 8% in 2009-
2012. Likewise, the use of probability scores (Prob) increased from 3% of analyses in 1990-
2000 to 13% of analyses in 2001-2008, before declining to 8% of analyses during 2009-2012.
Finally, Fig. 15 presents information on ‘other’ outcome measures used. For the periods 
1990-2000 and 2001-2008, the earlier review authors did not use an ‘other’ category for 
the main outcome measure used. However, for this review, we categorized a substantive 
number of analyses, 49% of analyses, in the ‘other’ category. This was mainly because in 
2009-2012 there was a trend to use importance scores or relative importance of attributes 
(25% of analyses) or preference weights (6% of analyses).
8. REVIEW OF ADAPTIVE CONJOINT ANALYSIS/ADAPTIVE CHOICE 
BASED CONJOINT STUDIES
Having summarized the ACA/ACBC studies in an additional file (because they use a 
fundamentally different approach to DCEs), we concluded that it was difficult to discern 
major trends in relation to these analyses across study periods. This is because our PubMed 
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search unearthed a total of only 26 analyses in 26 papers to review for the entire review 
period, 1990-2012. Nonetheless, for the interesting trends that have been discerned, the 
details have been provided in additional file 1.
Our searches (Table A1; see additional file 1 for all appendix Tables) unearthed no studies of 
this type for the period 1990-2000, 14 analyses for the period 2001-2008, and 12 analyses 
for the period 2009-2012. In contrast to the DCE literature, most of these analyses seemed to 
emanate from the USA, and the surveys were more likely to be computer administered. The 
analyses also tended to be designed using Sawtooth software (Table A2), and no analyses 
indicated the use of an alternative software package. Published analyses did not indicate 
whether they ever used the main estimation methods used for DCEs (Table A3), and all of 
them either fell into the ‘other’ or ‘not reported’ categories. Moreover, validity checks were 
rarely incorporated into ACA/ACBC analyses (Table A4).
9. DISCUSSION
The number of published health-related DCEs has increased dramatically over the last 2 
decades. There has also been a shift away from UK dominance of health-related DCEs, with 
a widening range of countries producing DCE studies.
The 2001-2008 review [3] noted a wide range of policy applications for DCEs; this continued 
during 2009-2012. In 2001-2008, the valuation of patient experience continued ‘‘to 
be the focus of the majority of studies’’ [3]. In contrast, this declined as the main focus 
during 2009-2012. Nevertheless, in 2009-2012, most DCEs continued to include attributes 
relating to patient experiences, but increasingly in order to examine trade-offs between 
health outcomes and experience factors. Also health outcomes and experience factors for 
respondents groups other than patients are encompassed by this category (e.g., Category 
C analyses).
The 2001-2008 review [3] reported that ‘‘willingness to pay continued to be a commonly 
used output from DCEs’’ over that period. However, the present review found evidence that 
the proportion of DCE studies using either a ‘per WTP unit’ or a ‘monetary welfare measure’ 
as their primary outcome has fallen. This could in part be attributable to concerns that have 
been raised in relation to the use of DCEs to elicit WTP. These include whether estimated 
WTP obtained via DCEs may be sensitive to the range specified for the monetary attribute 
or the presence or absence of payment per se [222], or the presence or absence of a non-
zero cost, rather than the level of cost indicated by the monetary attribute [223]. Other 
evidence suggests that the way attributes are ‘framed’ in a DCE questionnaire may impact 
upon estimated WTP [113]. Furthermore, the hypothetical nature of DCEs can hinder correct 
estimates of WTP because respondents will not be bound by the choices they make [143].
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Another issue arises because when estimating marginal willingness to pay (MWTP), it is 
commonly assumed that marginal utility of money is constant and the cost function is 
therefore continuous and linear. However, there is reason to believe that the cost gradient 
may not be continuous and linear [115]. Therefore, if WTP is calculated there is a need to 
proceed with econometric analysis that assumes more complex indirect utility functions 
[123, 124], for example, using interaction terms between attributes [224], or using non-
linear attribute transformations, such as the squaring of attributes [225], or taking natural 
logarithms [226].
In addition to using methods that can be used to identify unobserved preference 
heterogeneity, which we discussed in detail in Sect. 5.4, the issue of segmenting DCE 
data to examine the preferences of defined subgroups is sometimes important. One early 
analysis [227] segmented the DCE data according to the severity of symptoms associated 
with osteoarthritis, and the importance of a joint ache attribute was seen to increase in 
respondents with more severe symptoms. Other analyses relating to establishing priority 
criteria for allocating cadaveric kidney transplants [71, 72] have provided evidence of 
statistically significant differences in preferences between different stakeholder groups. A 
major finding to emerge from this research was that whilst non-ethnic minority patients 
would prefer to allocate kidney transplants to recipients with a good tissue match, ethnic 
minorities (who would be disadvantaged by use of such priority criteria) would not. 
Another interesting analysis relating to segmentation used segmentation because ‘‘health 
organizations need to understand whether the same health treatments, prevention 
programs, services, and products should be applied to everyone in the relevant population 
or whether different treatments need to be provided to each of several segments that are 
relatively homogeneous internally but heterogeneous among segments’’ [228]. Segmenting 
the data to facilitate subgroup analysis is particularly appropriate if policy-relevant 
differences in preferences between defined subgroups might be applicable.
The use of simulation may be important, when DCEs are applied, because simulation may 
enable you to do something useful with DCE data. For example, in a DCE relating to junior 
doctors’ preferences for specialty choice, it was found that increasing general practitioners 
(GPs) wages by $AUS50,000, or increasing opportunities for procedural or academic work, 
can increase the number of junior doctors choosing general practice by between 8 and 13% 
[174]. Another example of how useful simulation of DCE data can be is an analysis that was 
designed to predict the place of out-of-hours care. Using DCE data to predict market shares, 
it was predicted that a new GP cooperative could capture about a third of the market, ahead 
of the emergency department, the second most preferred service [183].
In Sect. 5.2, we pointed out that econometric methods are increasingly being used which 
can facilitate allowing respondents to ‘opt-out’ from registering a preference. An example 
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of why this might be important is apparent from an analysis relating to colorectal cancer 
screening [110]. This is because when screening for colorectal cancer, it was important to 
give people an ‘opt-out’ response in order to ensure that the choices respondents faced 
were realistic. Similarly, when evaluating two hypothetical smoking cessation mechanisms, 
it was important to provide respondents with an ‘opt-out’ option [128].
This review for 2009-2012 found an increasing trend towards presenting respondents with 
more DCE choice scenarios. Some evidence suggests [203] that later DCE responses might 
be more thought through, so this may be a welcome development. However, the optimal 
number of choices presented should ideally be established through piloting, because it is 
likely to be a function of the complexity of choices presented. There has also been an interest 
in developing approaches to cater for the inclusion of increased numbers of attributes within 
DCE designs [161, 198]. Another development has been a shift away from self-administered 
pen/pencil-response DCE questionnaires towards either interviewer-administered or, more 
particularly, computer-administered questionnaires and the use of internet panels.
The trend towards the increased use of D-efficient DCE designs noted by de Bekker-Grob 
et al. [3] has continued. Although there has been an increase in the proportion of analyses 
catering for interactions, main effects designs remain dominant. Trends away from the use 
of probit and random effects probit towards greater use of MNL reflect the increased use of 
DCEs incorporating more than two choices, or two choices plus an opt-out. Recent interest 
in the use of models catering for preference heterogeneity is welcome because when mixed 
logit or LCM is applied, it invariably identifies preference heterogeneity, which otherwise 
would have been overlooked. That said, one limitation of the mixed logit approach is that it 
requires the imposition of assumptions about the distribution of the random coefficients. If 
the distributional assumptions are not valid, then this can undermine the validity of findings 
about preference heterogeneity. LCM has the advantage over mixed logit that it does not 
involve the imposition of such distributional assumptions, but can have the disadvantage 
that it may be more time consuming to implement. 
There appears to have been a decline in the use of most validity tests during 2009-2012, 
including tests of non-satiation, transitivity, Sen’s expansion and contraction properties, and 
tests of compensatory decision making. We might have anticipated a decline in the use of 
such validity checks, because the usefulness of the results they yield has increasingly been 
called into question [144, 218, 229]. Reassuringly, however, during 2009-2012, there has 
been an improvement in the proportion of analyses using qualitative methods to enhance 
DCE processes and results, in some respects, including the use of qualitative methods to 
inform level selection; use of pilot pre-testing questionnaires; and the use of qualitative 
methods to strengthen understanding of responses (including debriefing choices). A 
remaining cause for concern, however, is that the use of qualitative methods to inform 
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attribute selection has declined since 2001-2008. This could lead to increased likelihood of 
omitted variable bias affecting DCE results. 
The main limitation of this study was that, like the published review for 2001-2008 [3], we 
only used PubMed to source literature. However, as that review noted [3], when additional 
searches are conducted on other databases, it does not markedly affect review findings. 
So in the interests of ensuring comparability with data from that earlier review, we also 
restricted our searches to the PubMed database.
10. CONCLUSIONS
The use of DCEs in healthcare continues to grow dramatically, as does the scope of 
applications across an expanding range of countries. There is increasing evidence that more 
sophisticated approaches to DCE design and analytical techniques are improving the quality 
of final outputs. That said, recent evidence that the use of qualitative methods to inform 
attribute selection has declined is of concern.
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ADDITIONAL FILE 1: THE USE OF ADAPTIVE CONJOINT ANALYSIS (ACA) 
/ AND ADAPTIVE CHOICE BASED CONJOINT (ACBC) STUDIES.
Some trends that can be discerned in relation to the Adaptive Conjoint Analysis (ACA) / and 
Adaptive Choice Based Conjoint (ACBC) studies are apparent from the data in Table A1. 
Table A1 | Background information on ACA / ACBC studies.
Item Category Period:
2001-2008 (N=14)
Period:
2009-2012 (N=12)
Country of origin UK 1 (7.1%) 0 (0%)
USA 11 (78.6%) 6 (50%)
Australia 0 (0%) 0 (0%)
Canada 0 (0%) 0 (0%)
Denmark 0 (0%) 0 (0%)
Netherlands 2 (14.3%) 4 (33.3%)
Germany 1 (7.1%) 1 (8.3%)
Other 0 (0%) 2 (16.7%)
Number of attributes 2 – 3 0 (0%) 0 (0 %)
4 – 5 6 (42.9%) 4 (33.3%)
6 1 (7.1%) 3 (25%)
7 – 9 2 (14.3%) 2 (16.7%)
10 0 (0%) 1 (8.33%)
>10 4 (28.6%) 2 (16.7%)
Not clearly reported 1 (7.1%) 0 (0%)
Attributes covered Monetary measure 2 (14.3%) 4 (25%)
Time 8 (57.1%) 6 (50%)
Risk 11 (78.6%) 10 (83.3%) 
Health Status domain 14 (100%) 12 (100%) 
Health care 12 (85.7%) 8 (66.7%) 
Other 1 (7.1%) 3 (25%) 
Number of choices per 
respondent
8 or less 3 (21.4%) 2 (16.7%) 
9 – 16 choices 2 (14.3%) 4 (33.2%) 
More than 16 choices 3 (21.4%) 6 (50%) 
Not clearly reported 6 (42.9%) 0 (0%) 
Administration of survey Self-completed questionnaire 0 (0%) 1 (8.3%) 
Interviewer administered 8 (57.1%) 0 (0%) 
Computerized review 6 (42.9%) 10 (83.3%) 
Not reported 0 (0%) 1 (8.3%) 
Notes: Some of the categories in tables do not add up to 100%, because they are not necessarily mutually 
exclusive, and studies may include multiple categories.
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Searches using PubMed using the search terms ‘Adaptive Conjoint Analysis’, ‘Adaptive 
Choice Based Conjoint’, and ‘menu-based conjoint’ uncovered no healthcare related studies 
of this type for 1990-2000. For 2001-2008 however we obtained 14 analyses in 14 papers 
(equivalent to 1.75 per year). Moreover, for 2009-2012 we obtained and reviewed 12 
analyses in 12 papers (equivalent to 3 per year). Many of these analyses have emanated from 
the USA (78.6% in 2001-2008, and 50% in 2009-2012), and the Netherlands (14.3% in 2001-
2008, and 33.3% in 2009-2012). All of the analyses involved 4 or more attributes (where the 
number of attributes was specified). Moreover, some of the studies involved in excess of 10 
attributes (28.6% in 2001-2008, and 16.7% in 2009-2012). The ACA / ACBC approach has 
the advantage that it can easily cater for designs with large numbers of attributes. Analyses 
often involved attributes which encompassed a wide range of domains (see Table A1). Like 
the DCE sample of analyses reviewed in the main paper, these analyses seemed to vary 
considerably in relation to the number of choices each respondent has faced. The analyses 
rarely seemed to involve completion of ‘Self-completed questionnaires.’ This is because 
they usually required the completion of computer-generated questionnaires. So they were 
usually either interviewer administered, with the interviewer inputting information into an 
ACA computer software package (occurred in 57.1% of analyses in 2001-2008; and 0% in 
2009-2012) or administered by computerized review (occurred in 42.9% of analyses in 2001-
2008, and 83.3% in 2009-2012).
The data in Table A2, indicates that when the design type is indicated (100% of cases in 
2001-2008, and 83.3% of cases in 2009-2012), the use of a fractional factorial rather than 
full factorial design is used. There seems to be a major problem in terms of the analyses not 
indicating whether a main effects design or a design involving main effects plus interaction 
effects is used (100% of cases in 2001-2008, and 100% of cases in 2009-2012). The design 
source was usually said to be Sawtooth software (100% in 2001-2008, and 91.7% in 2009-
2012), although one analysis in 2009-2012 (8.3%) just said it was an unnamed ACA software 
package.
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Table A2 | Background information on ACA / ACBC studies.
Item Category Period:
2001-2008 
(N=14)
Period:
2009-2012 
(N=12)
Design type Full factorial 0 (0%) 0 (0%) 
Fractional factorial 14 (100%) 10 (83.3%) 
Not clearly reported 0 (0%) 2 (16.7%) 
Design plan Main effects only 0 (0%) 0 (0%) 
Main effects, 2 or more way interactions 0 (0%) 0 (0%) 
Not applicable 0 (0%) 0 (0%) 
Not clearly reported 14 (100%) 12 (100%) 
Design 
Source
Software package 14 (100%) 12 (100%) 
    SPEED 0 (0%) 0 (0%) 
    SPSS 0 (0%) 0 (0%) 
    SAS 0 (0%) 0 (0%)
    SAWTOOTH 14 (100%) 11 (91.7%) 
    Other 0 (0%) 0 (0%) 
No further details 0 (0%) 1 (8.3%) 
Catalogue 0 (0%) 0 (0%) 
Website 0 (0%) 0 (0%) 
Expert 0 (0%) 0 (0%) 
Not clearly reported 0 (0%) 1 (8.3%) 
Method to 
create choice 
sets
Orthogonal arrays: Single profiles (i.e. binary choices) 0 (0%) 0 (0%) 
Orthogonal arrays: Random pairing 0 (0%) 0 (0%) 
Orthogonal arrays: Pairing with constant comparator 0 (0%) 0 (0%) 
Orthogonal arrays: Foldover – random pairing  0 (0%) 0 (0%) 
Orthogonal arrays: Foldover 0 (0%) 0(0%) 
D-efficiency 0 (0%) 0 (0%) 
Other (pragmatically chosen) 0 (0%) 0 (0%) 
Not clearly reported 0 (0%) 1 (8.3%) 
Other 14 (100%) 11 (91.7%) 
Table A3 provides information on the range of estimation procedures used. These did not 
tend to fall into the main categories used for the data analysis for DCEs because typically 
other data analysis methods were used8 (64.3% of analyses in 2001-2008, and 91.7% of 
analyses in 2009-2012), or there was a failure to report which methods were used (35.7% in 
2001-2008 and 8.3% in 2009-2012) with respect to a number of analyses.
8 The range of ‘other’ analyses used (n=9) which were indicated during 2001-2008 included 5 studies using 
ordinary least squares; 1 study using multiple logistic regression; 2 studies using Sawtooth Software generated 
utility values; and 1 study using Sawtooth Software to establish the percentage of patients preferring a 
treatment option. Moreover, the range of other analyses (n=11) indicated during 2009-2012 included 4 
studies using OLS estimation; 1 study using a least squares updating algorithm; 3 studies using Hierarchical 
Bayesian estimation; 1 study reporting the use of Sawtooth Software with calculation of adjusted odds ratios; 
1 study referring to use of Sawtooth ACA Software, and Hierarchical Bayesian and SMRT market simulation 
models; and 1 study which refers to use of ACA Software but did not define the package used. 
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Table A3 | Estimation procedures.
Estimation method Period: 
2001-2008 
(N=14)
Period: 
2009-2012 
(N=12)
Probit 0 (0%) 0 (0%) 
Random Effects Probit 0 (0%) 0 (0%) 
Logit 0 (0%) 0 (0%) 
Random Effects Logit 0 (0%) 0 (0%) 
MNL 0 (0%) 0 (0%) 
Nested Logit 0 (0%) 0 (0%) 
Mixed Logit / Random Parameter Logit 0 (0%) 0 (0%) 
Latent class (LCM) 0 (0%) 0 (0%) 
Other 14 (100%) 11(93.7%) 
Not clearly reported 0 (0%) 1 (8.3%) 
Further details about Mixed Logit [MXL] / 
Random Parameter Logit Analyses [RPL]
Period: 
2001-2008 
(N=14)
Period: 
2009-2012 
(N=12)
Number described as RPL only 0 (0%) 0 (0%)
Number described as MXL only 0 (0%) 0 (0%)
Number described as both RPL and MXL analyses 0 (0%) 0 (0%)
Number of analyses uncovering evidence of preference heterogeneity 0 (0%) 0 (0%)
Number of papers indicating the number of replications (e.g. the number 
of Halton draws)
0 (0%) 0 (0%)
Number of analyses saying they used a normal distribution for random 
parameters
0 (0%) 0 (0%)
Number of analyses saying they used a log distribution for random 
parameters
0 (0%) 0 (0%)
Number of analyses saying they assumed another type of distribution for 
random parameters
0 (0%) 0 (0%)
Number of analyses failing to provide information about distributional 
assumptions of random parameters
0 (0%) 0 (0%)
Estimation procedure ‘other’ 9 (64.3%) 11 (91.7%)
Estimation procedure not clearly reported 5 (35.7%) 1 (8.3%)
Table A4 contains information on the use of validity checks. These did not seem to be 
deployed very often for these types of analysis. For the period 2001-2008 we found little 
evidence that these had been deployed. However, one analysis deployed a test for non-
satiation (7.1%) and one analysis [1] undertook an external validity check (7.1%). For the 
period 2009-2012, 25% of analyses used validity checks to check for non-satiation. Moreover, 
25% of analyses used qualitative analysis to inform attribute selection, and 8.3% of analyses 
used qualitative analysis to inform level selection.
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Table A4 | Validity.
Item Category Period:
2001-2008 
(N=14)
Period:
2009-2012 
(N=12)
Validity tests External 1 (7.1%) 0 (0%)
Internal: Theoretical 0 (0%) 0 (0%)
Internal: Non-satiation 1 (7.1%) 3 (25%)
Internal: Transitivity 0 (0%) 0 (0%)
Internal: Sen’s expansion and contraction 0 (0%) 0 (0%)
Internal: Compensatory decision making 0 (0%) 0 (0%)
Use of qualitative 
methods to 
enhance DCE 
process & results
Increasing face validity: Attribute selection 0 (%) 3 (25%)
Increasing face validity: Level selection 0 (0%) 1 (8.3%)
Increasing face validity: Pre-testing questionnaire 0 (0%) 0 (0%)
Increasing face validity: Strengthen understanding 
responses – Debriefing choices
0 (0%) 0 (0%)
Finally, Table A5 provides information on the output of the ACA / ACBC analyses. During 
2001-2008, 21.4% of analyses related to valuing health outcomes (Category B type 
analyses), and 78.6% of analyses related to valuing trade-offs between health outcomes 
and experience factors (Category C analyses). Moreover, a range of outcome measures were 
used (for details refer to Table A5 and the footnotes to the Table).
During 2009-2012, 25% of analyses related to valuing health outcomes (Category B type 
analyses), and 58.3% of analyses related to valuing trade-offs between health outcomes 
and experience factors (Category C analyses). One analysis (8.3%) related to valuing health 
professionals’ preferences (Category G analysis) and another (8.3%) related to the category 
‘Other’ (Category H analysis). Moreover, a range of outcome measures was used (for details 
refer to table A5 and the footnotes to the Table).
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ABSTRACT
Background: Understanding public opinion and attitudes regarding vaccination is crucial for 
successful outbreak management and effective communication at the European level. 
Methods: We explored national differences by conducting focus group discussions in 
the Netherlands, Poland and Sweden. Discussions were structured using concepts from 
behavioural models. 
Results: Thematic analysis revealed that participants would base their vaccination decision 
on trade- offs between perceived benefits and barriers of the vaccine also taking into 
account the seriousness of the new outbreak. Except for those having chronic diseases, 
participants expected a low infection risk, resulting in a low willingness to get vaccinated. 
Information about the health status of cases was considered important since this might 
change perceived susceptibility. Participants displayed concerns about vaccine safety due 
to the limited available time to produce and test vaccines in the acute situation of a new 
pandemic. Swedish participants mentioned their tendency of doing the right thing and 
following the rules, as well as to get vaccinated because of solidarity with other citizens and 
social inﬂuences. This appeared much less prominent for the Dutch and Polish participants. 
However, Swedish participants indicated that their negative experiences during the 
Inﬂuenza A/H1N1 2009 pandemic decreases their acceptance of future vaccinations. Polish 
participants lacked trust in their national (public) health system and government, and were 
therefore sceptical about the availability and quality of vaccines in Poland. 
Conclusions: Although participants overall expressed similar considerations, important 
differences between countries stand out, such as previous vaccination experiences, the 
degree of adherence to social norms, and the degree of trust in health authorities.
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INTRODUCTION
Outbreaks of communicable diseases will cross borders, with Inﬂuenza A/H1N1 [1] and 
Ebola [2] being recent examples, and increased international travel and migration will 
facilitate their speed and spread [3]. Cross-border collaboration in the management of 
future outbreaks within Europe is therefore necessary. Since public health professionals 
and authorities will be focused on controlling the spread and impact of the new disease 
during such an outbreak [4], it is essential to timely update and improve existing European 
pandemic preparedness plans, preferably before outbreaks begin [5].
The success of mitigating a new outbreak is largely dependent on the willingness of the 
public to comply with recommended preventive measures. Understanding the public 
opinion and attitudes regarding preventive measures is thus crucial for successful outbreak 
management and effective communication. Reasons to accept or decline preventive 
measures in pandemic situations have been described [4, 6–12], but very little is known 
about potential differences herein across Europe.
We therefore conducted focus group discussions in three countries across Europe to explore 
(1) the public opinion and attitude regarding future pandemics and vaccination and (2) 
potential differences in opinions and attitudes between participants in the Netherlands, 
Sweden, and Poland.
METHODS
We opted for focus group discussions (FGDs) [13, 14] to explore public opinion and attitudes. 
FGDs were chosen because these enable unforeseen topics to arise and to be explored in 
depth [15]. We developed a theory based semi-structured question route based on the 
Health Belief Model and two elements from other behavioural models (additional files 1 
and 2). The question route was pilot tested, evaluated and improved where necessary. The 
Medical Ethics Committee of the Erasmus University Medical Center Rotterdam approved the 
study protocol (MEC-2012-263). Independent research agencies recruited 6–9 participants 
per FGD and used purposive sampling methods to ensure a diverse sample regarding age, 
sex, and educational level. Participants received a financial incentive for their contribution, 
adapted to the national norm.
In each country, moderators trained in performing qualitative research conducted two FGDs 
in large cities in 2012. One of the authors (DD) debriefed the Polish and Swedish moderators 
before the discussion about background of the study and the question route. All participants 
gave written informed consent prior to the discussions. FGDs lasted for approximately 90 
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minutes and were conducted in the native language. All FGDs were audio taped and field 
notes were made during each discussion. At the end of the FGDs, all participants completed 
a short questionnaire on socio demographics and previous experiences with preventive 
measures.
The discussions were transcribed verbatim and identifiable data was removed. The entire 
Swedish and Polish transcripts, and the selected Dutch quotes were translated into English. 
A thematic analysis was performed [14, 16]. First, two authors (DD and IK) independently 
read all transcripts in-depth. Second, they created a provisional coding tree, based on the 
themes that emerged from the data. Third, they each identified and coded relevant text 
passages in one transcript per country and refined the coding tree. Perceived discrepancies 
between coders were discussed until consensus was reached and the coding tree was 
finalized. Fourth, one author (DD) coded the three remaining transcripts using the final 
coding tree (Additional file 3) and discussed her findings with IK. All transcripts and codes 
were imported into NVivo software (version 10, http://www.qsrinternational.com/) to 
enable systematic comparisons between different countries. We followed the COREQ-
checklist when writing this paper [17].
RESULTS
In total, 41 people participated in six FGDs (Table 1). The median age ranged from 40 
(Sweden) to 47 (the Netherlands). Approximately half of the participants were female. 
Lower and higher educated people participated in each FGD. The results are presented 
according to the themes that emerged from the data and were used in the final coding tree 
(Additional file 3). Representative quotations for each theme were selected to illustrate the 
results. If a quotation characterizes a minority opinion, it is indicated. The quotations are 
numbered; an additional label refers to the FGD ID.
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Table 1 | Summary of participants’ characteristics (n=41).
Dutch 
participants1
(n=17)
Polish 
participants1
(n=12)
Swedish 
participants1
(n=12)
Median age in years (range) 47 (22–77) 46 (19–61) 40 (21–80)
Female 8/17 6/12 6/12
Low educational level2 12/17 6/12 8/12
Having children 9/17 8/12 3/12
Belonging to risk group 8/17 2/12 2/12
If yes, seasonal inﬂuenza vaccine 7/8 0/2 1/2
Vaccinated against H1N1 9/17 0/12 10/12
Preventive measures against H1N1, other than vaccination 4/17 2/12 9/12
If yes, type of preventive measures3
Hygiene4 4/4 2/2 6/9
Use nose-mouth mask – – 1/9
Avoid travelling abroad – – 1/9
Avoid crowded places – – 1/9
Not specified – – 3/9
Notes: 1 We conducted two focus group discussions in the Netherlands with nine and eight participants, 
respectively. In Poland and in Sweden six persons participated per discussion. 2In all countries, high 
educational level was defined as tertiary education; all other educational levels were defined as ‘low’. 3Some 
participants stated that they applied multiple measures. 4 Hygiene includes washing hands more often, use 
hand sanitizer, cleaning desktop more often, etc.
1. Pandemic outbreak
Participants of all countries argued that their degree of concern for a new disease would 
depend on the mode and speed of transmission. They also would want to know the 
consequences of a disease, especially if potentially fatal, before deciding to take preventive 
measures or not. Often, comparisons with previous communicable disease outbreaks were 
made:
‘I think it is all about this danger. If there is to be a new swine ﬂu, maybe you will not actually 
get vaccinated, because you think it’s not that dangerous. But if there is an Ebola epidemic. 
. .’ (Q1SE1).
Dutch participants discussed that there would be no immunity for an outbreak with a new 
virus, thus resulting in uncertainty regarding the course of the disease. Swedish participants 
reasoned that they would experience the threat of a new disease as severe because they 
live in such a safe country:
‘We do not have many other dangerous things to compare [the disease] with, so small things 
become dangerous to us’ (Q2SE1).
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Participants stated that they would weigh the threat of a new disease within the context 
of their own health status. Except for those who belong to a risk group (diabetes, asthma), 
most participants expected a low infection risk, e.g. thanks to healthy eating and living, 
and good personal hygiene. Participants considered information about the health status 
of infected people important, especially when also young and healthy people are infected, 
since this might change their perceived susceptibility. In addition, the proximity of cases 
was considered important; the closer the physical distance or the emotional relationship 
with a case, the higher the level of perceived susceptibility. However, it was remarked 
that proximity would be especially important in case of a severe disease. If relatives fell ill 
and the disease was not severe, participants did not intend to take safety measures. Most 
participants considered it wise to avoid visiting countries whit many people infected. Dutch 
and Swedish participants expressed their worry that communicable diseases might spread 
more rapidly nowadays:
‘And now we move so incredibly easily: we ﬂy and sail across the world. It can spread so 
easily’ (Q3SE1).
In one of the Dutch groups it was put forward that lack of herd immunity due to large groups 
of unvaccinated people [e.g. in the so called ‘Bible belt’ in the Netherlands] might increase 
the risk of getting the disease. Polish participants did not discuss perceived seriousness of 
the disease and perceived susceptibility to the disease frequently.
2. Vaccination
Across all countries, preventing the disease or reducing the severity of its symptoms was 
considered the most important benefit of vaccines. Participants stated that the need for an 
effective vaccine would be higher when a disease was perceived as more serious. Anticipated 
regret made Dutch participants less hesitant to get vaccinated (Q4), even if the effectiveness 
of the vaccine was unclear.
‘Doing something is better than doing nothing. . . if something is available you need to try 
it’ (Q4NL1).
Several Swedes expressed that getting vaccinated would not only be beneficial for themselves 
but would also prevent them from infecting other people. Polish participants however were 
sceptical about the availability and quality of the vaccines in their country:
‘Still you have to consider the fact that even if you got a loan just to get vaccinated, there 
probably wouldn’t be any vaccines available in Poland, as usual’ (Q5PL2).
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[Participant 1] ‘Don’t you get this impression, which I have, that they [‘like France, Denmark, 
the West’] get better vaccines while we get just the worst sort?’. [Participant 2] ‘Yes’. 
[Participant 3] ‘They get the ﬁrst grade while we get the fourth grade. We import it, so we 
get the leftovers’ (Q6PL2).
Several participants were opposed to vaccination in general as they believed it is healthiest 
if a body clears the virus without taking drugs:
‘Why protect yourself against everything, while, in my opinion, it’s more beneﬁcial to have 
the disease and ﬁght it yourself’ (Q7NL2).
The most common view however was to weigh potential benefits and barriers of the vaccine 
against the threat of the disease:
‘What’s worse? Getting very sick and dying, or suffering from side effects? You do have to 
make a choice’ (Q8NL1).
In general, the more severe the disease was seen, the less important the barriers to 
vaccination were considered:
‘I got vaccinated against ﬂu once and it’s taken a great toll on me. I had high fever and 
headaches for three days. . . though if my life was in danger. . . I’d get vaccinated’ (Q9PL1).
Participants displayed concerns about the safety of the vaccine due to the acute situation of 
a new pandemic, and limited time to produce and test vaccines and their safety:
‘It will probably go damn fast, and they will not have time to test it. And therefore we will 
have no clue about the possible side effects’ (Q10SE1).
Dutch participants expected their government to only introduce vaccines if they were 
considered safe:
‘I do not expect the government to introduce a vaccine if they do not trust it themselves, or 
if they do not have insights into the side effects’ (Q11NL1).
Across all countries, costs of the vaccine appeared to be a strong motivator in favour or 
against vaccination. Some participants stated that the price of a vaccine should not matter 
because life is precious, while others suggested that a vaccine should be available for the 
whole population and thus provided for free (e.g. by the government) (Q12, Q13). However, 
Polish participants did not believe that providing a vaccine for free would happen in their 
country (Q14).
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[Participant 1] ‘I think that if we have something so digniﬁedly called public health, we should 
make it free’. [Participant 2] ‘I think so too’. [Participant 3] ‘I think so too, not everyone can 
spare a hundred and ﬁfty Swedish Kronor’ (Q12SE1).
‘The costs are, in my opinion, the responsibility of the government. The government should 
simply protect its people, without putting a price tag on it’ (Q13NL1).
‘We would see the Prime Minster or the Minster of Health, who would tell us that the Polish 
government has decided to buy this vaccine and to provide it to us for free [laughs], which 
we wouldn’t believe’ (Q14PL1).
3. Social inﬂuences
Across all FGDs, it was expected that the new disease and vaccination would be discussed 
extensively by traditional mass media and on the Internet. Participants also frequently 
mentioned that this kind of information should be approached critically and that the source 
of information would really matter. One similar message disseminated across all media 
would be considered as more reliable. In general, Swedish participants were most trustful 
towards the national media (Q15), although some were critical (Q16).
‘We have serious news reports, what is said in the news that is true’ (Q15SE1).
‘I was very sceptical of all the media pressure, and how they pointed out people, saying they 
were not showing solidarity because they did not get vaccinated, that everyone has to do 
it’ (Q16SE1).
It was stated in the Dutch discussions that to prevent public panic, the government is 
expected to spread complete and trustworthy information as early in the pandemic as 
possible. Both Poles and Swedes agreed that in case of a pandemic a representative expert 
needs to step forward with the truth regarding the disease and vaccination (Q17), although 
Poles questioned the availability of such a person with that level of power and knowledge 
(Q18).
‘You have to hope and believe that the medical community will step forward and honestly 
declare that it is safe, or that forty percent can experience side effects’ (Q17SE2).
[Participant 1] ‘So it’s reliable knowledge provided by someone who’s competent’. [Participant 
2] ‘We have no such authorities’. [Participant 3] ‘All the good professors, specialists moved 
to the West’ (Q18PL2).
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Swedish participants considered the advice of relatives helpful in the decision about 
vaccination, while Polish participants did not:
‘We [Polish people] might discuss it with someone, but everyone makes such decisions on 
their own’ (Q19PL1).
The majority of Dutch participants expected to be personally invited by their general 
practitioner should they belong to a target group for vaccination:
‘I think that if I belonged to the target group, I would be invited automatically by my general 
practitioner’ (Q20NL1).
In the Dutch and Swedish discussions participants suggested that they would contact people 
who already have been vaccinated, to learn from their experience. However, participants 
were unsure if those opinions would alter their decision. Participants mentioned that seeing 
friends or family suffer from the disease, would make them feel not only more susceptible 
to the disease, but also more willing to get vaccinated:
‘I think that if someone close to me or an acquaintance of mine died of this disease, then it 
would decidedly make me get vaccinated faster’ (Q21PL2).
The vaccination decision of quite some Dutch and Swedish participants would be inﬂuenced 
by the vaccination behaviour of the majority of their peers. Although some stated that 
revising their opinion would depend on the number of and their relation with vaccinated 
peers:
‘If everyone in your vicinity gets vaccinated, it is clear that it will affect my decision. Then I 
will begin to wonder: should I really ignore this?’ (Q22SE2).
4. Population characteristics
It was mentioned by Swedish participants that during the H1N1 pandemic applying 
preventive measures was an automatic response to the government’s call to get vaccinated, 
and that it was an exception if one did not get vaccinated. They concluded that they were a 
generally risk aware, obedient, and very serious and equality focused population:
‘It was true that the authorities stepped forward and told everyone to get vaccinated. It was 
almost a command. You felt a bit guilty if you did not do it, I think’ (Q23SE2).
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‘We [the Swedes] are quick to agree with each other, and then we go home and grumble a 
little on our own. It’s a mentality. We are such herd animals; we do what everyone else does’ 
(Q24SE2).
‘We want to do the right thing. When you are sitting in your car, you should wear your seat 
belt. And if someone says that we will all get sick, so now you should take a vaccine, then I 
take that vaccine’ (Q25SE2).
Polish participants mentioned being sceptical and reluctant regarding vaccines and to be 
somewhat lacking in trust in doctors and the production process of vaccines:
‘I think they [‘conscious societies’, Norway is given as an example] would obediently arrive 
for the vaccination, and they wouldn’t hesitate. Whereas here [in Poland], people would 
start to speculate just like we’re speculating now. Should we do it, or maybe it’s not worth it, 
or maybe the devil’s in the detail’ (Q26PL1).
‘Abroad everyone trusts doctors. It’s scary in a way. They have a completely different attitude 
to doctors’ (Q27PL1).
5. Prior contact with similar diseases or vaccinations
Participants frequently referred to their experience with the Inﬂuenza A/H1N1 2009 
pandemic throughout the discussions, also without the moderators introducing this topic. 
Dutch and Swedish participants stated that due to their experience with the H1N1 pandemic 
they would perceive any new disease as less serious (Q28). Additionally, Swedish participants 
were sceptical regarding the safety of vaccines because of the debate concerning narcolepsy 
as a side effect of the 2009 pandemic vaccine (Q29).
‘The risk when a new one [a new outbreak] comes. . . Many may think that it is exaggerated, 
like the swine ﬂu was’ (Q28SE2).
‘But this [debating about the safety of vaccines] is a new phenomenon. Before the swine ﬂu 
came, we had never had this debate. People have been vaccinated for who knows how many 
years’ (Q29SE2).
Participating Poles reﬂected positively on their governments’ decision not to buy the 
pandemic vaccine:
‘Well, there was this propaganda to get vaccinated. Of course there was! There was 
propaganda all around the world. But it was limited in Poland and that’s good, because it 
turned out we were the only country in Europe that didn’t lose face then’ (Q30PL1).
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In addition, experiences with a previous pandemic or seasonal ﬂu may affect choices to get 
vaccinated for a new disease, in these cases positively:
‘My neighbour, a healthy boy of 13 years old, died of it [the Hong Kong ﬂu]. In my opinion, 
it is not relevant that there is a chance that the shot doesn’t work or that the outbreak will 
not end in an epidemic…if there are no horrible stories about it [the vaccine], I’ll take the 
shot’ (Q31NL1).
‘I had severe ﬂu complications several years ago. I ended up in the hospital, it was horrible. 
A disease like that makes you change the way you think [regarding vaccination]’ (Q32PL2).
6. Health authorities
Many participants put forward that doctors do not always agree on the use of preventive 
measures during pandemics. National Public Health Institutes were frequently mentioned 
as being trust- worthy and reliable sources of information during Dutch (Q33) and Swedish 
discussions, but not mentioned in the Polish discussions. Instead, participants complained 
about the status of the public health system in Poland (Q34). 
‘If the outbreak is as severe as you describe just now, the RIVM [National Institute for Public 
Health and the Environment in the Netherlands] needs to play an active role, and inform us, 
instead of us being dependent on subjective information’ (Q33NL2).
‘Prevention is more common there [in the West of Europe]. Maybe they feel protected by the 
state more. We don’t have that comfort’ (Q34PL1).
Polish participants were sceptical and distrustful when discussing their government, while 
the Swedish groups frequently discussed their trust in government and the tendency to 
obey the government, in spite of the decrease in trust since the H1N1 pandemic (Q35, Q36). 
They also mentioned the lack of trust in the government elsewhere.
‘You were really taken by surprise: My God, the state has given us something that was not 
good. You’re not used to it, after all’ (Q35SE2).
‘During the swine ﬂu days, the initial stand on the vaccine was: Everyone should take it, and 
it’s safe, we’re all going to die, so you have to get vaccinated. And then suddenly it changed: 
No, no, Sweden has signed an agreement about this vaccine. We [the Swedish nation] had to 
buy it, which meant that they [the pharmaceutical companies] wanted to sell it, and then it 
turned out that it had not actually been tested. I think that is crazy’ (Q36SE2).
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All groups discussed that people would want to make money on new vaccines. These 
expectations inﬂuenced participants’ opinion on getting vaccinated negatively, although 
several Dutch and Swedish participants tended to trust and defend their governments:
‘I cannot keep on being so terribly sceptical. . . I have decided that there are some government 
bodies that you trust. Otherwise I would probably feel that there is no point that they exist’ 
(Q37SE1).
In both Dutch discussions, the advantages of international cooperation regarding the 
outbreak and vaccination were put forward.
DISCUSSION
We explored public opinion and attitudes regarding vaccination during future pandemics 
and possible national differences by conducting FGDs in three European countries: the 
Netherlands, Poland and Sweden. Participants stated that they would base their vaccination 
decision on trade-offs between perceived benefits and barriers of the vaccine, also taking 
into account the seriousness of a new pandemic outbreak. Except for those who belong to a 
risk group, most participants in the present study expected a low infection risk, resulting in a 
lower willingness to get vaccinated. A questionnaire study on seasonal Inﬂuenza vaccination 
coverage and reasons to refrain among high-risk persons in four European countries, 
including Poland and Sweden [18] showed that individuals did not perceive themselves as 
susceptible to seasonal Inﬂuenza either. During future outbreaks, it is therefore necessary 
to provide the public with information regarding the health status of first cases, especially 
when also young and healthy people are infected, with information about the general level 
of susceptibility and a specification of which groups are considered vulnerable and are 
thus being targeted for vaccination. The displayed concerns regarding the safety of newly 
developed vaccines were also observed in a Canadian focus group study [4]; people were 
hesitant to accept vaccines during future pandemics due to the perceived uncertainties 
considering novel vaccines and seriousness of disease.
Importantly, some differences between European countries were observed that have 
implications for outbreak preparedness. We did observe differences in adherence to social 
norms and rules. Whereas Swedish participants displayed a tendency to do the right thing 
and to get vaccinated to protect others, this appeared much less prominent in the Dutch 
and Polish participants. In countries where there is a culture to follow social norms, such 
as in Sweden, communication might focus more on the social norm, e.g. by providing 
normative information, both descriptive (perception of the proportion of people opting for 
vaccination) and injunctive (perception of what is approved or disapproved by others) [19–
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21]. Trust in health authorities (or lack thereof) has implications for outbreak planning too. 
Dutch and Swedish participants displayed more trust in both health professionals as well as 
in national governments than Polish participants. This was also observed in a survey during 
the Inﬂuenza A/H1N1 2009 pandemic [22]. These different levels of trust have implications 
for the promotion of and response to public health messages from national governments 
and their public health agencies [23–26]. The lack of trust in e.g. statements issued by 
the national government can be problematic, since this has been linked to a reduction in 
vaccination behaviour [23, 25, 27, 28].
It is important to build trust in the pre-outbreak phase, maintain trust during outbreaks 
and, if necessary, restore or further develop trust after the pandemic ends [29,30]. To do so, 
reliable and trusted local representatives of the medical community need to communicate 
clear public health messages regarding the new outbreak and preventive measures. Swedish 
participants indicated that their experiences during the Inﬂuenza A/H1N1 2009 pandemic 
would reduce their tendency to accept vaccination advice. These discussions may be rooted 
in the Swedish government having signed a contract with a pharmaceutical company to 
buy pandemic Inﬂuenza A/H1N1 vaccines years before the outbreak [31] and the high 
incidence rates of narcolepsy following the Inﬂuenza A/H1N1 2009 pandemic, suggesting 
an association with vaccination [32, 33]. The seasonal Inﬂuenza vaccination coverage in 
Sweden decreased since the Inﬂuenza A/H1N1 2009 pandemic; it was 65.8% in 2008–2009 
but decreased to 44.3% in 2012–2013 [34]. Combined with the Polish participants being 
proud that their Minister of Health had not bought vaccines during the Inﬂuenza A/H1N1 
2009 pandemic, these findings confirm what Börjesson et al. concluded in 2013; previous 
experiences with outbreak situations play a crucial role in public opinions and future 
behaviour. Our study highlights that outbreak experiences differ between countries in many 
dimensions: with regard to cultural differences, with regard to government policies, and 
with regard to vaccination side effects (narcolepsy in Sweden). These differences stress the 
need to adapt communication strategies to local circumstances.
Although efforts to include individuals of different gender, age and educational level 
were successful, there might still be responder bias; individuals who participated might 
be particularly interested in the topic. This paper provides an illustration of opinions and 
attitudes regarding future pandemics and vaccination among members of the general public 
in three different European countries. Future research could also focus on opinions and 
attitudes of health care workers across European countries because of the example they 
represent for public opinion. Vaccination history as well as intentions of the general public to 
be vaccinated are positively associated with recommendations by health care workers to do 
so [35]. Conclusions drawn from this study should be considered with some caution as the 
findings are based on a small number of individuals, and may therefore not be generalizable 
to populations at large. In addition, we cannot exclude the possibility that some of the 
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observed differences relate to individual differences rather than to differences between 
countries. However, as there is hardly any research examining differences in opinions and 
attitudes regarding pandemics and vaccination across Europe, our results can be seen as a 
first step in this process.
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ADDITIONAL FILE 1: BEHAVIOURAL MODELS
 
We selected the Health Belief Model (HBM) [1] to create the focus group discussion guide 
because of its large empirically tested ability to explain and predict intention of complying 
with preventive medical care recommendations [2, 3]. 
The basic idea underlying the HBM (Figure 1) is that people react to a perceived threat, 
in this case a new pandemic outbreak, by performing some action. The perceived threat 
depends on both the perceived susceptibility to the disease (a person’s perception of the 
chance that he/she will contract the disease) and the perceived severity of the disease (a 
person’s belief on how serious contracting the disease would be for him/her, both medical 
and social consequences). According to the HBM model, people weigh this perceived 
threat to the perceived benefits of actions (beliefs regarding the effectiveness of preventive 
measures in reducing the disease threat) and to the perceived barriers of actions (potential 
negative aspects of the preventive measures). The HBM posits that prevention is more likely 
if there is a high threat, if people believe an available action will reduce their susceptibility 
or severity of the condition and if the barriers to actions are outweighed by the benefits. 
If perceived severity and susceptibility are low, people will not perceive the disease as 
threatening and will consequently not be inclined to act. Besides weighing the perceived 
threat to the perceived efficacy of the vaccination program, the HBM states that ‘cues to 
action’ (strategies to activate readiness) are affecting someone’s intention as well. These 
cues can either be internal (e.g. symptoms) or external (e.g. mass media campaigns, advice 
from others, illness of family member of friend, newspaper or magazine article, reminder)). 
Furthermore, according to the HBM the decisions people make are also dependent on 
certain variables that can be classified as: demographic (age, sex, race, ethnicity, etc.) and 
social psychological (personality, social class, peer and reference group behaviour, etc.) and 
structural (knowledge about the disease, prior contact with the disease).
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Figure 1 | Overview of Health Belief Model [1], adapted for the current study to new pandemic 
outbreaks.
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We also incorporated two concepts from other theories: 1) ‘self-efficacy’ (a person’s level of 
confidence in his/her ability to perform the preventive measure) from Protection Motivation 
Theory [4] and Bandura’s Social Cognitive Theory [5], and 2) emotions and affect which play 
a role in decision making [6, 7], also when deciding on prevention for infectious disease 
outbreaks [8].
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ADDITIONAL FILE 2: FOCUS GROUP QUESTION ROUTE
Request for the discussion leader: 
Ask the participants to sign and hand in the informed consent form.
Ask the participants to write their first names on the nameplates. 
---
Topic list, to be discussed during the focus group discussion: 
Welcome
• Welcome to this focus group discussion about vaccinations. Thanks for coming! 
• My name is … and I will lead the discussion today. Next to me is …, a researcher at 
… and she will assist me today.
Introduction by researcher
• Why do we do this study? It could be that there will be an outbreak of a new 
contagious disease in the future. Then, it’s important to know whether people 
are willing to get vaccinated against this disease. It’s also important to know what 
reasons people may have to get vaccinated or not. 
• Goal of today: discuss people’s opinions about vaccination and whether they are 
willing to get vaccinated against a new contagious disease. We are interested in 
your opinions as … citizens. So for tonight, imagine that you are living in … again. 
Practical
• Rules: everybody is free to give their opinion. There is no need to reach consensus. 
My role is limited; I will only lead the discussion, you will discuss as a group. 
• I would like to ask you to keep everything that will be said today confidential.
• The discussion will be recorded by using a voice recorder, so that we know what 
has been said literally later. When analysing the discussion, this will be done 
anonymously, no names will be mentioned. 
• What does this meeting look like? The discussion will last for approximately 2 
hours. Halfway, there will be a short break from 5 to 10 minutes. You’ll first discuss 
the new contagious disease. Thereafter you will discuss about a vaccination against 
this new disease. 
• Are there any questions before we’ll start?
[Turn on the voice recorder]
---
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We’ll start with a short introduction:
• What is your name and the reason that you are participating today? 
1) Is there anyone who can remember it: what was the last vaccination you got? 
a. Which vaccination was it? When was it? 
b. What were reasons for you to get vaccinated then? 
From now on, we’ll focus on vaccinations against new contagious diseases. 
Imagine a new contagious disease emerged abroad. People already died of the disease 
there. People got sick in … as well, but no one died yet. 
2) What would you like to know about this disease? And why? 
3) Are you actively going to search for information? Where are you looking for this 
information? 
4) Which media do you use to search for information about this new disease? 
5) How would you like to get informed about the new disease?
6) Who needs to give this information? 
7) Are you afraid to get sick? Why do you? Why don’t you? 
8) Will you look for preventive measures you can take against the disease? Which 
measures? 
Imagine a vaccination has to be produced against this new disease.
9) Some people only get vaccinated if they think the vaccination is ‘good’. What do 
you think is a good vaccine/ when do you think a vaccine is ‘good’? What attributes 
does the vaccine need to have?
10) How much would you like to pay for the vaccination? 
11) What role does the price play in your decision to get vaccinated or not? 
We’ll have a short break of 5 – 10 minutes. We’ll start again at…. pm.
After the break:
Now imagine that the vaccine has been produced and you are eligible to get a vaccine as 
well. 
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12) Will you be informed of this? If yes, by whom will you be informed? 
13) Will you be going to ask for advice before deciding about uptake of the vaccine? If 
yes, whom would you ask? And what do you do with this advice? 
14) Do you take the decision to get vaccinated only based on facts? If no, what is also 
important? 
15) Do your previous experiences with vaccinations inﬂuence the decision you have to 
make now? 
Imagine a person that is really important for you has already been vaccinated.
16) Does this affect your own decision, and if yes, how? 
Imagine, you’ve searched for information about the disease and the vaccine and you 
discussed about the vaccine with your friends and family. If you have decided to get 
vaccinated, you have an opportunity to do this tomorrow.
17) Is there anything that can stop you from getting vaccinated? If yes, what?
18) What practical matters are important now? 
We will now discuss a couple of situations. 
Scenario 1: All over the world more people get sick and more people are dying from the new 
disease. Also in …, more people are getting sick. The first … person died. 
19) The situation has changed. What does this change mean for you? 
Scenario 2: The whole world is under the spell of the new disease. More people died in … as 
well, because of the disease. Also a healthy … girl died. 
20) The situation has changed. What does this change mean for you? 
Scenario 3: Now, also someone in your close circle got infected with the new disease. It is 
unclear if he or she will survive. This person wasn’t vaccinated against the new disease.
21) The situation has changed. What does this change for you? 
22) What if this person has been vaccinated, but still contracted the disease? 
All the previous questions were about a vaccination for you. You now have to decide if you 
want your child to get vaccinated against the new disease. If you do not have children, 
please imagine for now that you have. 
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23) What (other) reasons are important now, when you need to decide if your child 
gets the vaccination or not? 
Until now, we discussed about what you would do if a new contagious disease will break 
out. Now, think back at the Mexican ﬂu (or swine ﬂu, or H1N1) outbreak from a couple of 
years ago. Remember, we are talking about the … situation. 
24) Were you worried to get sick then? Why? Why not? Did anyone in your close circle 
got sick of H1N1?
25) What did you think of the information available about the H1N1 and the precautions 
that you could take against the H1N1?
26) What did you do to avoid getting the H1N1? 
27) The last question: Do you think there are differences between … and other 
European countries in how people react to a new disease and in reasons to get 
vaccinated or not? If yes, what are those differences? Also think about differences 
in which things are organized. 
---
Requests for discussion leader: 
Ask the participants if they have anything to add to the things that are said today?
Ask the participants if they have other questions or remarks about the discussion? 
[Turn off the voice recorder] 
End the conversation. Thank the participants for their participation. 
Ask the participants to fill in the questionnaire.
Distribute the gift vouchers. Ask the participants to sign after receiving the voucher. 
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ADDITIONAL FILE 3: FINAL CODING TREE
1. Pandemic outbreak 
a. Perceived seriousness of contracting the disease 
b. Perceived susceptibility of contracting the disease
2. Vaccination
a. Perceived benefits of vaccinations
b. Perceived barriers to vaccinations 
3. Social inﬂuences
a. Mass media
b. Advice from others
c. Illness of friends and family
d. Peer behaviour
4. Population characteristics
5. Prior contact with similar diseases and vaccinations
6. Health authorities (health care practitioners, researchers, pharmaceutical 
companies, Institutes of Public Health, Ministry of Health, International 
Organizations, such as WHO).
4
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ABSTRACT 
This study aims to quantify and compare preferences of citizens from different European 
countries for vaccination programme characteristics during pandemics, caused by 
pathogens which are transmitted through respiratory droplets. Internet panel members, 
nationally representative based on age, sex, educational level and region, of four European 
Union Member States (Netherlands, Poland, Spain, and Sweden, n = 2,068) completed an 
online discrete choice experiment. These countries, from different geographical areas of 
Europe, were chosen because of the availability of high-quality Internet panels and because 
of the cooperation between members of the project entitled Effective Communication in 
Outbreak Management: development of an evidence-based tool for Europe (ECOM). Data 
were analysed using panel latent class regression models. In the case of a severe pandemic 
scenario, vaccine effectiveness was the most important characteristic determining 
vaccination preference in all countries, followed by the body that advises on vaccination. In 
Sweden, the advice of family and/or friends and the advice of physicians strongly affected 
vaccine preferences, in contrast to Poland and Spain, where the advice of (international) 
health authorities was more decisive. Irrespective of pandemic scenario or vaccination 
programme characteristics, the predicted vaccination uptakes were lowest in Sweden, and 
highest in Poland. To increase vaccination uptake during future pandemics, the responsible 
authorities should align with other important stakeholders in the country and communicate 
in a coordinated manner.
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INTRODUCTION 
In the past 100 years, there have been several large-scale influenza outbreaks with worldwide 
impact. These include the 1918 influenza A(H1N1) pandemic that caused between 50 and 
100 million deaths particularly in many healthy young adults [1], and more recently the 
2009 influenza A(H1N1)pdm09 pandemic [2]. Though characteristics (such as clinical attack 
rates and pathogenicity) and occurrence of a next influenza pandemic are unpredictable, 
experts agree there will be future influenza pandemics [2-5].
The World Health Organisation (WHO) urged countries to develop or update national 
influenza preparedness plans in response to the avian influenza A(H5N1) pandemic threat 
in 2005 [6]. Such plans subsequently needed to be improved taking into account the lessons 
learnt from the response to the influenza A(H1N1)pdm09 pandemic [4,7,8]. In addition, 
countries could learn from each other by sharing information and best practices [9].
Preventive measures are very important in limiting the spread of an influenza pandemic [10-
12] and if available, vaccination constitutes the control cornerstone [13,14]. The success of 
mitigating influenza pandemics depends on many factors, including national public health 
policies and the availability of vaccines, vaccine effectiveness, and the public’s willingness 
to get vaccinated. Unfortunately, vaccination coverage has proven to be (too) low across 
Europe during the influenza A(H1N1)pdm09 pandemic. Vaccination coverage among the 
general public of the European Union, Norway and Iceland, varied between countries from 
0.4% to 59% [15].
Countries within Europe differ from each other with regard to languages, cultures, public 
trust in health authorities, health system infrastructures, and public health capabilities and 
capacities. Research has shown that implementing international guidelines at the local level 
can be a complex process [16]. Having insights into country-specific reasons to accept or 
decline pandemic influenza vaccination can facilitate the adaptation of preparedness plans, 
including vaccination strategies, to the local situation [17].
Thus far, only a limited number of reports have focused on the comparison of pandemic 
influenza vaccination preferences between people of different European countries [18,19], 
and formal quantitative techniques such as discrete choice experiments (DCEs) [20,21] 
have not yet been used. The primary aim of this study was to quantify and compare the 
preferences of European citizens for vaccination programmes for future pandemics. Although 
we focus on influenza pandemics, we quantified vaccination programme preferences for 
any emerging or re-emerging large-scale infectious disease outbreak that spreads through 
respiratory droplets. Our findings might therefore also be applicable to other respiratory 
infections than influenza, such as, for example, severe acute respiratory syndrome (SARS)-
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coronavirus (CoV) or Middle East Respiratory Syndrome (MERS)-CoV, should vaccines be 
available for these viruses in the future. A secondary aim was to calculate the expected 
uptake of vaccination under different pandemic scenarios. The approach and results might 
help health policymakers to improve pandemic preparedness plans and communication 
strategies, in order to make future vaccination programmes more successful.
METHODS
Study population
We surveyed a representative sample of the general public (age 18 years and over) of 
countries from different parts of Europe: eastern Europe (Poland), northern Europe 
(Sweden), southern Europe (Spain) and western Europe (Netherlands). These countries 
were chosen because of the availability of high-quality Internet panels (i.e. panels that are 
ISO certified and/or follow international quality standards for market research) and also 
because of the cooperation between project members of different work packages within 
the Effective Communication in Outbreak Management: development of an evidence-based 
tool for Europe (ECOM) project (www.ecomeu.info). The public health policies of the four 
included countries with respect to seasonal influenza and influenza A(H1N1)pdm09 are 
described in Table 1.
Discrete choice experiments
A DCE is a survey-based stated-preference methodology that originates in mathematical 
psychology [22]. The method has been increasingly used in healthcare, whereby the number 
of published DCEs has increased from a mean of three per year in the period from 1990 to 
2000 to 45 per year between 2009 and 2012 [23]. In a DCE, the relative importance of 
characteristics (i.e. attributes) of a certain product or intervention is assessed by presenting 
a series of choice sets to respondents [20,21]. In each choice set, respondents are asked 
to choose a preferred alternative from a set of two or more hypothetical product or 
intervention alternatives with systematically varying attribute levels [20,21].
Survey
The survey started with an explanation of the DCE exercise. Next, respondents were asked 
to imagine that a large-scale emerging infectious disease, that started abroad, had spread 
to the country they lived in. It was stated that the disease spreads through respiratory 
droplets, that it was vaccine-preventable, and that vaccines were available in their country. 
Respondents then completed a series of choice sets, followed by questions about socio-
demographic characteristics (including previous vaccination experiences), and questions 
that assessed the perceived difficulty of the survey. The survey ended with an open question 
in which respondents were given the opportunity to comment on the survey.
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In each choice set, a hypothetical pandemic scenario based on two disease variables 
(susceptibility to the disease (i.e. a number of 1,000 people will get sick) and severity of 
the disease (i.e. a number of the sick people will develop severe symptoms) was presented. 
Respondents were then asked to choose between three alternatives: no vaccination, 
vaccination A, and vaccination B. The vaccination was described by several attributes, and 
the presented levels differed systematically between vaccination A and vaccination B. In 
the following choice sets, both the pandemic scenario and the presented attribute levels 
for vaccination A and B differed. In order to select realistic, relevant and understandable 
attributes and attributes levels, we conducted a literature study, expert interviews, and 
focus group discussions. In addition, we closely cooperated with project members when 
selecting the attributes and levels. PubMed, Embase and Psychinfo were strategically 
searched for relevant research articles on vaccination preferences. Expert interviews (n = 9) 
were conducted with both national and international experts (physicians, researchers, 
policymakers) in the field of infectious diseases, vaccinations, preventive behaviour, 
and implementation of prevention. We conducted eight focus group discussions with 
representatives of the general population, of which four in the Netherlands, two in Poland, 
two with Spanish citizens during their temporary stay in the Netherlands, and two in 
Sweden. Eligible participants were recruited by research companies and via our network, 
using purposive sampling to ensure a diverse sample. The focus groups revealed that 
similar vaccination programme attributes and attribute levels could be included in the 
DCE for all countries (Table 2). It is not feasible to present a single respondent with all the 
possible combinations of the included attribute levels. We therefore generated a subset 
of 48 choice sets by minimizing the D-efficiency criterion using the software programme 
Ngene (ChoiceMetrics, version 1.1.1). The 48 choice sets were grouped in three different 
survey versions such that each block has (near) attribute level balance. Each respondent 
thus needed to answer 16 choice sets. For more information on this part of a discrete choice 
experiment, see e.g. Reed Johnson et al. [24].
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Table 2 | Attributes and attribute levels included in the survey investigating public preferences for 
vaccination programmes during pandemics caused by pathogens transmitted through respiratory 
droplets, Netherlands, Poland, Spain, and Sweden, 2013 (n = 7 attributes).
Pandemic scenario variables1 Levels
Susceptibility to the disease2 5%, 10%, 20%
Severity of the disease3 5%, 25%, 50%, 75%
Vaccination programme attributes4 Levels
Effectiveness of the vaccine 30%, 50%, 70%, 90%
Safety of the vaccine5 Unknown, expected to be safe (reference level)
Unknown, no experience with similar vaccines yet
Advice regarding the vaccine Family and/or friends recommend vaccination (reference level)
Family and/or friends discourage vaccination
Your doctor recommends vaccination
Your doctor discourages vaccination
Government and National Institute for Public Health 
recommend vaccination
International organizations recommend vaccination
Media attention about the vaccine6 Traditional media positive (reference level)
Traditional media negative
Social and interactive media positive
Social and interactive media negative
Out-of-pocket costs7 €0, €50, €100
Notes: 1The scenario variables were the same for all alternatives in one choice set. 2Defined as the proportion 
of population affected by the emerging disease, i.e. having symptoms. 3Defined as the proportion of the 
infected population that had severe symptoms or outcomes (death, life-threatening events, hospitalisation 
and severe or permanent disability). 4The attributes safety of the vaccine, advice about the vaccine and 
media attention about the vaccine were included in the latent class analysis as categorical variables. 5Safety 
of the vaccine with regard to long-term severe side effects (death, life-threatening events, hospitalisation, 
severe or permanent disability, or side effects leading to birth defects in an unborn fetus). 6Traditional media 
were defined as radio, newspapers and television. Social and interactive media were defined as blogs, Twitter 
and social network websites. 7The levels presented in the Table are the selected levels for the Netherlands. 
Levels for the out-of-pocket costs attribute were converted to local currency of the other three countries and 
adapted according to the Organisation for Economic Co-operation and Development (OECD) price levels of 
May 2013 [26]. Levels of: 0 zloty, 120 zlotys, 240 zlotys for Poland; 0 euro, 45 euros and 90 euros for Spain 
and 0 kronor, 500 kronor, 1,000 kronor for Sweden.
The survey was first developed in Dutch and subsequently tested using think-a-loud inter-
views (n = 5) and a pen-and-paper pilot (n = 29). This resulted in some minor changes to the 
layout and phrasing of the Dutch survey. To be able to use the survey in the other countries, 
some further changes to the survey were made. For example, we adapted country naming, 
and currencies for the cost attribute based on Organisation for Economic Cooperation 
and Development (OECD) comparative price levels [25] of May 2013 [26]. Hereafter, the 
survey was translated into Polish, Spanish and Swedish. A second translator reviewed each 
translated survey. To minimise differences between the original Dutch and the translated 
versions of the survey and to check for inconsistencies, native speakers (speaking Dutch 
and the respective languages) translated each survey back into Dutch. In Spain, Sweden and 
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Poland, we asked 30 respondents per country to complete the adapted and back-translated 
survey online and to give their suggestions for improvement. No suggestions were given. 
More details of the DCE for the current study have been described elsewhere [27].
Data collection
An ISO certified market research company (ISO 26362 [28], ISO 20252 [29], and ISO 14001 
[30]), was hired to administer the online survey. This company used their own panel to 
collect data in the Netherlands, while another company’s panels were used to collect data in 
the other three countries. Both companies follow international quality standards for market 
research [31]. Panel members were emailed an URL to the survey. Quota sampling was used 
to ensure that samples were representative for each country based on age, sex, educational 
level and region. We aimed to have 500 completed surveys per country in order to obtain 
reliable outcomes [32]. All respondents gave informed consent before participating in 
the study and received a small financial incentive in local currency for their contribution 
to the study from the research company. The amount differed per country according to 
what is customary in the given country (e.g. Dutch respondents were paid 2.20 euros). Data 
collection took place between June and September 2013. A declaration of no objection was 
received from the Medical Ethics Committee of the Erasmus MC, University Medical Center 
Rotterdam (MEC-2012-263) after they reviewed the study protocol. According to Dutch 
legislation, the methodology of this study, a survey among volunteers of Internet panels, 
does not fall within the scope of the Medical Research Involving Human Subjects Act [33]. 
Although the aim of the study is of medical nature, respondents are not being subjected to 
any treatment or behavioural adjustments.
Data analysis
The choice observations resulting from the DCE were used to estimate the impact of 
pandemic scenario variables and vaccination programme attributes (independent variables) 
on the respondents’ choices for vaccination or opting-out (dependent variable). A significant 
independent variable in this choice model indicates that the attribute or attribute level 
has a significant impact on vaccination preferences and the sign of the coefficient reflects 
whether this impact has a positive or negative effect. Note that pandemic scenario variables 
could only be included as an interaction effect, as the scenario was the same in the three 
alternatives presented in each choice set. Several types of discrete choice models can be 
estimated. We chose a latent class model, since this is a closed form model (i.e. does not 
rely on complex simulations) that can take the panel nature of the data into account (i.e. 
dependencies between choice observations by a single respondent) [34].
A latent class analysis assumes the existence of subgroups (i.e. classes) of respondents with 
homogenous preferences. The researcher pre-specifies the number of classes based on 
the best model fit using the Akaike Information Criterion (AIC) and sound interpretation of 
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classes. Class membership is latent in that the researcher does not determine who belongs 
to which class a priori. Instead, class membership is expressed by class probabilities that 
may depend on the respondent’s characteristics. In addition to the choice model, we fitted 
a class membership model to test whether class membership is dependent on country of 
residence. Using the output of the class membership model, the class probabilities adjusted 
for country of residence can be calculated.
Calculation of the relative importance of the attributes enables a direct comparison of 
preferences between classes. The percentages represent the proportion of someone’s 
preference (utility) that is based on that attribute. The relative importance can be calculated 
by dividing the difference in coefficient values between the highest and lowest level for a 
single attribute by the sum of the differences of all attributes for that class, considering 
interaction effects [35]. The mean expected uptake of a vaccine per class was calculated by 
taking the exponent of the total utility for vaccination divided by the exponent of utility of 
both vaccination and no vaccination. We were able to calculate these uptakes per country, 
by weighing the class-specific uptake with the class probabilities per country. The relative 
importance of the attributes and the expected vaccination uptake were calculated for 
two pandemic scenarios: a mild scenario in which 5% of the population gets the disease 
(susceptibility to the disease), and 5% of the sick people developing severe symptoms 
(severity of the disease), and a severe scenario in which 20% of the population gets the 
disease, and 75% of the sick people develops severe symptoms.
We used NLogit 4.0 software to estimate the latent class model and SPSS 21.0 software for 
all other analyses, such as chi-squared tests to compare proportions between countries.
RESULTS
Study population
In total 7,272 panel members were invited to participate in the study. Of these, 2,651 started 
the survey (response rates ranged from 29% (627/2,186) for Spanish panel members up to 
63% (677/1,083) for Dutch panel members; Figure 1). Of those who started, 2,068 completed 
the survey, ranging from 73% (510/698) of Swedish panel members up to 82% (512/627) of 
Spanish panel members. The country samples were approximately representative regarding 
age, sex, educational level and region (Table 3). However, compared with national census 
data, lower educated Poles were slightly underrepresented as well as respondents from the 
western region of Spain.
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Figure 1 | Response to the survey to investigate public preferences for vaccination programmes during 
pandemics caused by pathogens transmitted through respiratory droplets, Netherlands, Poland, 
Spain, and Sweden, 2013.
 
Number of panel members who received an 
invitation: N=7,272 
- NL 1,083  - PL 1,730 
- SP 2,186 - SE 2,273 Number of panel members who did not 
respond: N=4,621 
- NL 406 - PL 1,081 
- SP 1,559 - SE 1,575 
Number of panel members that responded to the 
questionnaire (response rate):  N=2,651 (36%) 
- NL 677 (63%)   - PL 649 (38%)  
- SP 627 (29%)   - SE 698 (31%) 
Number of panel members who stopped before 
signing informed consent: N=117 
- NL 19 - PL 40 
- SP 20 - SE 38 
Number of panel members who did not 
complete the whole questionnaire: N=427 
- NL 110 - PL 89 
- SP 88  - SE 140 
Number of panel members excluded due to low 
response quality: N=39  
- NL 12  - PL 10 
- SP 7  - SE 10 
Number of panel members included in the 
analysis (completion rate): N=2,068 (78%) 
- NL 536 (79%) - PL 510 (79%) 
- SP 512 (82%) - SE 510 (73%) 
Abbreviations: NL Netherlands; PL Poland; SE Sweden; SP Spain.
Notes: 1Low response quality was defined as completing the survey in less than 4 min.
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Respondents took a mean of 19 min (standard deviation: 31 min) to complete the survey. 
The majority of the respondents indicated that the survey topic was interesting or very 
interesting (81%; 1,677/2,068), and clear or very clear (74%; 1,528/2,068). A minority of 
respondents (9%; 179/2,068) found the survey hard or very hard to complete (ranging from 
5% (28/510) for Poland to 13% (72/536) for the Netherlands). The proportion of choice 
sets in which the ‘no vaccination’ alternative was chosen was highest in the Swedish 
sample (51%; 4,145/(16*510=8,160)). The proportion of respondents that chose the ‘no 
vaccination’ alternative in all 16 choice sets was also higher in the Swedish sample (27% 
(136/510), p < 0.01) than elsewhere (10% for Poland (52/510) and Spain (54/512), and 11% 
(61/536) for the Netherlands). Additionally, the proportion of respondents that always 
opted for vaccination was lowest in the Swedish sample (16%; 81/510), and highest in the 
Spanish sample (31%; 161/512).
Latent class analysis
Three latent classes, numbered from one to three, were identified (Table 4). The average 
class probability was 0.44, 0.35 and 0.21, for class 1, 2, and 3 respectively. The country 
of residence partly explains class membership, which is an indication for preference 
heterogeneity between countries. Respondents from Poland and Spain had a significantly 
higher chance to belong to class 1 (0.55 and 0.53 respectively, p < 0.01) than respondents 
from other countries, those from the Netherlands had a significantly higher chance to 
belong to class 2 (0.42, p < 0.01), and those from Sweden to class 3 (0.36, p < 0.01).
Irrespective of the class they belonged to, respondents preferred a more effective vaccine 
that is expected to be safe, recommended by others, discussed positively in the media and 
with lower out-of-pocket costs, as can be seen by the positive and negative signs of the 
coefficients. The significant constant in all three classes indicates that, without considering 
any vaccination programme attributes, respondents of class 2 and 3 had a rather negative 
attitude towards vaccination, while respondents belonging to class 1 did not. Almost all 
vaccination programme attributes were significant. The positive recommendation of 
international organisations did not significantly explain preferences of respondents within 
class 3. The coefficient for social/interactive media attention was not significantly different 
from positive traditional media attention for respondents of class 3 (both positive and 
negative social/interactive media attention) and class 1 (only negative social/interactive 
media attention), meaning that social media only marginally influences respondents’ 
preferences for vaccination. Significant interaction effects between both susceptibility to 
and severity of the disease, and effectiveness of the vaccine in all classes indicate that the 
preference for the level of effectiveness of a vaccine is dependent on the seriousness of 
the pandemic. In other words, the more serious the pandemic, while the effectiveness of a 
vaccination remains the same, the more the preference for vaccination increases relative to 
no vaccination.
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Relative importance
In the case of a mild scenario, the two most important attributes for class 2 and 3 were 
advice regarding vaccination and out-of-pocket costs, while effectiveness of the vaccine 
and advice regarding vaccination were the most important attributes for class 1 (Figure 2). 
Although advice regarding vaccination was important irrespective of class membership, 
for respondents belonging to class 3, the advice of friends and/or family and the advice 
of physicians were most important for vaccination choice (based on differences between 
coefficients of advice regarding vaccine), while the advice of both national and international 
health authorities was important for respondents belonging to class 1. Additionally, all 
respondents were more sensitive to advice against compared with advice in favour of 
vaccination. The relative importance of attributes varied with the seriousness of the 
pandemic scenario. Effectiveness was the most important attribute in the case of a severe 
scenario in all the latent classes and not only for respondents from class 1.
Predicted vaccine uptake
Assuming a realistic vaccination programme (i.e. a vaccination that is 70% effective, expected 
to be safe, recommended by family and/or friends, positively discussed in traditional media, 
and without out-of-pocket costs), the mean expected uptake in the case of a mild scenario 
was lowest for Swedish respondents with 43% (220/510; 95% confidence interval (CI): 40–
47%)), followed by 54% (292/536; 95% CI: 51–58%) for Dutch respondents, 62% (318/512; 
95% CI: 59–65%) for Spanish respondents, and highest for respondents from Poland with 
63% (323/510, 95% CI: 60–66%). In the case of a mild scenario, advice regarding the vaccine 
and out-of-pocket costs had a relatively large impact on vaccination uptake in all countries, 
while media attention had little effect on uptake. For example, when out-of-pocket costs 
increased from 0 to 100 euros, the uptake decreased to 32% (163/510; 95% CI: 29–35%) for 
Swedish respondents, followed by 41% (222/536; 95% CI: 38–45%) for Dutch respondents, 
51% (263/512; 95% CI: 48–55%) for Spanish respondents, and 53% (269/510; 95% CI: 49–
56%) for Polish respondents. The uptake rates were expected to increase dramatically in the 
case of a severe scenario with up to 65% (331/510; 95% CI: 61–69%) for respondents from 
Sweden, and 82% (419/510; 95% CI: 80–85%) for respondents from Poland.
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DISCUSSION
Statement of principal findings
In the case of a severe pandemic scenario, vaccine effectiveness was the most important 
characteristic determining vaccination preference in all countries. The body that advises a 
vaccine was found to strongly affect preferences in all countries as well, with respondents 
being more sensitive to advice against compared with advice in favour of vaccination. 
Preference heterogeneity between countries was substantial, especially in the case of a mild 
pandemic scenario; a strong effect on vaccine preferences was found for the advice of family 
and/or friends and the advice of physicians in Sweden, in contrast to Poland and Spain, where 
the advice of (international) health authorities was more important. Besides the vaccination 
advice, out-of-pocket costs were important for Dutch and Swedish respondents, while for 
respondents from Poland and Spain the effectiveness of the vaccine was important in case 
of a mild pandemic scenario. Irrespective of pandemic scenario or programme attributes, 
the predicted vaccination uptakes were lowest in Sweden, and highest in Poland.
Strengths and weaknesses of the study
So far, only a limited number of healthcare-related DCEs have quantitatively compared 
preferences between respondents from different countries and this is, to our best 
knowledge, done for the first time in the field of infectious diseases. An additional strength 
is the advanced analysis technique we used in this study. While already used extensively in 
the field of transport economics, latent class analysis has been used for only 3% of all health-
related DCE analyses conducted between 2009 and 2012 [23]. A possible weakness of our 
study is that the preferences are stated and based on hypothetical pandemic scenarios. 
Respondents might have given socially desirable responses. It is not known to what extent 
the stated preferences differ from preferences during an actual pandemic. However, the 
external validity of the DCE method has been studied in other health related contexts, and 
results are encouraging with respect to prediction of preferences on an aggregate level 
[36,37]. In addition, the hypothetical nature of the study enabled us to compare preferences 
between different possible future pandemic scenarios. The findings might thus help to 
prepare for a future pandemic. Additionally, all coefficients had the expected sign, which 
suggests theoretical validity of the DCE [38]. Another possible weakness is the complexity of 
the choice sets, due to inclusion of risks as attributes. However, we thoroughly pilot tested 
the survey and, during the online survey, only a minority of respondents stated that they 
experienced problems completing the choice sets.
Results in relation to other studies
Our study showed that the expected vaccination uptake is largely dependent on the 
seriousness of a pandemic. This was also shown in previous studies, including studies 
conducted in the Netherlands, Poland, Spain and Sweden [39-45]. During the influenza 
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A(H1N1)pdm09 pandemic, the perceived vulnerability was low and respondents believed 
that they were less likely to become infected than other people [41,46]. This might have been 
one of the reasons for the lower than expected uptake during that pandemic with overall, 
30%, 27% and 59% of the Dutch, Spanish and Swedish population respectively, having been 
vaccinated (Table 1). Interestingly, we found that Swedish respondents were least willing 
to get vaccinated in future influenza pandemics, both in mild and severe scenarios. As 
previous experiences are likely to influence future vaccination uptake [45], the difference 
between our study results and actual influenza A(H1N1)pdm09 vaccination coverage might 
be assigned to the negative experiences Swedish citizens had with vaccination during the 
2009 pandemic. In Sweden, the controversy on the association between pandemic vaccines 
and narcolepsy is still ongoing [47]. In addition, Swedish respondents in the current study 
less often had received seasonal influenza vaccination in the previous year compared with 
e.g. Dutch respondents (41% vs 65%, Table 3). Research, conducted in the Netherlands, 
has shown that trust in health authorities is related to pandemic influenza vaccination 
uptake [48] and that it is necessary to build up and sustain trust before, during and after 
an influenza pandemic [16]. Furthermore, during the influenza A(H1N1)pdm09 pandemic 
Dutch and Swedish participants had more trust in healthcare professionals compared with 
Polish and Spanish participants [18]. Our research shows the same inter-country differences. 
Poland did not implement a national vaccination programme during the influenza A(H1N1)
pdm09 pandemic [15,44] (Table 1). Seasonal influenza vaccination coverage is reported to 
be less than 10% for the target population older than 55 years [49]. Reported reasons for the 
Polish public to reject influenza (both seasonal and pandemic) vaccination include the low 
level of confidence in the quality and effectiveness of the vaccine [18,50]. Our finding that 
effectiveness of a pandemic vaccine had by far the strongest effect on vaccination choice 
of Polish respondents, confirmed this. The lowest seasonal influenza vaccination coverage 
contrasts with our finding that Polish respondents were more willing to get vaccinated 
than respondents from other countries. However, in our study, the level of effectiveness 
of the vaccine was presented to respondents as a known rate, which might explain why 
we estimated a higher vaccination uptake. Safety of the pandemic vaccine was not as 
dominant in the current study as in other studies [39,40]. The choice of attribute levels for 
our DCE might explain this difference in relative importance. We included realistic attribute 
levels, instead of presenting a certain vaccination risk (e.g. 1 in 100,000) to respondents. 
We also analysed safety as an interaction with the pandemic scenario variable ‘severity of 
the disease’, but with no meaningful outcome. We found almost no effect of social media 
attention (compared to traditional media) on pandemic vaccination preferences and 
predicted uptake. The objective framing of this attribute in the DCE survey might explain the 
finding. However, social media will likely be influential in future pandemics in other ways, 
e.g. by creating online applications that provide credible health information [51].
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Implications for clinicians and policymakers
Our results show that seriousness of a pandemic influences vaccination uptake dramatically. 
In order to increase pandemic vaccination coverage, it is essential that susceptible people 
feel susceptible and perceive the pandemic as a serious threat. This can be achieved, for 
example, by honest and open communication regarding the seriousness of the pandemic, 
and avoiding conflicting messages and information overload [17,52] and by providing public 
health messages that include descriptive and injunctive normative information [53,54]. 
The WHO Regional Office for Europe and the European Centre for Disease Prevention and 
Control (ECDC) recommend more flexible pandemic preparedness planning, i.e. planning 
that takes into account different pandemic scenarios [8,9,19]. Findings of our study may 
facilitate responses to future influenza pandemics with different levels of severity, as 
our study provides the option to calculate the expected vaccination uptake for different 
pandemic scenarios, and provides insights into how several vaccination programme 
attributes influence these uptakes. Additionally, our study also shows that the availability 
of an effective pandemic vaccine is of paramount importance in order to reach certain 
coverage levels. Unfortunately, such a highly effective vaccine might not be available due to 
the crisis situation that is inherent to a pandemic, or proof that the vaccine is effective might 
be lacking as time is usually limited. In addition, due to contracts or limited availability of 
vaccines, there are usually only one or two different vaccines available for policymakers to 
choose from. For all countries, given the high impact of vaccine effectiveness on vaccination 
preferences, it is therefore important that there is open communication regarding the 
expected effectiveness, so that the public can make an informed choice whether to get 
vaccinated or not. The vaccination programme attributes that can be influenced by 
policymakers directly are out-of-pocket costs and how/what to communicate. As our results 
show that by whom a vaccine is advised had a different effect on uptake in the included 
countries, it is important that during future pandemics the responsible authorities align with 
other important stakeholders in the country and communicate in a coordinated manner.
Unanswered questions and further research
We found differences in preferences for pandemic vaccinations between difference 
European countries. Further research could focus on differences within these countries, 
e.g. whether preferences of those who previously received seasonal influenza vaccination 
differ from preferences of those who had not, as previous research shows that the uptake 
of seasonal influenza vaccination was positively associated with influenza A(H1N1)pdm09 
vaccination decision-making [39,55,56]. Additionally, future research could focus on 
subgroups of the population, such as healthcare workers or under-vaccinated groups. It 
is unknown whether preferences differ between countries within the same geographical 
area of Europe. Therefore, it might be useful to conduct the same DCE in other European 
countries as well. Unfortunately, timely access to vaccinations is not self-evident [57]. It 
is not known in advance which respiratory pathogen will cause a next pandemic and 
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production capacities might be inadequate. In the case of an influenza pandemic, other 
preventive measures such as quarantine, and antiviral drugs might be helpful to limit the 
spread of the virus during the first phase [10]. Further research into preferences for other 
preventive measures, and differences herein across European countries, using the DCE 
methodology is thus recommended. Moreover, the DCE methodology could also be used 
to study motivations and barriers for vaccinations other than pandemic vaccination among 
different countries.
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ABSTRACT
Background: Preventive measures are essential to limit the spread of new viruses; their 
uptake is key to their success. However, the vaccination uptake in pandemic outbreaks 
is often low. We aim to elicit how disease and vaccination characteristics determine 
preferences of the general public for new pandemic vaccinations.
Methods: In an internet-based discrete choice experiment (DCE) a representative sample 
of 536 participants (49% participation rate) from the Dutch population was asked for their 
preference for vaccination programs in hypothetical communicable disease outbreaks. We 
used scenarios based on two disease characteristics (susceptibility to and severity of the 
disease) and five vaccination program characteristics (effectiveness, safety, advice regarding 
vaccination, media attention, and out-of-pocket costs). The DCE design was based on a 
literature review, expert interviews and focus group discussions. A panel latent class logit 
model was used to estimate which trade-offs individuals were willing to make.
Results: All above mentioned characteristics proved to influence respondents’ preferences 
for vaccination. Preference heterogeneity was substantial. Females who stated that they 
were never in favour of vaccination made different trade-offs than males who stated that 
they were (possibly) willing to get vaccinated. As expected, respondents preferred and were 
willing to pay more for more effective vaccines, especially if the outbreak was more serious 
(€6–€39 for a 10% more effective vaccine). Changes in effectiveness, out-of-pocket costs 
and in the body that advises the vaccine all substantially influenced the predicted uptake.
Conclusions: We conclude that various disease and vaccination program characteristics 
influence respondents’ preferences for pandemic vaccination programs. Agencies 
responsible for preventive measures during pandemics can use the knowledge that out-of-
pocket costs and the way advice is given affect vaccination uptake to improve their plans 
for future pandemic outbreaks. The preference heterogeneity shows that information 
regarding vaccination needs to be targeted differently depending on gender and willingness 
to get vaccinated.
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INTRODUCTION
Worldwide viral infection outbreaks with, e.g. Influenza A(H1N1), SARS and H5N1 avian 
influenza, have been of serious impact in the past [1]. If a new outbreak would occur, 
the global spread is likely to be very rapid due to increased travel and urbanization [2]. 
Extrapolation of the 1918–1920 avian influenza pandemic mortality rates indicates that 62 
million people would be killed if a similar pandemic would happen these days [3]. Preventive 
measures, such as social distancing measures or vaccination programs, are very important 
in limiting the spread of new viruses [4,5]. However, the lack of willingness to act according 
to such measures in crisis situations has proven to be a major issue in the European Union 
[6]. Consequently, it is important to have insights into what motivates individual people 
to decide for or against vaccination. If motivations are known, these can be addressed in 
pandemic preparedness plans and vaccination strategies to increase vaccination rates and 
thus reduce the spread of viral outbreaks. Furthermore, insight in motivations can lead to 
an accurate prediction of the uptake of vaccinations, which is helpful when implementing 
vaccination programs.
Various studies have been conducted to explore reasons why individual members of the 
general public accepted or declined pandemic vaccinations, especially focusing on the 
Influenza A(H1N1) pandemic of 2009 [6–8]. These studies showed that participation in 
vaccination programs is based on weighing the burden of the vaccination (e.g. risk of side 
effects), against its potential benefits (e.g. reduce the risk of infection), in a given context 
(e.g. severity of first cases of the disease). Several European countries reported that public 
perception factors, such as poor confidence in the need for the vaccine and concerns 
about the relatively new vaccine, may have contributed to the low vaccination coverage 
rates during the Influenza A(H1N1) pandemic of 2009 [9]. Despite the presence of studies 
investigating reasons of members of the general public to get vaccinated or not, quantitative 
studies that assess the relative importance of these reasons are lacking. It is precisely this 
information that is needed to make highly effective health care policy plans regarding 
pandemic outbreaks and vaccinations.
The aim of this study is to investigate the preferences of the general population for pandemic 
vaccinations quantitatively. Additionally, we aim to calculate the expected uptake of base 
case vaccination programs for certain hypothetical outbreaks. The current study is conducted 
within the scope of the project Effective Communication in Outbreak Management: 
development of an evidence-based tool for Europe (ECOM, http://www.ecomeu.info/). 
This project aims to develop an evidence-based behavioural and communication strategy 
for health professionals and agencies throughout Europe in case of major outbreaks, by 
integration of social, behavioural, communication, and media sciences.
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METHODS
Ethics Statement
A declaration of no objection was received from the Medical Ethics Committee of the Erasmus 
MC, University Medical Center Rotterdam (MEC-2012-263) after they reviewed the study 
protocol. The methodology of this study, a survey amongst healthy volunteers of an internet 
panel, does not fall within the scope of the Medical Research Involving Human Subjects Act 
(in Dutch: WMO). Although the aim of the study is of medical nature, participants are not 
being subjected to any treatment or behavioural adjustments.
Discrete choice experiments
DCE methodology is a survey-based stated preference technique to quantitatively 
investigate individual preferences. DCEs have been widely used in health care to examine 
stakeholder preferences [10, 11] and have been previously used to examine preferences 
for non-emergency vaccination programs, such as Human Papilloma Virus (HPV) 
vaccinations and seasonal influenza vaccinations [12, 13]. In DCEs, it is assumed that a 
medical intervention, such as a vaccination program, can be described by its characteristics 
(attributes; e.g. effectiveness of a vaccine, safety of the vaccine, and costs of the vaccine). 
Those characteristics are further specified by variants of that characteristic (attribute levels; 
e.g. for effectiveness of a vaccine: 30%, 50%, 70% and 90% effective). A second assumption 
is that the individual’s preference for a medical intervention is determined by the levels of 
those attributes [14]. The relative importance of attributes can be assessed by presenting 
respondents a series of questions in which they are asked to choose a preferred alternative 
from a set of two or more hypothetical intervention alternatives with varying combinations 
of attribute levels [15]. DCEs are based on Lancaster’s consumer theory [16] and random 
utility theory (RUT) [17] which assume that an individual acts rationally and always chooses 
the alternative with the highest level of utility. We followed recent guidelines for good DCE 
practice [18, 19].
Selection of attributes and attribute levels
Only a limited number of attributes and attribute levels can be used in a DCE, since otherwise 
the precision and reliability of the results will decrease. On the other hand, one also needs to 
include all relevant attributes and attribute levels to avoid that respondents make significant 
inferences on omitted attributes or levels [19,20]. 
To obtain insights into possible attributes and their levels to be included in this DCE, we 
conducted a strategic literature search in three databases (searching for literature related to 
DCEs and/or vaccination preferences in PubMed, Embase and PsychINFO), semi-structured 
expert interviews and a focus group study. For the expert interviews, we have spoken to 
nine experts of different relevant fields, e.g. infectious diseases, vaccinations, preventive 
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behaviour and implementation of preventive measures. For the focus group study, we 
conducted seven focus group discussions with the general population from the Netherlands; 
targeting urban populations (two groups); populations of more rural areas (two groups); and 
ethnic minorities in the Netherlands (three groups). Eligible participants were recruited by a 
research company and via the network of a researcher of the department of Public Health of 
the Erasmus MC, University Medical Center Rotterdam, using purposive sampling to ensure a 
diverse sample. Participants were informed that they would receive a financial incentive (40 
euros) for their contribution and to cover travel costs and they were informed that the data 
would be analysed anonymously. All participants gave written informed consent prior to 
the discussions. All focus groups were audio taped, transcribed verbatim and anonymously. 
The transcripts were analysed using thematic analysis using NVivo Software (version 10, 
http://www.qsrinternational.com). The focus group study approach was included in the 
study protocol for which a declaration of no objection was received from the Medical Ethics 
Committee of the Erasmus MC, University Medical Center Rotterdam. We used a topic list 
based on the literature search and on two theoretic models, i.e. the Health Belief Model 
[21] and to a lesser extent the Protection Motivation Theory [22], to structure the focus 
group discussions on outbreaks of new diseases and preventive measures. These models 
assume that people react to a perceived threat, by performing some action. The level of 
threat depends on the perceived susceptibility to a disease and the perceived severity of a 
disease. People weigh this threat to perceived benefits (such as effectiveness) and barriers 
(such as costs) of actions. The model assumes that also other factors influence someone’s 
intention to take some action, such as cues to action (e.g. media attention) and variables 
(age, sex, peer pressure etc.). We used these models as a base for the topic list because of 
their largely empirically tested ability to explain and predict intention of and complying with 
preventive medical care recommendations, including vaccinations [7, 23, 24]. Additionally, 
during the focus group discussions, participants were asked to write down and rank the 
most important reasons for them to get vaccinated during future pandemic outbreaks. 
Using these results and through extensive discussion with ECOM project members, we 
selected two disease specific scenario variables and five vaccination program attributes 
and their corresponding levels (Table 1). For each scenario (which is a combination of the 
susceptibility to the disease and severity of the disease), three alternatives were presented, 
namely (i) No vaccination, (ii) Vaccination A, and (iii) Vaccination B, where the latter two 
are represented by combinations of effectiveness, safety, advice, media and out-of-pocket 
costs. We aimed at selecting a sufficient wide range of attribute levels that are realistic 
now and will remain so in the near future and levels that were relevant to policy as well 
as plausible and understandable for the respondents. Furthermore, for each continuous 
attribute we selected at least three levels to be able to test for non-linear relationships.
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Table 1 | Scenario variables, vaccination program attributes and their levels included in the DCE survey.
Scenario variables Levels
Susceptibility to the disease1 5%
10%
20%
Severity of the disease2 5%
25%
50%
75%
Vaccination program attributes Levels
Effectiveness of vaccine 30%
50%
70%
90%
Safety of the vaccine3,4
 
Unknown, expected to be safe (reference level)
Unknown, no experience with similar vaccines yet
Advice regarding the vaccine3 Family and/or friends recommend vaccination (reference level)
Family and/or friends discourage vaccination
Your doctor recommends vaccination
Your doctor discourages vaccination
Dutch government & RIVM recommend vaccination
International organizations recommend vaccination
Media coverage about the vaccine3 Traditional media5 positive (reference level)
Traditional media5 negative
Social / interactive media6 positive
Social / interactive media6 negative
Out-of-pocket costs €0
€50
€100
Notes: Levels of the no vaccination option were defined as: not applicable (n.a.), no side effects, n.a., n.a., 
€0 respectively. The scenario variables were the same across all alternatives in one choice set. Abbreviation 
used: RIVM = Dutch abbreviation of National Institute for Public Health and the Environment. 1Defined as 
the proportion of population infected with new disease, i.e. having symptoms. 2Defined as the proportion 
of infected population that suffered severe symptoms (death, life-threatening events, hospitalization and 
severe or permanent handicap). 3The attributes ‘safety of the vaccine’, ‘advice about the vaccine’ and ‘media 
coverage about the vaccine’ entered the analysis as categorical variables. 4Long term severe side effects 
(death, life-threatening events, hospitalization, severe or permanent handicap, or side effects leading to 
birth defects to an unborn foetus). Before the start of the choice tasks, respondents were informed that 
on the short term, vaccinations resulted in mild side effects only. 5Traditional media were defined as: radio, 
newspapers and television. 6Social / interactive media were defined as: blogs, Twitter and social network 
websites.
Study design and questionnaire
If all combinations of attribute levels were to be presented in choice sets, this would have 
led to 576 (21 * 31 * 42 * 61) hypothetical vaccination alternatives for 12 (31 * 41) different 
disease outbreaks (scenarios). As it is not feasible to present a single individual with all these 
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scenarios and alternatives (i.e. full factorial design), a subset of scenarios and alternatives 
(i.e. fractional factorial design) was generated [25]. Zero priors for all categorical variables 
and best-guess priors for all linear variables were used to generate an efficient design by 
maximizing D-efficiency (using Ngene software, version 1.1.1, http://www.choice-metrics.
com/). With this design we were able to estimate all main effects and a number of two-way 
and higher order interactions between attributes. Presenting a single individual with a large 
amount of choice sets is expected to result in a lower response rate and/or lower response 
reliability [26]. To reduce the burden on respondents, a blocked design was used [15], which 
resulted in dividing the 48 choice sets of the efficient design into 3 questionnaire versions 
containing 16 choice sets each in which we ensured sufficient variation in attribute levels by 
finding blocks with near attribute level balance.
Each questionnaire started with the introduction of a hypothetical scenario (Additional file 
1). To facilitate comprehension of the DCE task, respondents were provided with detailed 
information about the attributes and attribute levels as well as with a clearly explained 
example of a choice task prior to preference elicitation. The main part of each questionnaire 
comprised 16 choice sets. In each choice set, respondents first received some additional 
information about the disease (i.e., the two scenario variables). Choice sets consisted of 
two unlabelled vaccination alternatives (vaccination A and vaccination B) and one opt-out 
alterative (see additional file 2 for a screenshot of a choice set). This opt-out was necessary 
since, as in real life, respondents are not obliged to take a vaccination. Respondents were 
asked to consider all three alternatives in a choice set as realistic alternatives and to choose 
the option that appealed most to them in the given situation.
Attributes needed to be described as clearly as possible in the choice sets since previous 
research has shown that respondents may have difficulties with interpreting probabilities 
[27] and that framing effects can influence DCE results [28–30]. Therefore, we included 
graphs to demonstrate percentages and rates, used realistic presentation of attributes (e.g. 
integers when discussing rates that included humans), and used cost as the last attribute. 
Furthermore, experts in the field of risk communication advised us on how to present 
the choice sets in this DCE. For example, we were advised to use the same type of graphs 
to present risks across both scenario variables and attributes. The last section of each 
questionnaire included questions on socio-demographic data and questions on previous 
experiences with vaccination. It also contained questions assessing experienced difficulty 
of the questionnaire (five-point scale). The questionnaire was presented to respondents in 
Dutch.
In order to test the survey, we conducted a formal pen and paper pilot with 29 respondents 
in the Netherlands. Additionally, we conducted five think-a-loud interviews [31] to 
qualitatively test for any problems in interpretation, for the understanding of the questions 
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and to indicate whether respondents were providing a meaningful response. This resulted in 
minor changes to the layout and phrasing of the questionnaire. There was no need to adapt 
the selected combinations of scenarios or attribute levels of the DCE design. Since there 
were some adaptations to the questionnaire, data of these pre-tests were not included in 
the final analysis. The questionnaire is available from the authors on request.
To check the convergent validity of the DCE, we asked respondents to rank the five 
vaccination program attributes from most important to least important. External validation 
was not possible since we were using a hypothetical disease outbreak.
Data collection
A market research company (Flycatcher) was hired to administer the online questionnaire 
to a representative sample of the general adult population of the Netherlands. Their online 
panel comprises 16,000 members and is ISO certified (ISO-26363). Recruitment of potential 
new members is done by digital media, paper invitations, face-to-face meetings and via 
intermediates. Assuming a participation rate of 50%, a random sub sample of 1,083 adult 
panel members (see sample size calculation below) was emailed a link to the questionnaire 
to participate in the current study. Quota sampling was used to ensure even distributions 
with respect to age, gender, education and region. A further quota was applied to each 
‘questionnaire version’ to ensure comparable numbers of respondents in each of the three 
blocks of the design. Progress bars and error messages were incorporated to encourage 
completion. After completing the questionnaire, respondents were given the opportunity 
to comment on the questionnaire or topic at hand by filling out the free text question. The 
questionnaire was online for twelve days in June 2013, when the target number of 500 
respondents was reached. All panel members gave informed consent prior to participating 
in the study and received a small incentive (€2.20, in the form of credits) for completion of 
the questionnaire.
Sample size calculation
The mean sample size for DCE studies in health care published between 2005 and 2008 was 
259, with nearly 40% of the sample sizes in the range of 100 to 300 respondents [32]. No 
adequate statistical methods exist to determine sample sizes for DCEs. Therefore, the rules 
of thumb as suggested by Orme [33] are frequently used. These rules recommend sample 
sizes for DCEs to be at least 300 respondents and suggest that also the number of tasks and 
alternatives should be taken into account when determining sample sizes. Based on this 
information, we aimed to have at least 500 respondents completing the questionnaire.
Statistical analysis
To assess preference heterogeneity, we used a latent class model to analyse the DCE data. 
A latent class model [34,35] can be used to identify the existence and the number of 
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segments or classes in the population (i.e. identifying different utility (preference) functions 
across unobserved subgroups). Class membership is latent (i.e., unobserved) because each 
respondent belongs to each class up to a modelled probability and not deterministically 
assigned by the analyst a priori. The model is flexible in that the probability that sampled 
respondents belong to a particular class can be linked to covariates (e.g. age, gender), hence 
allowing for some understanding as to the make-up of the various class segments [34].
To account for the panel nature of the data, with each respondent completing 16 choice 
tasks, we used a panel version of the latent class model. In order to determine the number 
of classes, we selected the model with the best fit. We tested a number of different 
specifications for the utility function (e.g., categorical or numerical attribute levels, linearity, 
two-way interactions between all attributes and several attribute transformations, see 
Additional file 3 for specifications of the functions) and selected the model with the lowest 
Akaike Information Criterion (AIC).
The latent class model estimates parameters in a class assignment model (which includes 
socio-demographic variables and thereby expresses the likelihood of a certain individual 
belonging to a certain class) and class-specific coefficients for each attribute (or interaction 
of attributes and scenario variables) in the utility function. For the class-specific coefficients 
and interactions, the statistical significance of a coefficient (P-value ≤ 0.05) indicated that, 
conditional on belonging to that class, respondents considered the attribute important when 
making stated choices. In terms of the class assignment parameters, statistically significant 
parameter estimates indicate that the covariate can be used to distinguish between the 
different classes. For example, if the covariate male gender is negatively and significantly 
associated with a particular class in the assignment model, then this is indicative that men 
are less likely to belong to that particular class than women.
The sign of the coefficient reflects whether the attribute had a positive or negative effect 
on utility. The value of each coefficient represents the importance respondents assign to 
an attribute (level). However, different attributes utilize different units of measurement. 
For example the coefficient ‘effectiveness of the vaccine’ represented the importance 
per 10% protection rate. When looking at a vaccine that generates a 90% protection rate, 
the coefficient needs to be multiplied 9 times (9 times coefficient of ‘effectiveness of the 
vaccine’ of 10% = coefficient of ‘effectiveness of the vaccine’ of 90%).
We calculated class specific importance scores (IS) to visualize the relative importance 
of a given attribute in that class by dividing the difference in utility between highest and 
lowest level for a single attribute by the sum of the differences of all attributes for that 
class, taking interaction effects into account [36]. An attribute with an IS of 1 represents the 
most important attribute, while an attribute with an IS of 5 represents the least important 
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attribute. Furthermore, we also calculated overall importance scores, by taking class 
probability into account.
Expected uptake of the vaccine
Choice probabilities (mean uptakes) were calculated to provide a way to convey DCE results 
to policy makers that are more easily understandable. We calculated the choice probability 
(i.e. the mean uptake) for a base case vaccination for three given outbreaks by taking 
the exponent of the total utility for vaccination divided by the exponent of utility of both 
vaccination and no vaccination taking the class probabilities into account. The base-case 
vaccination program was chosen to resemble real life situations, and included the following 
attribute levels: vaccine effectiveness 70%, supposed to be a safe vaccine, advised by friends 
and positive traditional media attention, and no out-of-pocket costs. Outbreaks were 
defined as mild, moderate and severe (respectively a susceptibility and severity of 5% and 
5%; 10% and 25%; and 20% 75%).
Trade-offs
We calculated willingness-to-pay (WTP) values for the effectiveness of the vaccine attribute 
for mild, moderate and severe outbreaks (respectively a susceptibility and severity of 5% 
and 5%; 10% and 25%; and 20% and 75%). A WTP value represents how much one is willing 
to pay for a one unit change in the attribute of interest, and is calculated by taking the ratio 
of the derivative of the effectiveness attribute and the derivative of out-of-pocket costs. 
Since effectiveness was included as both a main effect and as part of an interaction effect 
with susceptibility to the disease and severity of the disease, it is necessary to calculate the 
derivatives with respect to all parts of the utility function where the attribute appears [37]. 
Because a latent class model was used, overall WTP measures can be calculated by weighing 
the conditional WTP values by the probability that respondents belong to a given class. We 
computed the confidence intervals using the Krinsky and Robb procedure [38] (additional 
file 3).
We used NLogit 4.0 software (www.limdep.com) to estimate the latent class models and SPSS 
21.0 software (http://www-01.ibm.com/software/analytics/spss/) for all other analysis.
RESULTS
Respondents
The participation rate was 677/1083 (63%, Figure 1), which reflected the expected response 
rate for this online panel. Of the 677 respondents, 548 completed the questionnaire. 
Respondents who completed the questionnaire did not differ regarding sex (p = 0.11) or 
educational level (p = 0.11) compared to respondents who did not complete the questionnaire. 
Chapter 5  |  127 
However, respondents who completed the questionnaire were younger (median age 50 vs. 
53, p,0.01). Twelve respondents were excluded from the analysis, because they completed 
the questionnaire too quick; they completed the whole questionnaire in less than five 
minutes. Data of 536 (49%) respondents were included in the analysis.
Figure 1 | Overview of respondents accessing the study.
 
1083 panel members 
received an invitation 
406 did not respond 
677 (63%) panel members 
responded to the questionnaire 
19 stopped before signing informed consent 
110 did not complete the whole questionnaire 
536 (49%) questionnaires were 
included in the analysis 
12 removals due to low response quality 
Respondents had a median age of 50 years (interquartile range (IQR): 35–64), with a 
minimum of 18 and a maximum age of 89 years old (Table 2). 30% had a high educational 
level and 22% of the respondents indicated that they had a positive attitude regarding 
vaccination, i.e. that they would always get vaccinated. The sample was representative for 
the Dutch population regarding age, gender, educational level and region.
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Table 2 | Characteristics of respondents who completed the DCE survey (N=536).
Characteristics Subcategory Sample statistics CBS statistics
Median IQR
Age in years 50 35-64
n % %
Age groups 18-24 years 49 9.2 11
25-34 years 78 15 16
35-44 years 84 16 19
45-54 years 107 20 19
55-64 years 92 17 16
> 65 years 126 24 19
Gender Male 289 54 49
Country of birth Netherlands 517 96 -
Educational level Low 184 34 34
Average 192 36 40
High 160 30 26
Civil status Married 296 55 -
Registered partnership 48 9.0 -
Unmarried 133 25 -
Divorced 38 7.1 -
Widow / widower 21 3.9 -
Children Yes 345 64 -
Income in euros per year Minimal (< 11.000) 37 6.9 -
Less than modal (11.000-23.000) 69 13 -
Modal (23.000-34.000) 127 24 -
1-2 times modal (34.000-56.000) 103 19 -
2 times modal or more (>56.000) 78 15 -
Do not know / do not want to say 122 23 -
Religion Yes 244 46 -
Perception of health Lower health than average 41 7.6 -
Medium health 195 36 -
Better health than average 300 56 -
Attitude regarding 
vaccination
Always get vaccinated 120 22 -
Only if benefits > harms 259 48 -
Only if benefits > harms, but I do 
not think this is the case in the real 
world
116 22 -
Never get vaccinated, even if 
benefits > harms
41 7.6 -
Belongs to target group for 
seasonal ﬂu vaccine
Yes 239 45 -
No 270 45 -
No, but receives ﬂu vaccination via 
work
27 5.0 -
Belongs to the target group 
and received seasonal ﬂu 
vaccination last year
Yes 160 60 -
Abbreviations: CBS Statistics Netherlands; IQR Interquartile range.
Chapter 5  |  129 
The median completion time of the whole questionnaire was 13 minutes (median, IQR: 
9.6–19). It took respondents a median of 6.3 minutes (IQR: 4.2–9.6) to complete 16 choice 
tasks. The time respondents needed to fill in one choice task decreased from a median of 39 
seconds (IQR: 20–62) for choice task 1 to 15 seconds (IQR: 10–24) for choice task 16. 67% of 
the respondents marked the number of choice tasks as ‘exactly the good number’ and 76% 
marked the questions as clear or very clear. A minority (13%) of the respondents found the 
questions hard or very hard to answer. Most of the respondents found the topic interesting 
or very interesting (87%). Responses to the free text question indicated that respondents 
felt that they were adequately informed to answer the questions in the questionnaire.
Direct ranking showed that respondents considered effectiveness the most important 
vaccine specific attribute, followed by safety of the vaccine and advice regarding the vaccine 
(Figure 2a–2c). Respondents marked their doctors’ advice as most important, followed by 
the advice of international organizations and the advice of the Dutch government & National 
Institute for Public Health and the Environment (Dutch abbreviation: RIVM). Traditional 
media influenced the decision regarding vaccination more than social media.
Figure 2 | a. Direct ranking of attributes1; b. Direct ranking of attribute levels2; c. Direct ranking of 
attributes levels3
 
41%
29%
19%
4%
7%
Effectiveness of
vaccination
Safety of
vaccination
Advice regarding
the vaccination
Media coverage
about the
vaccination
Price of the
vaccination
 
2%
45%
26% 27%
Family & friends Physician Dutch government &
RIVM
International
organizations
 
10%
90%
Social Media Traditional Media
Notes: 1The percentages represent the proportion of people that ranked that vaccination program 
attribute as most important when deciding on vaccination. 2The percentages represent the proportion 
of people that ranked that vaccination program attribute level of advice regarding the vaccination as 
most important when deciding on vaccination. 3The percentages represent the proportion of people 
that ranked that vaccination program attribute level of media coverage about the vaccination as most 
important when deciding on vaccination.
a
b c
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Discrete choice experiment results
The ‘no vaccination’ option was chosen in 37% of the choice sets. 61 respondents (11.0%) 
always chose the ‘no vaccination’ option. 113 respondents (21%) never chose the ‘no 
vaccination’ option.
Using a latent class model, two classes were identified (Table 3). The average class 
probabilities within the sample were 0.63 for class 1 and 0.37 for class 2. The probability 
to belong to a specific class was dependent on two socio-demographic variables: the sex 
of the respondent and the attitude of the respondent regarding vaccination. Males and 
individuals who stated that they (possibly) wanted to get vaccinated had the highest chance 
to belong to latent class 1, while females and individuals who stated that they would never 
get vaccinated had the highest chance to belong to latent class 2. Other socio-demographic 
variables were not significantly explaining class assignment probabilities.
The sign of the coefficient indicates whether the attribute had a positive or negative effect on 
utility (Table 3). For example, the positive sign for effectiveness and for side effects unknown, 
but expected to be safe indicated that an effective and safe vaccination was preferred over 
a vaccination which was less effective and with which there was no experience yet. The 
negative sign for out-of-pocket costs of vaccination indicated that respondents preferred 
vaccinations with lower out-of-pocket costs. The positive sign of the constant indicates that, 
everything else being equal, respondents preferred no vaccination over vaccination.
Nearly all of the vaccine specific characteristics were statistically significant (Table 3), 
proving to influence respondents’ preference for vaccination. The interactions between the 
disease specific characteristics and effectiveness were significant and positive. This indicates 
that the preference for the level of effectiveness of a vaccination is dependent upon the 
levels of severity and susceptibility. If the susceptibility to or severity of a disease are higher, 
while the effectiveness of a vaccination is the same, preference for vaccination increases 
relative to no vaccination. In other words, if the susceptibility to the disease or the severity 
of a disease is higher, lower vaccination effectiveness will result in the same utility level. 
Note that the two disease characteristics cannot be included as a main effect but only as 
interaction effects, since they are scenario variables that are constant across all vaccine 
alternatives. All other 2-way interactions were not statistically significant.
When comparing the overall importance scores (Table 3) with the direct ranking question 
(Figure 2a), effectiveness of the vaccine was considered the most important attribute in 
both preference elicitation methods, especially when an outbreak was more serious, and 
media coverage of the vaccine as the least important attribute. These results support the 
convergent validity of the results.
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Table 3 | Preferences of respondents for vaccinations in pandemic situations based on a panel latent 
class logit model (N=536).
Attributes Latent class 1 Latent class 2 Overall
Value2 S.E. IS3 Value2 S.E. IS3 IS3
Constant (no vaccination) 0.22** 0.05 2.46** 0.15
Effectiveness of vaccine (per 10%) 0.07** 0.01 1 0.01 0.03 1 1
Side effects unknown, but expected to be safe (ref)1 0.21 - 4 0.27 - 5 5
Side effects unknown, no experience yet -0.21** 0.01 -0.27** 0.05
Family and/or friends recommend (ref)1 -0.33 - 2 -0.04 - 3 2
Family and/or friends discourage -0.50** 0.03 -0.39** 0.11
Your doctor recommends 0.42** 0.03 0.51** 0.10
Your doctor discourages -0.67** 0.03 -1.02** 0.15
Dutch government & RIVM recommend 0.58** 0.03 0.48** 0.10
International organizations recommend 0.49** 0.03 0.45** 0.09
Traditional media is positive (ref)1 0.15 - 5 0.39 - 4 4
Traditional media is negative -0.20** 0.03 -0.28** 0.09
Social / interactive media is positive 0.16** 0.02 0.18* 0.08
Social / interactive media is negative -0.11** 0.03 -0.29** 0.09
Out-of-pocket costs of the vaccination (per 10 euro) -0.06** 0.00 3 -0.17** 0.01 2 3
Interactions between attribute levels
Interaction: effectiveness of vaccine (per 10%) x 
susceptibility to the disease (per 10%)
0.12** 0.00 - 0.11** 0.00 - -
Interaction: effectiveness of vaccine (per 10%) x  
severity of the disease (per 10%)
0.02** 0.00 - 0.01** 0.00 - -
Class probability 
model
Subcategory
Constant - - - 1.63** 0.47 - -
Sex Male - - - - 0.80** 0.22 - -
Attitude regarding 
vaccination
I will never get vaccinated (ref) - - - <0.01 <0.01 - -
I will always get vaccinated - - - -4.09** 0.73 - -
I will only get vaccinated if 
advantages > disadvantages
- - - -1.88** 0.50 - -
I will only get vaccinated if 
advantages > disadvantages, 
however I do not think that is 
the case in the real world
- - - -0.78 0.48 - -
Class probability
Average 0.63 - - 0.37 - - -
Model fit
AIC 1.64 - - - - - -
Log likelihood -6989 - - - - - -
R2 0.26 - - - - - -
Abbreviations: S.E. = standard error; IS = importance score; REF = reference level; RIVM = Dutch abbreviation 
for National Institute for Public Health and the Environment.
Notes: Effects coded variables used for safety of the vaccine, advice about the vaccine, media coverage 
about the vaccine. Number of observations: 25728 (16*3*536). 1The values of the vaccination program 
attributes reference levels equals the negative sum of the coefficients of the included attribute. 2**, * 
denotes significance at the 1% and 5% respectively. 3The IS were calculated for a severe outbreak with a 
susceptibility to the disease of 20% and a severity of the disease of 75%.
132  |  Chapter 5
Preference heterogeneity was substantial; respondents belonging to latent class 1 seemed 
to place more weight on the effectiveness of the vaccine than respondents of latent class 2 
(IS of 2 for class 1 compared to an IS of 5 for class 2, in case of a mild outbreak). However, 
in case of a severe outbreak, effectiveness was the most important attribute for both latent 
classes. Respondents belonging to class 2 were more influenced by the media and more 
sensitive to costs than respondents belonging to latent class 1 (respectively an IS of 3 and 
1 for class 2, and an IS of 5 and 3 for class 1, in case of a mild outbreak of the disease). 
For respondents of both classes, the advice regarding vaccination of others was important. 
Respondents in class 1 were most influenced by the advice of the government & RIVM and 
international organizations, while respondents in latent class 2 were most influenced by the 
recommendation or discouraging of their physician.
Trade-offs
Based on the expressed preferences, respondents were willing to pay €6.0 (95% Confidence 
Interval: €3.7-€8.3) to receive a 10% more effective vaccine in case of a mild pandemic 
outbreak (Table 4). If a pandemic outbreak was more severe the willingness to pay for a 
vaccine which was 10% more effective increased up to €20 (€18-€22) in case of a moderate 
outbreak and €39 (€36-€44) in case of a severe outbreak.
Table 4 | Willingness to pay.
Attribute To receive a vaccination WTP (€, CI)
Mild 
pandemic1
Moderate 
pandemic2
Severe 
pandemic3
Effectiveness of vaccine With 10% more effectiveness 6.0 (3.7-8.3) 20 (18-22) 39 (36-44)
Abbreviations: WTP = willingness to pay; € = euro; CI = 95% confidence interval based on the Krinsky 
and Robb method adjusted for class probabilities and taking into account interaction effects (see 
Figure S3 for more information). 
Notes: 1Mild pandemic is defined as a disease with a susceptibility of 5% and a severity of 5%. 
2Moderate pandemic is defined as a disease with a susceptibility of 10% and a severity of 25%. 3Severe 
pandemic is defined as a disease with a susceptibility of 20% and a severity of 75%.
Expected uptake of the vaccine
The mean predicted uptake of the base-case vaccination program increased from 50% in 
a mild pandemic up to 88% for a severe pandemic (Figure 3a-3c). The more serious an 
outbreak was, the more the predicted uptake depended on effectiveness of a vaccine, e.g. 
a vaccine that was 40% less effective compared to the base case vaccination decreased the 
vaccination uptake 11, 20 and 28 percent points, for a mild, moderate or severe outbreak 
respectively. Irrespective of the disease scenario; higher out-of- pocket costs had a relatively 
large impact on the vaccination uptake, compared to the base case vaccination which was 
free. 
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Furthermore, recommendation of the vaccine by physicians, the government & RIVM or 
international organizations resulted in a substantial increase of the predicted uptake of the 
base case program (e.g. an increase of 16, 18 and 17 percent points respectively in case of a 
mild outbreak). Assuming that all bodies advised positively regarding the vaccine (including 
friends and family) the predicted uptake increased with 32 percent points in case of a mild 
outbreak.
DISCUSSION
This DCE showed that effectiveness, safety and out-of-pocket costs of the vaccine, as 
well as advice regarding and media coverage about the vaccine all influenced the general 
populations’ preference for pandemic vaccinations. Preference heterogeneity was 
substantial; two latent classes with different preferences were identified by a latent class 
model. Female respondents and individuals who stated that they would never get vaccinated 
were more influenced by the media and more sensitive to costs than male respondents 
and individuals who stated that they were (possibly) willing to get vaccinated. As expected, 
respondents preferred and were willing to pay more for more effective vaccines, especially if 
the outbreak was more serious. Changes in effectiveness, out-of-pocket costs of the vaccine 
and in the body that advises the vaccine substantially influenced the predicted uptake.
This is the first DCE investigating how characteristics of pandemic vaccinations influence 
preferences for vaccination programs in different pandemic outbreaks. Two systematic 
reviews assessed which factors were associated with uptake of the Influenza A (H1N1) 
pandemic vaccine. These also showed the need for targeted messaging to reach vaccination 
goals [7,8]. Especially the conclusion of one of these reviews [7] that social pressure and 
confidence in sources of information had an effect on the intention to vaccinate, is in 
line with our results. To gain insight in factors explaining willingness to vaccinate against 
Influenza A(H1N1) in The Netherlands, a questionnaire study was conducted among the 
general Dutch population during the 2009–2010 pandemic [39]. Similar results as we found 
were reported: people who were afraid of the disease, who perceived it as a severe disease, 
who believed in the efficacy of the vaccine and who trusted the information the government 
provided had higher odds for vaccination. Furthermore, the majority of respondents trusted 
the information provided by their general practitioner and more than half of the respondents 
trusted the information provided by the Dutch government and RIVM. Another questionnaire 
study regarding the Influenza A(H1N1) pandemic in the Netherlands showed results that 
are in line with our results as well; most respondents wanted to receive information about 
infection prevention from municipal health services, health care providers, and the media. 
Higher levels of intention to receive vaccination were associated with increased government 
trust, fear or worry about the disease, and perceived vulnerability to the disease [40]. 
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Several DCEs on non-pandemic vaccines [12,13,41] showed the influence of similar 
characteristics on vaccination preferences as we found in our study. In a DCE on preferences 
for HPV vaccination [12], it was found that the degree of protection positively influenced the 
preference of girls for vaccination, while the risk of side effects had a negative effect. A DCE 
among parents preferences for influenza vaccination for their children [13], showed that 
the efficacy of a vaccination and the recommendation of physicians positively influenced 
parents’ preferences, while the risk of temporary side effects had a negative effect. A DCE on 
marginal WTP for HIV vaccines [41] found that biomedical characteristics of a hypothetical 
HIV vaccine, such as efficacy, vaccine induced seropositivity and side effects, were the most 
important attributes for vaccination programs.
Our results suggest that side effects of the vaccine are less important than the other 
included attributes when deciding on vaccinations, while in other studies (including 
DCEs) safety of vaccinations was dominant [7,12,13,41,42]. This difference can probably 
be assigned to the choice of attribute levels since respondents in the current DCE were 
informed that the chance of side effects was expected to be low and either comparable to 
vaccines that are already on the market or expected to be low, but with no experience with 
a similar vaccination yet, i.e. a totally new vaccination. Our study showed that preference 
heterogeneity was substantial. Findings on heterogeneity are supported by a focus group 
study on acceptance of hypothetical pandemic vaccinations in Canada, where parents with 
non-mainstream beliefs showed different concerns regarding vaccinations [43].
This study had several limitations. First, we measured preferences for hypothetical vaccines 
in hypothetical pandemic outbreaks. Although we were not able to measure the external 
validity of our results, the results may be very helpful in helping to prepare for pandemic 
outbreaks. Additionally, the signs of the coefficients were generally consistent with our a 
priori hypothesis (a higher susceptibility to the disease, a higher severity of the disease 
and a higher effectiveness would have a positive effect on vaccination) and therefore, 
theoretically valid. Second, the participation rate of 49% was not optimal and selection bias 
cannot be excluded. However, this participation rate is equal or even higher than most other 
DCEs in health care. Furthermore, the participation rate was comparable to the average 
rate of the internet panel we used. We expect our results to be generalizable since age, 
gender, level of education and region of our sample are comparable to that of the general 
population of the Netherlands. Third, due to both the number and the type of attributes 
and levels that respondents needed to take into account when completing the choice tasks, 
it can be expected that respondents might have experienced difficulties, which might have 
influenced the results. However, piloting and think-a-loud interviews in the preparation 
phase, as well as questions that assessed the experienced difficulty of the questionnaire 
showed that the majority of respondents had no problems with completing the tasks. 
Fourth, we included safety of the vaccine as a categorical attribute, instead of a numerical 
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attribute, which would have helped respondents to compare risks of vaccinations with risks 
of the disease. However, when designing the DCE, expert interviews showed that safety of 
the vaccine is more or less a fixed attribute (either being sure that the vaccine will be safe, or 
that there is no experience with the vaccine yet and there is thus a chance of long-term side 
effects). Therefore, we included the safety of the vaccine as an attribute with categorical 
levels.
Insights in the factors influencing the intention to accept or decline a pandemic vaccine may 
have implications for both national and international policy and for further research. When 
communicating public health messages regarding vaccination, one should be aware of 
preference heterogeneity and therefore use different sources and channels to distribute the 
messages [44]. The current study provides guidance on how to target public health messages, 
by the identification of two classes with different preferences for pandemic vaccinations. To 
immediately reduce the number of susceptible people, a possible strategy could be to target 
the message for the first phase of a vaccination program to the more vaccination minded 
persons, here latent class 1. This can be done by using the government and RIVM as bodies 
to advice the vaccine to males and focus more on the expected effectiveness of the vaccine. 
Next, physicians can advise females to take the vaccine. Additionally, out-of-pocket costs 
need to be as low as possible, as our study showed the negative relation between out-
of- pocket costs and vaccination decisions. For public health messages during vaccination 
programs, it is also important to monitor side effects. Updates of the side effects of the 
vaccine need to be given on a regularly basis to make sure that an informed choice can 
be made and to reduce fear of the side effects of the vaccine. Furthermore, policy makers 
can use the expected uptake probability of hypothetical vaccinations when predicting the 
number of vaccinations that is needed. Although these numbers are rough estimates and 
it is not known if they are externally valid, the expected uptake can still be useful when 
other information is lacking. Additionally, these numbers can guide communication on the 
expected vaccination uptake. Since this is the first quantitative study in motivations for 
pandemic vaccinations, we do not know to what extent differences exist between countries 
regarding preferences for vaccinations. There is some evidence, including a questionnaire 
study in four countries investigating reasons why high risk people reject influenza vaccination 
in four countries of Europe suggests differences between respondents of the different 
countries [45]. Therefore, further international research is recommended.
We conclude that various disease and vaccination program attributes influence respondents’ 
preferences for pandemic vaccination programs. Agencies responsible for preventive 
measures during pandemics can use the findings of this study that out-of-pocket costs and 
the way advice is given affect vaccination uptake to change the way vaccination is marketed 
during future pandemic outbreaks. The preference heterogeneity shows that information 
regarding vaccination needs to be targeted differently depending on gender and willingness 
to get vaccinated.
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ADDITIONAL FILE 1: HYPOTHETICAL SCENARIO
This scenario was presented to respondents in Dutch. 
“Imagine, a new disease emerged abroad. This disease is highly contagious, because 
the disease spreads by droplets. All over the world, people become infected, also in the 
Netherlands. You can do some things yourself to prevent you of getting the disease (such 
as washing hands, etc.). However, the most effective preventive measure is a vaccination. 
Vaccinations are available for everyone in the Netherlands.”
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ADDITIONAL FILE 2: EXAMPLE OF A CHOICE SET
Choice sets were presented to respondents in Dutch. 
Additional information regarding the new disease (the situation without vaccination): 
 
 
Susceptibility to the disease 
 
50 out of 1.000 people will get sick (develop symptoms) 
 
 
Severity of the disease 
 
25% of all sick people will get severe symptoms 
 
 
You can choose the following 3 options, what do you choose? 
 
 Option 1: No vaccination 
Option 2: 
Vaccination A 
Option 3: 
Vaccination B 
 
Effectiveness of the vaccine  
 
n.a. 
 
This means: 
 
 
 
 
 
50 out of 1.000  
people will get sick 
 
 
25% of these sick people  
will get severe symptoms 
 
 
Effectiveness: 30% 
  
This means: 
 
15 out of 1.000  
people will not get sick, 
due to vaccination 
 
35 out of 1.000  
people will get sick,  
despite the vaccination 
 
25% of these sick people  
will get severe symptoms 
 
 
Effectiveness: 70% 
 
This means: 
 
35 out of 1.000  
people will not get sick, 
due to vaccination 
 
15 out of 1.000  
people will get sick,  
despite the vaccination 
 
25% of these sick people  
will get severe symptoms 
 
Safety of the vaccine  
(long term severe side effects) No side effects 
Unknown, but  
expected to be safe 
Unknown,  
no experience yet 
Advice about the vaccine n.a. Recommended by  your doctor 
Recommended by family  
and friends 
Media coverage about the vaccine n.a. Radio, newspapers  and television positive 
Radio, newspapers  
and television negative 
Out-of-pocket costs 0 euro 50 euros 50 euros 
 
What do you choose for yourself? 
(please tick one box only)    
 
Healthy
Sick
Healthy
Mild symptoms
Severe symptoms
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ADDITIONAL FILE 3: UTILITY FUNCTIONS
The utility function for no vaccination in the model with the best fit was: 
V (no vaccination) nsj|c = β 0|c      (Eq.1)
The utility function for vaccination in the model with the best fit was: 
V (vaccination) nsj|c = β 1|c effectiveness nsj|c + β 2|c side effects (unknown) nsj|c + β 3|c advice (friends 
advise against) nsj|c + β 4|c advice (doctor recommends) nsj|c + β 5|c advice (doctor advises against)
nsj|c + β 6|c advice (government & RIVM recommend) nsj|c + β 7|c advice (international organizations 
recommend) nsj|c + β 81|c media coverage (traditional media negative) nsj|c + β 9|c media coverage 
(social media positive) nsj|c + β 10|c media coverage (social media negative) nsj|c + β 11|c costs nsj|c + β 
12|c effectiveness nsj|c x susceptibility nsj|c + β 13|c effectiveness nsj|c x severity nsj|c                  (Eq.2)
where
Vnsj|c   represents the observable utility that respondent n belonging to class 
segment c has for alternative j in choice set s for vaccination; 
β 0|c  is an alternative-specific constant reflecting respondents’ preferences for 
no vaccination compared to receive a vaccination for a certain class; 
β 1-11|c are class-specific main-effects regression coefficients of the attributes, 
indicating the relative weight individuals place on certain attribute levels. 
β 12-13|c are class-specific two-way interaction effects (i.e. an effect where the 
influence of one attribute depends on the level of another attribute).
In addition to the utility function for vaccination (Eq. 1 and Eq. 2), the final model allowed 
for several covariates to enter into the class assignment model. The class assignment utility 
function for the final model was: 
Vnc =  β 0|c + β 1|c gender n + β 2|c attitude to vaccination (always positive) n + β 3|c attitude to 
vaccination (in favor when advantages > disadvantages) n + β 4|c attitude to vaccination (in favor 
when advantages > disadvantages, but don’t thinks that’s the case in the real world) n             (Eq. 3)
The WTP was calculated by taking the ratio of the parameter for the effectiveness attribute 
to the parameter related to out-of-pocket costs. Since effectiveness was included as both 
a main and an interaction effect, it was necessary to take also values of the attributes 
susceptibility to the disease and severity of the disease into account when calculating the 
WTP [1]. Because a latent class model was used, overall WTP measures could be calculated 
by weighing the conditional WTP values by the probability that respondents belong to a 
given class (given by the class assignment probability in Equation (1) and (2)). We calculated 
the WTP for three different pandemic outbreaks, using the values 5%, 10% and 20% for 
susceptibility and the values 5%, 25% and 75% for severity.
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ABSTRACT
Within a healthcare system with managed competition, health insurers are expected to 
act as prudent buyers of care on behalf of their customers. To fulfil this role adequately, 
understanding consumer preferences for health plan characteristics is of vital importance. 
Little is known, however, about these preferences and how they vary across consumers. 
Using a discrete choice experiment (DCE) we quantified trade-offs between basic health 
plan characteristics and analysed whether there are differences in preferences according to 
age, health status and income. We selected four health plan characteristics to be included 
in the DCE: (i) the level of provider choice and associated level of reimbursement, (ii) the 
primary focus of provider contracting (price, quality, social responsibility), (iii) the level of 
service benefits, and (iv) the monthly premium. This selection was based on a literature 
study, expert interviews and focus group discussions. The DCE consisted of 17 choice sets, 
each comprising two hypothetical health plan alternatives. A representative sample (n=533) 
of the Dutch adult population, based on age, gender and educational level, completed the 
online questionnaire during the annual open enrolment period for 2015. The final model 
with four latent classes showed that being able to choose a care provider freely was by 
far the most decisive characteristic for respondents aged over 45, those with chronic 
conditions, and those with a gross income over €3000/month. Monthly premium was the 
most important choice determinant for young, healthy, and lower income respondents. We 
conclude that it would be very unlikely for half of the sample to opt for health plans with 
restricted provider choice. However, a premium discount up to €15/month by restricted 
health plans might motivate especially younger, healthier, and less wealthy consumers to 
choose these plans. 
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INTRODUCTION
The health insurance system in the Netherlands was radically reformed by the introduction 
of a universal health insurance scheme with managed competition in 2006 [1, 2]. Similar 
reforms were introduced in other Western countries, e.g. Switzerland, Germany, Belgium, 
and the United States (Medicare Advantage, Medicare part D and ACA Marketplaces) [3, 
4]. A key feature of the model of managed competition is that health insurers are provided 
with incentives to act as prudent buyers of care on behalf of their enrolees. To that end, 
insurers are expected to compete on the dimensions that consumers find important, for 
example price and quality of care, in order to maintain or increase their market share [5, 6]. 
Dutch consumers are expected to critically assess the available health plans annually, and 
to switch to another insurer’s health plan if that better meets their preferences. Eventually, 
this competition in the health insurance market might result in better health care outcomes 
in terms of quality and costs. 
The model of managed competition has, however, two related caveats. First, there is growing 
empirical evidence that many people are having trouble making optimal health plan choices 
because they face difficulties in understanding relevant health plan differences [7-10]. If 
consumers do not have the information and/or cognitive abilities to adequately choose an 
insurance plan, or when search costs and switching costs are substantial, competition among 
health insurers may not yield the desired outcomes. Such barriers to adequate decision 
making are likely to be a major cause of consumer inertia (or a preference for the status 
quo) typically observed in health insurance markets [11]. Second, given that consumers are 
having trouble making optimal health plan choices, market design and regulation may be 
needed to improve outcomes. As recently argued by Handel & Kolstad [10]: “How consumers 
value different product attributes, what consumers know about those attributes, and how 
these preferences and information translate into choices is fundamental to market design 
and regulation, for health insurance and beyond. Without detailed knowledge of these 
micro-foundations it is difficult to precisely answer key policy questions such as which type 
of plans to allow insurers to offer and how those plans should be presented and priced.” 
Actual health plan choices are widely studied. Research shows, for example, that younger 
consumers are more sensitive to premium compared to older consumers, who are more 
sensitive to quality [12-14]. A drawback of studying actual health plan choices is that only 
preferences that are observable from the available market data can be revealed. In addition, 
health insurance premiums are heavily regulated, which makes inferring willingness-to-pay 
from market observations difficult or even impossible. Most of these revealed preference 
studies do not provide insights in the relative importance of health plan characteristics. 
An exception is a recent study among Massachusetts state employees that examined to 
what extent enrolees of an insurance plan were willing to switch to a limited provider 
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network in return for a premium discount [15]. The findings suggest that switching to a 
limited provider network is very sensitive to financial incentives and that the healthiest 
individuals are somewhat more likely to switch, although the differences by health status 
are not substantial.
In this paper, we use the method of discrete choice experiments (DCEs) to elicit and 
quantify consumer preferences and trade-offs for health plan characteristics. A DCE is a 
stated-preference technique that has become increasingly popular in health economics 
over the past years [16]. This technique originates from mathematical psychology [17] and 
is grounded in random utility theory [18, 19]. In DCEs, respondents are presented with 
a series of hypothetical scenarios (called choice sets) in which they are asked to choose 
between two or more alternatives that are distinguished from each other by systematically 
varying characteristics (called attributes) [20, 21]. Several studies used DCEs, or other 
stated-preference techniques, to examine consumer preferences for health plans in 
various institutional contexts, such as community micro health insurance in Malawi [22] 
and health insurance settings in Colombia [23], the US [24, 25], and Switzerland [26]. In 
The Netherlands, several DCE-studies were performed just before [27, 28] and shortly after 
the Dutch health insurance reform [29, 30]. In addition, two other DCEs [31, 32] examined 
consumer sensitivity to various incentives to visit preferred providers. The most recent DCE 
study in this field stems from the year 2009 and was conducted among a small sample (n=97) 
of Dutch hospital patients only [33]. Recent studies among large representative samples of 
the national adult population are lacking. 
The aim of this paper is twofold. First, we want to quantify consumers’ trade-offs between 
basic health plan characteristics after almost ten years of experience with managed 
competition in the Dutch health care system. Since the reforms in 2006, additional changes 
have taken place, including more attention for quality of care, and an increase in selective 
contracting practices. In addition, people are more accustomed to the role they are 
expected to play in the system: being critical and choosing as consumers. They are faced 
with widespread annual media attention around the choice of health plan, and are now 
also used to experience the consequence of their choices made in the preceding year. In 
contrast to most previous DCE studies, our study is based on a large representative sample 
of the national adult population. Second, we want to analyse whether these consumer 
preferences differ according to age, income, and health status.
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MATERIALS AND METHODS
Study context
Since the fundamental health system reform in 2006, Dutch citizens are obliged to buy 
individual basic health insurance with a legally standardized comprehensive basic benefit 
package at a community-rated premium from a private insurance company (for a more 
detailed description of the Dutch health care system, see [5, 34] and for comparisons with 
systems from other countries, see [35]). Insurers on the other hand are obliged to accept 
any applicant for basic health insurance, irrespective of the applicant’s health. Additionally, 
a supplementary insurance that covers benefits not included in the basic benefit package 
(primarily dental care for adults and physiotherapy, for which no referral by a general 
practitioner is needed), can be taken out by citizens on a voluntarily basis in an unregulated 
market with risk-rated premiums. Dutch citizens have the possibility to switch health plans 
annually during a 2-month open enrolment period. In 2015, citizens could choose one of 
the 71 basic health plans offered by 25 insurers belonging to one of the in total 9 different 
health insurance companies [36]. Basic health plans may vary in terms of reimbursement 
– in-kind, in-cash or a combination – and by the network of contracted providers. Health 
insurers are allowed to selectively contract with health care providers and increasingly do 
so. As a consequence the number of basic health plans with a limited provider network 
steadily increased from a single plan in 2008 to 17 plans in 2015, accounting for about 7.5 
percent of the insured population [36]. Limited provider plans typically reimburse only 
part of cost of non-contracted providers [36]. Supplementary insurance does not provide 
full reimbursement for non-contracted health care providers of care covered by the basic 
insurance. Citizens with limited provider plans thus need to pay attention to which providers 
are contracted by their insurer in order to avoid extra payment. The basic idea behind the 
reform is that insurers negotiate contracts with providers based on price, quantity, and 
quality of care [5]. To date, however, insurer-provider negotiations are mainly focused on 
price and volume rather than quality. This is at least partly caused by the absence of reliable 
quality indicators [12, 37, 38].
Attributes and attribute levels 
The first step in a DCE is to carefully select the attributes and levels to be included in the 
DCE. As the validity of the DCE depends on this process, it needs to be reported clearly as 
well [39, 40]. We selected four attributes: level of provider choice and associated level of 
reimbursement, the prime focus of insurers’ contracting practices, service benefits provided 
by the insurer, and monthly premium (Table 1). This selection was based on a literature 
study (including previous stated-preference studies on the same topic and grey literature), 
interviews with experts in the field of health insurance (researchers, policy makers, and 
employees of a health insurance company, n=5) and focus group discussions (FGDs, n=4) 
with a total number of 23 participants. Each of the four FGDs consisted of at least five 
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members of the Dutch adult population with mixed characteristics based on age, gender, 
educational level and health status. Following semi-structured discussions, participants 
ranked a list of attributes according to the nominal group technique [41]. For this matter, a 
predefined attribute list (n=9) based on the literature and expert interviews was completed 
with attributes that were mentioned during the discussions (with a maximum of n=17 
attributes to rank).The attributes that were ranked highest were considered for inclusion in 
the DCE. If not indicated otherwise below, the corresponding attribute levels were chosen 
based on the health plans available on the market at the time of the study. 
As the level of provider choice in the Netherlands is mostly determined by the level 
of reimbursement for services by non-contracted health care providers, we choose to 
combine these two aspects into one attribute. At the time of study, health insurers had to 
cover at least 75 percent of the costs of services, when delivered by health care providers 
not contracted by the insurer. In 2014 the Dutch government proposed to remove all 
restrictions on the reimbursement level for non-contracted care in order to reinforce the 
bargaining position of health insurers vis-a-vis health care providers. This proposal would 
have allowed insurers to set the reimbursement rate for non-contracted care at zero. 
However, by the end of 2014 the bill to enact this proposal was rejected in the Senate. 
We nevertheless also included an attribute level based on zero reimbursement of care 
by non-contracted providers to assess the potential impact of this dismissed government 
proposal. Furthermore, based on the expert interviews we selected two different levels for 
the attribute on prime focus of insurers’ contracting practices, namely price and high quality 
care. A third level, social responsibility, was included because FGD participants frequently 
mentioned their preference for trustworthy and ethical health insurers – for whom the 
emphasis is not on financial gains but on a sustainable relationship with the contracted 
professionals, their enrolees and society. As no general grading system for service benefits 
exist, we chose positive and negative ratings on consumer websites as attribute levels for 
the attribute on service benefits provided by the insurer. 
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DCE design
Each choice set consisted of two basic health plan alternatives, alternative A and alternative 
B, with systematically varying attribute levels. We chose not to include a ‘no basic health 
insurance’ alternative (i.e. opt-out), because basic health insurance is obligatory in 
the Netherlands. In addition, the DCE did not include an individual-specific status quo 
alternative because the objective of this study was to estimate trade-offs between health 
plan characteristics and not the expected uptake of certain basic health plans. As it is not 
feasible to present a single respondent with all the possible combinations of the included 
attribute levels, we generated a subset of 30 choice sets (by minimizing the D-error) using 
Ngene design software (ChoiceMetrics, version 1.1.1.). It was assumed unrealistic to include 
combinations of the lowest level of ‘provider choice and associated level of reimbursement’ 
with the highest ‘premium’ level and vice versa. The 30 choice sets were blocked into two 
different questionnaire versions, such that each block has (near) attribute level balance 
[42]. The D-error of our final design was 0.35 and the S-estimate was 124. The design was 
optimised for a multinomial logit (MNL) model. Hence, while a loss in efficiency is expected 
due to the estimation of a latent class model, we expect this loss to be fairly small [43].
Questionnaire
The questionnaire contained two parts. Part one included an introduction to the study 
topic and the DCE task, a choice set example including an explanation of the terms used, 
and either one of the blocks of 15 choice sets. In addition, we included two extra choice 
sets per respondent to test two important axioms underlying DCE methodology [44-
46], namely (i) whether or not more attractive attribute levels were preferred over less 
attractive levels (monotonicity axiom) and (ii) whether or not respondents’ preferences 
were stable (completeness axiom). Thus, each respondent needed to complete 17 choice 
sets in total. Part two of the questionnaire consisted of questions about the respondent’s 
socio demographic characteristics and previous experiences with health insurance. The 
questionnaire ended with an open text question where respondents could provide feedback 
about the questionnaire. We conducted four think aloud interviews to gain insights in how 
respondents interpreted the questions and answering categories, and whether or not 
anything was unclear to them. Based on these interviews, we made some minor changes 
to the wording of the questionnaire. Hereafter, we conducted a formal pilot test with 56 
randomly selected internet panel members. Choice data was analysed using a MNL model, 
and estimates were used to update the priors for the experimental design. Additionally, 
based on the feedback of respondents on the open text question, some small adjustments 
to the wording of the questionnaire were made. 
Sampling and data collection
A Dutch research company (CG selections) invited 17,000 of their internet panel members 
to participate in the current study by sending them an email with an URL to the final 
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questionnaire. Quota sampling was applied, based on age, gender, level of education, 
and on questionnaire version to ensure an equal distribution of these characteristics over 
the two questionnaire blocks. Based on the rule of thumb as suggested by Orme [47], we 
aimed to have at least n=500 respondents to complete the questionnaire. Post hoc analysis 
showed that this sample size was larger than the minimum required sample size based on 
the S-estimate. The data was collected during the annual open enrolment period in which 
Dutch citizens have the opportunity to switch health plans. The questionnaire was online 
from the 17th of December 2014 to the 6th of January 2015, when the target number of 
respondents with complete responses was reached. 
Statistical analysis
The choice for a particular health plan alternative is modelled as a function of the attributes 
and their levels in Nlogit (Econometric Software, version 5.0). As one of the aims of our study 
was to test for preference heterogeneity, both panel latent class models (LCMs) and panel 
mixed logit models are suitable [48]. The LCM had a better model fit (based on pseudo-R-
squared) and is therefore presented in this paper. 
LCMs assume the existence of subgroups (called classes) of respondents with homogeneous 
preferences. Class specific regression coefficients indicate the relative weight respondents 
of a certain class attach to certain attribute levels. The sign of a coefficient reflects whether 
the attribute level has a positive or negative effect on health plan preferences. The utility 
function for basic health plans in the LCM with the best fit was: 
Visj|c = β1|c provider choice and associated level of reimbursement (80% (75%)) isj|c+ 
β2|c provider choice and associated level of reimbursement (100%) isj|c + β3|c contracting 
(quality) isj|c + β4|c contracting (social responsibility) isj|c + β5|c service level (positive) 
isj|c + β6|c premium isj|c
The systematic component of utility, V, describes the utility that respondent ‘i’ belonging 
to class ‘c’ has for alternative ‘s’ in choice set ‘j’. The attributes ‘provider choice and 
associated level of reimbursement’, ‘primary focus of provider contracting’, and ‘level of 
service benefits’ were dummy coded. We included the premium attribute as a linear term. 
Transformations (such as logarithmic and square root) did not improve model fit. 
The researcher pre-specifies the number of classes, based on model fit. Class membership is 
latent in that the researcher does not determine who belongs to which class a priori. Instead, 
class membership is expressed in class probabilities that may depend on the respondent’s 
characteristics. Thus, every respondent has a certain probability to belong to one of the 
latent classes. In addition to the choice model, we fitted a class assignment model to test 
whether class membership is dependent on age, health status and income. These three 
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variables were selected based on literature [12-15]. Gross household income per month was 
measured on a categorical scale. Respondents’ answers were subdivided into four groups: 
low (less than €2000), average (between €2000 and €3000), high (€3000 or more), and 
does not know, or does not want to tell. Answers for respondents of the latter group were 
imputed in SPSS (version 22) using single imputation based on regression methods for the 
DCE analysis. Health status was self-reported: respondents were asked to select whether 
they suffered from one or more of the 28 chronic disease categories from a predefined list 
as used by Statistics Netherlands in health research. The final class assignment model was: 
Vic =  β 0|c + β 1|c age (30-44 years) i + β 2|c age (45-59 years) i + β 3|c age (60+ years) 
i + β 4|c chronically ill (yes) i + β 5|c income (average) i + β 6|c income (high) i
The reference level for age was the youngest age group (18-29 years), the reference level for 
health status was having no chronic disease, and the reference level for income was having 
a low income (less than €2000 per month).
The class specific relative importance of the attributes was calculated by dividing the 
difference in utility between the highest and lowest level of a single attribute by the sum 
of the differences of all attributes for that class. The proportions represent the part of 
someone’s preference that is based on that attribute. The higher the percentage the more 
important the attribute is for health plan choice. Marginal monthly willingness-to-pay (WTP) 
estimates were calculated by taking the ratio of the change in the attribute level of interest 
over the negative coefficient of the premium attribute. 
RESULTS
Respondent characteristics
The sample (n=533) was representative for the Dutch adult population based on age 
groups, gender, and educational level (Table 2). Approximately half of the respondents 
(55.3%) suffered from one or more chronic diseases, which is higher than in the general 
adult population (35.5%) [49]. Of all respondents, 14.8% did not know what type of health 
plan they had in 2014 (Table 3). 77.1% of respondents stated to have a supplementary 
insurance and 57.2% was insured via a group contract, which is lower than in the general 
population (84% and 70%) [36]. Internet was the most common source of information 
for those respondents who actively searched for information about health plans and 
insurance companies because they considered switching, 75.0% stated to use comparison 
websites, while 69.7% stated to look at the website of the insurance company. Almost half 
of the sample (45.6%) had switched health plans since the reform in 2006, which is higher 
compared to the general population (31%) [50]. The latter number includes only people that 
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switched between insurers, and not those that switched to another health plan of the same 
insurer, while the former number includes both. The most common reason not to switch 
to another health plan is ‘being satisfied with current plan’, followed by ‘losing benefits of 
group contract’. 
Table 2 | Demographic characteristics of the study population (n=533).
Study 
population
Dutch adult 
population1
Age in years Mean ± SD 47.0 ± 14.9
Range 19-70
Age group 18-29 years (%) 18.8 19 (17-20)
30-44 years (%) 25.3 27 (24-29)
45-59 years (%) 27.6 27 (25-29)
60+ years (%) 28.3 28 (25-30)
Gender Female (%) 50.7 51 (46-55)
Educational level2 Low (%) 24.0 22 (20-24)
Average (%) 42.0 42 (38-46)
High (%) 34.0 34 (31-37)
Gross income per month3 Low (%) 34.1
Average (%) 19.9
High (%) 27.4
Does not know, or does not want to tell (%) 18.6
Chronic diseases Mean ± SD 1.2 ± 1.5
Range 0-9
None (%) 44.7
1 disease (%) 24.2
2 diseases (%) 14.1
3 diseases (%) 8.3
> 3 diseases (%) 8.8
Abbreviations: SD standard deviation.
Notes: 1Based on numbers provided by the Center for Information Based Decision Making & Marketing 
Research (MOA) in cooperation with Statistics Netherlands [51]. Between brackets is the range of proportions 
that is considered representative for the Dutch adult population for a sample of n=500). 2Educational level 
was subdivided into three groups: low (primary education and lower secondary education, average (higher 
secondary education and intermediate vocational education), and high (tertiary education). 3Low (less than 
€2000), average (between €2000 and €3000), high (€3000 or more).
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Table 3 | Previous experiences with health insurance (n=533). 
Percentage
Type of health plan in 2014 In-kind benefits 17.3
Cash benefits 67.9
Unknown 14.8
Supplementary insurance in 2014 Yes 77.1
No 21.6
Unknown 1.3
Group contract in 2014 Yes 57.2
No 41.1
Unknown 1.7
Voluntary deductible in 2014 Yes 13.9
No 84.1
Unknown 2.1
Time spent annually on considering 
switching to other health plan
none 32.5
1 – 29 minutes 17.3
30 – 59 minutes 17.8
60 – 179 minutes 21.6
≥ 180 minutes 10.9
Source of information1 Comparison websites 75.0
Website insurance company 69.7
Family and friends 28.9
Consumer federation 20.8
Call to insurance company 16.1
Health care provider 6.4
Other 2.8
Switched health plan since 2006 No 53.1
Yes 45.6
Unknown 1.3
Reasons for not switching since 20062 Satisfied with current health plan 79.9
Losing benefits of group contract 19.1
Transaction costs 12.0
Afraid of non-acceptance by health insurer 7.8
Never thought of it 2.1
Late with payments 1.8
Did not know how to switch 0.4
Other 2.1
To what extent a supplementary 
insurance affects choices for basic health 
insurance
Much or very much 60.8
To some extent 22.5
Not at all 16.7
Notes: 1The sum of the percentages is more than 100% as it was possible to give multiple answers. Only those 
respondents that indicated to spent time on (potential) switching were included to calculate percentages 
(n=360 (67%)). 2The sum of the percentages is more than 100% as it was possible to give multiple answers. 
Percentages were calculated using answers of only those who stated not to have switched health insurance 
since 2006 (n=283 (53%)).
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Analysis of choice data
Only few respondents (7.3%) found the choice sets hard or very hard to answer. Almost 
all respondents (97.0%) preferred the alternative with better levels to the alternative with 
worse levels, while 82.4% of respondents had stable preferences, implying that respondents 
behaved according to the monotonicity and completeness axiom. Almost a quarter of the 
respondents (22.9%) opted for the alternative with the highest level of provider choice 
and associated level of reimbursement in every choice set. Few respondents opted for the 
alternative with the lowest premium (2.4%), positive rating of service levels (1.9%), quality 
as primary focus of provider contracting (0.8%), or social responsibility as primary focus of 
provider contracting (0.2%) in every choice set in which it was included.
The choice model with the best fit included four latent classes (Table 4). The model 
distinguishes a class where freedom of choice dominates (class 1), a class that is service 
oriented (class 2), a class that is quality minded (class 3), and a cost-conscious class (class 
4). The average class probabilities indicate that the majority of respondents was assigned to 
class 1 (50%), followed by 26% to class 4, and 12% to both class 2 and 3.
The class probability was dependent on age, health status and income (Table 4, class 
assignment model). Respondents aged 45 or over more often belonged to the class where 
freedom of choice (and associated reimbursement level) dominates compared to younger 
respondents who more often belonged to the cost-conscious class (p<0.01). Likewise, those 
who suffered from one or more chronic conditions, and those with a monthly income of 
€3000 or more had a higher probability to belong to the class where choice dominates than 
to the cost-conscious class (p<0.05). Those with an income of €3000 or more per month 
were also more likely to belong to the quality minded class compared to those with a lower 
income, who more often belonged to the cost-conscious class (p<0.05).
The coefficients had the expected sign, indicating theoretical validity of the DCE. Respondents 
across all classes preferred a free choice of care providers to restricted provider choice 
(and associated reimbursement level). All respondents also preferred selective contracting 
that was primarily focussed on quality of care over selective contracting focussed on price 
of care (reference level), whereas contracting focussed on social responsibility was only 
preferred over the reference level by the service demanders (class 2) and the quality minded 
responders (class 3). As expected, health plans with positive ratings of service benefits were 
significantly preferred over plans with negative ratings of service benefits, and lower priced 
health plans were preferred over higher priced ones.
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The relative value attached to health plan attributes differed between the classes (Table 
4). Provider choice and associated reimbursement level was, compared to the other three 
attributes, by far the most important attribute in class 1. In class 2, provider choice and 
associated reimbursement level was also the most important attribute; however, this 
was followed closely by the service benefits provided by the insurer. The primary focus of 
provider contracting was, besides the level of provider choice and associated reimbursement 
level, the most important attribute for respondents of class 3. For respondents of class 4, 
monthly premium was most important, followed by level provider choice and associated 
reimbursement level. 
The class specific WTP estimates are all statistically significant, except the estimates for a 
change in primary focus of provider contracting from price to social responsibility in class 
1 and 3 (Table 5). Estimates differ importantly between the classes, except for class 2 and 
3 where confidence intervals overlap for all attributes. The high WTP estimates in class 1 
are in direct contrast with the lower estimates in class 4. These high WTP estimates in class 
1 indicate that those respondents will never choose a health plan with restricted provider 
choice and lower reimbursement levels. Except for class 3, WTP estimates for a change 
in the primary focus of provider contracting from price to quality are low, indicating that 
consumers do not value the focus of insurers on quality of care highly. The wide CIs in class 3 
indicate heterogeneous preferences within this class, while the narrow CIs in class 4 indicate 
homogenous preferences. 
DISCUSSION
The level of provider choice and the associated reimbursement level was by far the most 
decisive health plan characteristic for respondents aged 45 or over, those with one or more 
chronic conditions, and those with a higher income. Although this characteristic was also 
important for those young, healthy, and with a low or average income, monthly premium 
was their most important determinant of choice. Health insurers with a focus on contracting 
high quality providers were preferred rather than lower-priced providers, although the WTP 
estimates (€12, €39, €222 and €3 for class 1, 2, 3 and 4 respectively) were low compared to 
the other WTP estimates of a given class, except for class 3. A minority of the respondents 
preferred insurers with a focus on social responsibility rather than price when contracting 
providers. 
Interpretation of the results
A possible explanation for the dominance of the provider choice attribute in the current 
study might be that respondents prefer to choose health care providers regardless of 
financial considerations. In addition, the dominance might partly be related to an objection 
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to the government proposal allowing insurers to set a lower level of reimbursement of 
care by non-contracted providers. At the time of data collection, this proposal was heavily 
disputed by the medical profession and widely covered by the media. Restricting provider 
choice was also one of the reasons for the backlash against Managed Care Organizations 
in the US in the 1990s [53, 54]. A DCE study in the US setting also found that the physician 
network was the most important attribute for health plan choice, followed by prescription 
coverage and costs per visit [24]. Earlier Dutch DCEs found a negative WTP of €76 per year for 
physician choice from a predefined network, and of €137 for choice from a list established 
by the health insurer, compared to physician choice based on the gatekeeper model (i.e. a 
model in which general practitioners decide on referral of patients to medical specialists). 
From these studies it follows that the WTP for free physician choice was positive (€79) [29, 
30]. Our results differ from the most recent DCE study that found no effect of the level of 
provider choice on insurance preferences [33]. Bergrath and colleagues suggested that the 
insignificance had to do with consumers being not fully aware of all the aspects that play 
a role in a health care system with managed competition. Our study confirms earlier DCE 
findings of preference heterogeneity with respect to restrictions on provider choice and 
premium [29, 30, 33]. Our results indicate that consumers do not value the focus of insurers 
on quality of care highly. This might indicate that consumers do not expect insurers to play 
an important role as purchasing agents of high quality care. Instead, consumers seem to rely 
on their general practitioner to select which are the best care providers to go to [55]. 
Strengths and limitations
The paper contributes to the existing literature in three different ways. First, our study 
provides insights in (unobserved) consumer preferences about health plan characteristics 
after almost ten years of experience with managed competition in the Netherlands. Second, 
relevant preferences for plan characteristics were identified by a combination of extensive 
literature search, expert interviews and focus groups discussions. Third, in contrast to the 
most recent Dutch DCE study in the field of health plans, our study is based on a large 
representative sample of the national adult population. This study is also subject to some 
limitations. First, we specified only one aspect of provider choice (i.e. reimbursement level) 
whereas other aspects, such as the location of the (non-)contracted providers, may be 
relevant as well. More specifically, respondents might not care about the level of provider 
choice (and associated reimbursement level) when the health plan contracts all nearby 
hospitals. In that case, other health plan characteristics, such as premium, might become 
more important for their decision. Second, because only a limited number of attributes 
and attribute levels can be included in a DCE we only selected the four most important 
attributes based on the qualitative study. Given that for the majority of respondents 
characteristics of supplementary health insurance affect their choice for basic health 
insurance much or very much (60.8%, Table 3) it is unfortunate that because of the large 
heterogeneity of supplementary insurance products we were not able to take the role of 
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a supplementary insurance in health plan choice explicitly into account. Third, as many 
different implementations of basic health plans exist in the Netherlands, it was not possible 
to define one specific status quo alternative that would be applicable to all respondents. In 
addition, we chose not to include an individual-specific status quo alternative. This absence 
of a status quo in this context prevents to draw conclusions on uptake of different health 
plans based on stated preferences of consumers. Although calculation of uptake rates 
is a very useful application of DCE data, we feel that the information on trade-offs that 
consumers make between different features of health plans is useful in itself, both for policy 
makers and health insurance companies.
Policy implications
Despite these limitations, this study provides useful evidence on consumer preferences, and 
the heterogeneity herein, that can inform policy decisions on the design and regulation of the 
insurance market. Although consumers strongly prefer free choice of provider, respondents 
still trade off free provider choice against premium. Given the high WTP estimates in 
class 1 however, it is likely that half of the respondents will never opt for restricted health 
plans. Apparently, health insurers will not be able to steer these respondents to preferred 
providers. Conversely, respondents belonging to class 4 (class probability: 26%) are willing 
to accept limited provider choice for a monthly premium discount of €13 (95% CI: €11; €15), 
as well as some respondents from class 2 (class probability: 12%) given that the lower level 
of the 95% CI is €26. These estimates are larger than the €7 difference in monthly premiums 
between restricted and non-restricted health plans in the year of the study, 2014 [36]. 
Insurers lowering the premium for choice restricted health plans might therefore attract 
a selective group of new clients, namely the young, healthy and less wealthy consumers. If 
insurers are able to provide objective quality information of the contracted providers that 
is easy to understand, consumers might make more well-considered insurance choices that 
do include quality of contracted care. As a result, consumers might be more willing to accept 
less freedom of provider choice. Recently, the Dutch minister of Health advised the insurers 
to be more transparent about their contracting practices [56]. 
CONCLUSION
We conclude that it would be very unlikely for half of the sample to opt for health plans with 
restricted provider choice. However, a premium discount up to €15/month by restricted 
health plans might motivate especially younger, healthier, and less wealthy consumers to 
choose these plans.
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ABSTRACT
Objective: The aim of this study was to investigate personal health record (PHR) preferences 
of potential users.
Materials and Methods: We performed a discrete choice experiment (DCE), which consisted 
of 12 choice scenarios, each comprising 2 hypothetical PHR alternatives and an opt-out. 
The PHR alternatives differed based on five characteristics. The survey was administered to 
Internet panel members of the Dutch Federation of Patients and Consumer Organizations 
(NPCF). We used latent class models to analyse the data. 
Results: 1,443 potential PHR users completed the DCE. We identified three latent classes: 
“refusers” (class probability 43%), “eager adopters” (37%) and “reluctant adopters” (20%). 
The predicted uptake for the reluctant adopters ranged from 4% in case of a PHR with the 
worst attribute levels to 68% in the best case. Those with one or more chronic diseases 
were significantly more likely to belong to the eager adopters’ class. The facilitating party for 
storage of PHR was the most decisive aspect for the eager and the reluctant adopters, while 
the costs were most decisive for the refusers. Across all classes, healthcare providers, and 
independent organisations were the most preferred facilitators of data storage. 
Discussion and Conclusion: More than one third of potential PHR users indicate great interest 
in a PHR, irrespective of its characteristics. Policymakers who aim to expand the use of PHRs 
will be most successful when healthcare providers and health facilities, or independent 
organizations facilitate the storage of PHR data, while refraining to include market parties 
in storage of the data. 
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BACKGROUND AND SIGNIFICANCE
Personal health records (PHRs) can be defined as: “An electronic application through which 
individuals can access, manage and share their health information, and that of others 
for whom they are authorized, in a private, secure, and confidential environment” [1]. In 
contrast to the clinician’s medical record, PHRs are managed by patients [2]. PHRs can have 
varying characteristics, for example PHRs can offer secure patient-provider communication, 
and hold various sources of static and dynamic information for patients [3]. Furthermore, 
both the provider and the patient may be able to add data [4] either self-entered or through 
“wearables”. Additional convenience features include online appointment scheduling and 
requesting medication refills. Large scale implementation of PHRs [3, 5] is expected to yield 
cost reductions [6, 7], increase quality of care [8] and increase efficiency of care [3]. They are 
seen as a tool to empower patients and give patients control over their healthcare process 
[9]. As such, PHRs can serve as a clinical information system in patient-centred care, and 
support well-informed, activated and empowered patients [6]. 
PHRs are generating an increased interest and are high on the agenda of policy makers in 
the Netherlands [10]. In contrast to other countries, such as Australia in which a national 
PHR was implemented in 2012 [11], there is currently no national PHR initiative in the 
Netherlands. However, a number of PHR platforms are available, e.g. Microsoft’s Health 
Vault and Patient1 [12]. Comparable platforms in other countries include Dossia HMS in the 
USA, and Patients Know Best in the UK [13]. Involving potential users in the development, 
testing, and implementation of PHRs could provide a base for further implementation 
of PHRs [14]. Furthermore, insights into the value that citizens place on various PHR 
characteristics can help developers to improve their products and advice policy makers on 
furthering conditions for the use of PHRs [2, 15]. 
To our knowledge, there is little quantitative information available on the number of users 
of PHRs in developed countries. However, sources report that the current uptake of PHRs 
is limited [16, 17]. A recent study among members of a panel of patients and consumers 
in the Netherlands reports that 9% of the people have a PHR [18]. It has been argued that 
PHRs that are currently available on the market are not based on patients’ needs [19]. The 
limited uptake may be an important reason for the scarce evidence of PHR advantages [2, 
20-24]. If a significant diffusion of PHRs is to take place, it is essential that potential users 
envisage sufficient added value of PHRs relative to the status quo [25]. Individuals with 
poorer digital literacy are less inclined to adopt PHRs [14, 25, 26]. Moreover, chronically ill 
people, frequent healthcare users, and those with a role as caregiver are more likely to use 
PHRs [27-31]. However, the design and usability of PHRs will affect the eventual uptake [31], 
also for these groups. A barrier for PHR use expressed in many studies is the concern about 
security and privacy of the data in the PHR [14, 25, 26, 29, 32, 33]. Another barrier is the 
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lack of standardisation of the formats in operational systems [34], i.e. data must be entered 
manually into most PHRs. 
OBJECTIVE
In this study, we aim to investigate potential users’ preferences for PHR characteristics. 
Individuals who face the decision to opt for a PHR trade off the negatively valued aspects 
with positively valued aspects of PHRs. This study aims to mimic this trading behaviour by 
imitating the real choice situation, adopting or not adopting a PHR, by means of the discrete 
choice experiment (DCE) methodology [35]. A DCE is a survey-based stated-preference 
method that has been increasingly used in healthcare to address a wide range of policy 
questions over the past years [36]. To date, no DCEs have been conducted to explore PHR 
preferences. The research questions of this paper are: 1) Can we identify subgroups of 
potential users with different PHR preferences across groups? 2) What PHR characteristics 
are most important within subgroups?, and 3) What is the potential uptake of PHRs?
MATERIALS AND METHODS
Discrete choice experiments
DCEs originate from mathematical psychology [37] and have a strong theoretical foundation 
in random utility theory (RUT, [38, 39]) and Lancaster’s theory of value [40]. In a typical DCE 
survey, respondents are presented with a series of hypothetical scenarios (called choice sets) 
in which they are asked to choose between two or more alternatives that are distinguished 
from each other by systematically varying characteristics (called attributes) [41-44]. RUT 
assumes that respondents will choose the alternative within a choice set that yields the 
highest utility (benefit or satisfaction). Based on respondents’ choices, preferences can be 
elicited, willingness-to-pay (WTP) estimates can be calculated (if a cost attribute is included), 
and uptake rates can be predicted. 
Experimental DCE design
We selected five attributes with two to six levels each (Table 1) based on literature search, 
expert interviews (policy makers, researchers; N=5), and focus group discussions with the 
general population (N=4, 25 participants in total). Each of the four focus group discussions 
consisted of at least six members of the Dutch adult population with mixed characteristics 
based on age, gender, educational level and health status. Following semi-structured 
discussions, participants ranked a list of attributes according to the nominal group technique 
[45]. For this matter, a predefined attribute list (n=17) based on the literature and expert 
interviews was completed with additional attributes that were mentioned during the focus 
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group discussions (with a maximum of n=23 attributes to rank). The attributes that were 
ranked highest were considered for inclusion in the DCE. 
Table 1 | Attributes and corresponding levels included in the DCE.
Attributes Short name Attribute levels
Facilitating party for storage of PHR data Facilitator Commercial company
Independent organization or platform
Government
Healthcare providers or health facility
Level of connectivity Connectivity Standalone
Tethered with the system of your GP
Tethered with the system of your hospital
Interconnected
Use of anonymized data by third parties Use of data No, never
Yes, after permission
Option to upload the person’s own data 
into PHR
Data adding No
Yes
PHR costs per capita per year as a proxy 
of the price that persons would pay for 
a PHR1
Costs €0, €15, €30, €50, €70, €95
Abbreviations: PHR personal health record; GP general practitioner.
Notes: 1We included the following costs levels in the pilot survey based on earlier research by the NPCF [18]: 
€0, €2, €5, €15, €30 and €50. The results of the pilot study showed the need to expand the range of cost 
levels by increasing the highest level, and to broaden the intervals between the levels.
A choice set consisted of two unlabelled hypothetical PHR alternatives; PHR A and PHR B, 
with systematically varying attribute levels, and an opt-out alternative (i.e. no PHR). This 
opt-out was necessary since, as in real life, respondents are not obliged to have a PHR. 
Additional file 1 shows an example of a choice set. By minimizing the D-error, a Bayesian 
efficient design based on best guess priors was generated using Ngene design software 
(version 1.1.1.). These priors (small positive and negative values) were used to increase 
the efficiency of the design by avoiding dominant choice sets. We generated a subset of 
12 choice sets to ensure level balance, as well as enough degrees of freedom to estimate 
a main effects only model (assuming that the cost attribute is non-categorical). For more 
information on these more technical elements of a DCE, see e.g. Reed Johnson et al. [46].
Survey instrument 
An inclusion criterion for the current study was that respondents currently did not have 
a PHR. The survey started with an introduction to the study and the topic (Additional file 
1). Hereafter, the included attributes and their corresponding levels as well as the DCE 
task were explained to respondents, followed by a clearly explained choice set example. 
Subsequently, respondents completed the 12 choice sets. An example of a choice set is 
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shown in Additional file 1. The survey concluded with additional questions on respondents’ 
intention to use a PHR, questions on sociodemographic characteristics, a question on 
whether or not respondents had previously experienced a medical error, and questions on 
digital literacy (internet use, type of internet use and risky digital behaviour). The survey was 
pilot tested using think aloud interviews (N=4) to test for respondent understanding and to 
improve the wording of the survey. Next, a formal pilot test (N=51, from the same Internet 
panel as used for the final data collection, see below) was conducted to test randomisation 
and to improve the wording of the questionnaire. Pilot data was analysed using multinomial 
logit models and estimates were used as priors for the final DCE design. 
Data collection
The survey was administered to Internet panel members of the Dutch Federation of 
Patient and Consumer Organizations (NPCF) in December 2015 and January 2016. All panel 
members (N=22,841) received an email with the URL to the online survey and were asked 
to complete it on a voluntary basis. Data-collection was terminated once the number of 
respondents completing the survey had decreased to a few respondents per day. Because 
of practical limitations at the NPCF, no reminders were sent out. Formal testing of the 
study protocol by a Medical Ethics Committee was not necessary, as a questionnaire study 
amongst volunteers of an Internet panel does not fall within the scope of the Dutch Act on 
Medical Research Involving Human Subjects. 
Discrete choice data analysis
The choices respondents made in the choice sets were used to estimate the impact of 
the attributes (independent variables) on the respondents’ choices for PHR or opting-out 
(dependent variable). A significant independent variable indicates that the attribute level 
has a significant impact on PHR preferences and the sign of the coefficient reflects whether 
this impact has a positive or negative effect. Several types of discrete choice models can be 
estimated. We have chosen to perform a latent class analysis, since this is a model that can 
take both preference heterogeneity and the panel nature of the data (i.e. dependencies 
between choice observations by a single respondent) into account [47]. In addition, it is a 
closed form model (i.e. does not rely on complex simulations) [47]. A latent class analysis 
assumes the existence of subgroups (called classes) of respondents that differ with respect 
to preferences. The researcher decides on the number of classes based on the model 
fit (AIC, BIC, pseudo-R2) and sound interpretation of classes. Class membership is latent 
in that the researcher does not determine who belongs to which class a priori. Instead, 
class membership is expressed as class probabilities that may depend on the respondent’s 
characteristics. We hereto fitted a class probability model in addition to the choice model 
where we tested the presence of individual-level drivers (age, health status, previous 
experience of a medical error) and individual-level barriers for the use of PHR (health 
literacy and digital literacy (internet use, type of internet use and risky digital behaviour)) 
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as predictors of the classes. These characteristics were selected based on literature [14, 25-
31]. Choice data was analysed in Nlogit version 4.0 (Econometric Software). 
The class specific relative importance of the attributes was calculated by dividing the 
difference in utility between the highest and lowest level of a single attribute by the sum of 
the differences in utility of all attributes for that class. The higher the proportion the more 
important the attribute is for PHR choice. We calculated annual WTP estimates by taking 
the ratio of the attribute level of interest over the negative coefficient of the cost attribute. 
We calculated the class-specific uptake of PHRs by taking the exponential of the total utility 
for a particular PHR divided by the exponential of the sum of utilities for the particular PHR 
and the opt-out (no PHR). In addition, we calculated the average uptake (weighted average, 
based on class probabilities).
RESULTS
Descriptive statistics
1,443 panel members fulfilled the inclusion criteria. Table 2 shows that respondents were 
on average 61 years of age, and half of the sample was highly educated (50%). The majority 
of respondents suffered from one or more chronic diseases (77%). Compared to the general 
population, our sample is older, more highly educated and more often chronically ill. About 
one third of respondents had at least once experienced a medical error (e.g. receiving a 
wrong drug). The stated intention to use a PHR within two years from now was high for a 
quarter of the sample (25%). 
Discrete choice data
The improvement in model fit (AIC, BIC, pseudo-R2) was very limited for a model with more 
than three classes. The final latent class model therefore included three latent classes (Table 
3). The average class probabilities were: 43% for class 1 (we refer to this class as “refusers”), 
followed by 37% for class 3 (referred to as “eager adopters”), and 20% for class 2 (referred 
to as “reluctant adopters”). Tests for class probability showed that those with one or more 
chronic diseases had a significantly higher probability of belonging to class 3 compared 
to class 1 (p-value 0.03) and class 2 (p-value <0.01). The other individual-level drivers and 
barriers were not significant class probability predictors. 
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Table 2 | Descriptive statistics.
Sample (N=1,443) Census data1
Mean (SD) Mean
Age 61 (11) 41.3
N (%) %
Age groups in years 18-40 57 (4.3) 33.7
40-65 704 (53) 44.0
65-80 533 (40) 16.9
80 or older 44 (3.3) 5.5
Gender Female 698 (51) 50.5
Male 671 (49) 49.5
Education2 Low 254 (18) 32.9
Average 443 (32) 39.3
High 706 (50) 27.8
Health status Healthy 325 (23) 69.9
One or more chronic diseases 1118 (77) 30.1
Subjective health literacy3 Low 29 (2.0) -
Adequate 1395 (98) -
Experienced a medical error No 926 (65) -
Yes 500 (35) -
Digital literacy N (%)
Internet use Easy 1187 (83) -
Not easy, not hard 216 (15) -
Hard 23 (1.6) -
Type of Internet use Mainly for fun 765 (53) -
Mainly for other purposes 678 (47) -
Mean (SD)
Risky digital behaviour4 10.9 (4.4) -
PHR N (%)
Stated intention to use a PHR 
within 2 years from now
Low (0-4) 727 (51) -
Average (5 or 6) 346 (24) -
High (7-10) 364 (25) -
Abbreviations: SD standard deviation; PHR personal health record
Notes: 1Based on numbers provided by Statistics Netherlands, 2015 [48] 2Educational level was 
categorized into three groups: low (primary education and lower secondary education), average 
(higher secondary education and intermediate vocational education), and high (tertiary education). 
3Subjective health literacy was measured based on the validated Dutch questions of the Set of Brief 
Screening Questions (SBSQ-D) of Chew [49]. 4Risky digital behaviour was measured by means of four 
statements where respondents had to mark on a scale of 1-7 how (un)likely this behaviour was for 
them (maximum score is thus 28). We hereto adapted the statements included in the domain-specific 
risk-taking (DOSPERT) scale for adult populations [50] to fit our research question. 
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The constant for no PHR was large and positive in class 1 indicating that all else equal 
respondents of this class prefer not to have a PHR. On the contrary, the constant for no 
PHR was very large and negative in class 3 indicating that all else equal respondents of this 
class prefer to have a PHR. Respondents of class 2 were somewhere in between the other 
two classes. Their constant for no PHR was small and positive, indicating that they might 
prefer to have a PHR if the characteristics meet their preferences. For both the eager and 
the reluctant adopters, the facilitating party of PHR data storage was the most important 
attribute, followed by cost. For the refusers, cost was by far the most decisive attribute, 
followed by the facilitator of data storage. 
Across all classes, independent organisations and care providers were the most preferred 
facilitators of data storage (largest positive WTP estimates, Table 4). Although the government 
level was not significant for refusers and reluctant adopters, it was significantly preferred 
over commercial companies by the reluctant adopters. The reluctant adopters preferred a 
PHR that is tethered with their general practitioner (GP), with an interconnected PHR being 
the next best alternative. The eager adopters preferred a PHR tethered with their GP as 
well, although this was followed by a PHR tethered with their hospital. The WTP estimate 
for the latter was significantly higher than the WTP for the reluctant adopters. Although the 
interconnected level was not significant for the eager adopters, it was significantly preferred 
over a standalone PHR. Both reluctant and eager adopters preferred to give permission for 
anonymized data use by third parties compared to no use of their personal data. Across all 
classes, having the possibility to add own data was preferred over not having this possibility. 
The WTP estimate for data adding, however, was highest for the reluctant adopters. 
Irrespective of the PHR characteristics and their ranges considered in the DCE, the predicted 
PHR uptake for the refusers was always below 9%, while the uptake of the eager adopters 
was predicted to always be above 91%. Amongst the reluctant adopters uptake was highly 
sensitive to PHR attribute levels. The expected uptake for the worst imaginable PHR 
(commercial company, standalone, no use of data, not possible to add own data, 95€) was 
4%, while the expected uptake for the best imaginable PHR (care provider, tethered with 
their GP, use of data after permission, adding own data, zero costs) was 68%. On average, 
over all three classes, the predicted uptake was 35% for the worst PHR (if constructed as 
above), while it was 52% for the best PHR (if constructed as above).
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DISCUSSION
We identified three classes of potential PHR users with different preference structures: 
those who prefer not to have a PHR (“refusers”, average class probability 43%), those who 
prefer to have a PHR (“eager adopters”, 37%), and those who prefer a PHR only if the tool 
is designed in accordance with their preferences (“reluctant adopters”, 20%). Those with 
one or more chronic diseases had a higher probability of belonging to the class of eager 
adopters. The facilitating party for storage of PHR was the most decisive aspect for the eager 
and the reluctant adopters, while the costs were most decisive for the refusers. Across all 
classes, care providers or facilities, and independent organisations were the most preferred 
facilitators of data storage. The predicted uptake for the reluctant adopters ranged from 4% 
in case of worst PHR to 68% in case of a PHR with the best attribute levels. The predicted 
uptake for the refusers was always below 9%, while it was always above 91% for the eager 
adopters.
Our study, like earlier studies [14, 25, 26, 29, 32, 33], showed that privacy concerns are a 
barrier to the adoption of PHRs. Privacy thus outranks the potential improvement of quality 
of care that PHRs yield. The facilitators of data storage that respondents preferred most are 
the healthcare providers or health facilities and independent organisations or platforms. 
When a commercial organisation or government would store their data, this would reduce 
the willingness to use a PHR. 
The finding that the chronically ill had a higher probability of belonging to the eager 
adopters of PHRs might be explained by the fact that chronically ill individuals interact 
frequently with multiple care providers and need to rely on their cooperation to get the 
best possible care. This can only be realized when all healthcare providers have access to 
up-to-date information on the care that was delivered to their patient by other providers. 
Use of PHRs also promotes sharing of information among healthcare providers and as such 
enable patient-centred care [52, 53]. This could be achieved best by an interconnected PHR. 
However, we found that the eager adopters prefer a PHR that is tethered to either their 
GP or their hospital system. This result can possibly be interpreted as respondents being 
hesitant towards such integration of data because of privacy reasons. 
Study limitations
This study has a number of limitations. First, as in all DCEs, the number of attributes and 
levels that can be included is limited. We aimed to include all relevant attributes and 
levels by carefully studying the literature, interviewing experts, conducting focus group 
discussions with potential PHR users and pilot testing the DCE. However, we cannot exclude 
the option that we missed an attribute or a level that would have affected our results. 
Second, although we obtained enough power for the analysis in this paper, the response 
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rate was low. We were unfortunately not able to track how many respondents read the 
invitation, or started but did not complete the survey. We expect that the reason for the 
low completion rate is that panel members of NPCF are not used to this type of questions 
and that no reminders were sent. Those panel members that were not interested in PHRs 
might not have accessed the survey. It could therefore be argued that the size of class 1 may 
be even bigger than estimated and therefore, that the majority of the Dutch population at 
present is not interested in using a PHR. Third, our sample may not be fully representative 
for the Dutch general adult population. Respondents were older, more highly educated, and 
more often had chronic diseases. This pattern is similar to earlier surveys that used the same 
panel [18, 54]. We performed sensitivity analyses to test the robustness of our findings with 
respect to uptake in subsamples that are representative for the general population based 
on age, education or health status (Additional file 2). Except for the uptake of the refusers 
in the representative sample based on health status, predicted uptakes are relatively stable. 
Despite the fact that our sample is not representative for the general population, it is an 
interesting sample because of the overrepresentation of people with a chronic illness. 
Implications of the study
The first practical implication of this study is that it is of importance that policy makers and 
PHR producers target their information campaign to chronically ill people given our finding 
that those respondents had a higher probability to belong to the eager adopters. This large 
class of respondents (more than one third of the sample) showed to have great interest 
in PHRs, irrespective of its characteristics, with an uptake that was predicted to always be 
above 91%. Given that our sample consisted of people that currently do not have a PHR, 
they might be willing to have a PHR, but they might not know how to get one, or the PHRs 
that are currently on the market are not interesting to them. The reasons for this might be 
an area for further research. 
The second practical implication is that it appears to be extremely difficult to increase the 
uptake of PHRs by creating a better product given our finding that the PHR uptake of only 
20.0% of respondents was influenced by the characteristics of a PHR. The ideal PHR of 
this group would be a PHR, which is facilitated by the care provider and tethered with the 
GP system. The data would be used for other purposes after permission only and adding 
own data would be possible at zero costs to the user. There were no incongruences across 
reluctant and eager adopters with respect to the best imaginable PHR. Policymakers who 
aim to expand the use of PHRs will be most successful when healthcare providers and health 
facilities, or independent organizations facilitate the storage of PHR data, while refraining 
to include market parties in storage of the data. Low costs, some form of connection with 
other systems, and the option to upload own data are valued positively by potential users, 
but our results suggest that these aspects will only affect uptake marginally. Producers of 
PHRs need to convince the potential users that they secure the privacy of the PHR data. 
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CONCLUSIONS
More than one third of potential PHR users indicate great interest in a PHR, irrespective of 
its characteristics. Policymakers who aim to expand the use of PHRs will be most successful 
when healthcare providers and health facilities, or independent organizations facilitate the 
storage of PHR data, while refraining to include market parties in storage of the data. 
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ADDITIONAL FILE 1: DCE SURVEY
Example of a choice set
 
A B
What do you prefer?
Personal Health Record A Personal Health Record B
Facilitating party for storage of PHR data Commercial company Government
Level of connectivity Standalone Tethered with your hospital 
Use of anonymized data by third parties No, never Yes, after permission
Option to upload the person’s own data into the PHR No Yes
The price you pay per year is: €15 €30
A B No PHR
What would you choose?
PHR introductory text
There are many different definitions of personal health records (PHRs). It is important that 
everyone completes this survey with the same definition in mind. We will therefore first 
describe what is meant with PHRs in this survey.
 
A PHR is a digital tool that enables you collect, manage and share information about your 
health, for example, information on diagnosis, treatments, referrals, etc. This information can 
be obtained from your healthcare providers (e.g., medical specialists, general practitioners, 
physiotherapists) and / or yourself. Some PHRs include additional functionalities, for 
example, being able to schedule appointments with your healthcare provider, request 
medication refills, providing medication reminders, advice and / or information on health 
and diseases.
 
In a PHR you control the data. You decide who you provide access to your data and what 
parts of your PHR this person can see. Persons that were not given access by you cannot see 
your data. A PHR is complementary to the registration systems used by healthcare providers.
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ABSTRACT
The literature on which unforced choice format to use in discrete choice experiments (DCEs) 
is sparse. We investigate the implications of using different unforced choice formats in 
different settings: 1) opt-out versus neither in a market where there was no status quo (SQ), 
and 2) including SQ in addition to opt-out in a market with a SQ. A DCE on Dutch citizens’ 
preferences for personal health records served as our case, and 3404 respondents were 
randomized to the different unforced choice formats. We used mixed logit error component 
models to estimate preferences. We found that the use of different unforced choice formats 
affects marginal utilities and welfare estimates and hence the conclusions that will be 
drawn from the DCE. Only a minority of respondents (14.3%) stated that they interpreted 
the neither alternative as analysists normally code it (as a zero option). When adding a 
SQ alternative, this option was chosen in 55.7% of choice sets, while opt-out was chosen 
in 11.2% of the choice sets. We recommend that future DCE studies use opt-out instead 
of neither, and that a SQ should be included in addition to opt-out in markets where a SQ 
exists.
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1. INTRODUCTION
Discrete choice experiments (DCEs) are increasingly being used within the health care context 
to address a wide range of policy questions [1]. It is acknowledged that the hypothetical 
choice situations in a DCE should represent the real market situation as closely as possible 
(e.g. [2-5]). If respondents are forced to choose between hypothetical alternatives in a DCE, 
while they are not in real markets, welfare estimates might be biased and participation 
rates overestimated [6]. Therefore, DCEs are often presented as unforced choice situations 
in which respondents are allowed not to choose any of the hypothetical alternatives 
through inclusion of an opt-out alternative. However, few authors have paid attention to 
the influence of different unforced choice formats on DCE results. 
Three formats are commonly used to ensure unforced choices in DCEs: 1) respondents are 
given the possibility not to buy the good or not to choose the service (hereafter referred to 
as opt-out, see for example: [7-9]), 2) respondents are given the possibility to choose ‘none 
of these’, or ‘neither of the alternatives’ (hereafter referred to as neither, see for example: 
[10-15]), and 3) respondents are given the possibility to choose their current alternative 
over the hypothetical alternatives (hereafter referred to as status quo (SQ), see for example: 
[16-20]). The literature on when to use which format is rather sparse [2, 3, 5, 21-25], and 
does not offer explicit guidance on which format fits a specific situation. A general advice 
is to specify to respondents what opt-out, neither, or SQ mean. In addition, researchers 
are encouraged to collect information on respondents’ SQ (if applicable) and include this 
information in the analysis of the choice data. 
In this study we aim to investigate the implications of using different unforced choice formats 
in two different settings: 1) the use of opt-out versus neither in a market where there is no 
SQ, and 2) including SQ in addition to opt-out in a market where respondents have a SQ. 
To our best knowledge, there are no published studies that have compared the inclusion 
of opt-out with neither. In addition, we are aware of only two studies (outside of health 
economics) that assess the impact of using a SQ alternative versus an opt-out alternative [2, 
25]. Both studies found that results differed between the two formats. It was recommended 
to consider the applicability of format carefully [2], and to choose a format that enhances 
the realism of the exercise [25]. Hence, using an opt-out in situations where the SQ may be 
preferred can bias results, just as the opposite may hold true. Our study adds to the findings 
of [2] and [25] by investigating how the inclusion of a SQ in addition to an opt-out alternative 
affects DCE results. This has not been studied before although a few studies (one within 
health economics) have used this approach empirically to elicit preferences [26-29]. 
The remainder of the manuscript is divided into five sections. Section 2 ‘Research questions’ 
provides a description of the research motivation and research questions. Section 3 
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‘Methods’ includes a description of the case study, the design of the study, and the 
data-collection procedure. In addition, it provides details on the data analysis. Section 4 
‘Results’ contains the comparisons between the different unforced choice formats. Section 
5 ‘Discussion’ concludes with a discussion of the results, the limitations of the study, and 
recommendations for future studies.
2. RESEARCH QUESTIONS
2.1 Opt-out versus neither
In DCE guidelines, the term opt-out is used to encapsulate both the neither and the opt-
out alternative. The only exceptions are the work by [21, 30] where the authors explicitly 
distinguish between these two formats. Likewise, the opt-out and neither alternatives are 
usually coded similarly when analysing the data, i.e. as zeros or as missing attribute levels 
[23]. Although some respondents may interpret choosing neither of the alternatives as a 
pure opt-out (not to buy the good or use the service), others may interpret neither in terms 
of a better alternative for which the researcher usually does not know the associated levels. 
For example, a DCE on patients’ hospital choice in the UK [11] included a neither alternative, 
and respondents were explicitly explained that: “… choosing ‘neither’ corresponded to a 
decision to look either for alternative treatment outside of the NHS, or opting not to have the 
operation”. This uncertainty surrounding respondents’ interpretation leads to challenges 
when modelling the neither alternative and may bias the DCE results if zero or missing values 
are used in cases where other levels would have been more appropriate. Previous studies 
that included a neither alternative also raised this point about multi-interpretability. For 
example, in a DCE on family planning (FP) and HIV services [31] where a neither alternative 
was included, it was stated that “… ‘neither’ responses could be interpreted either as a 
choice not to use FP or not to use any service at all. This would obscure the preferences of 
individuals who would like to use a service, but who find that the alternatives presented 
are not suitable”. And, in a DCE on preferences for key dimensions of quality of care [32], it 
was stated that “… the study may have not clearly specified what a ‘no’ response meant—
whether it indicated seeking care at a private facility or not seeking facility-based care—
which may have implications for the interpretation of the constant terms”. 
In the first part of this study, we assess empirically whether DCE results are affected by 
the inclusion of either an opt-out or a neither alternative, and we survey respondents’ 
interpretation of neither. To the extent that choice format does not affect elicited preferences, 
we conclude that neither is generally interpreted equivalently to opt-out, i.e. as a zero 
alternative. However, to the extent that the results differ, this is an indicator that the use 
of neither introduces other interpretations amongst respondents, hereby changing their 
decision rule and/or choice behaviour. In this case there is no clear alignment between the 
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respondents’ perception of the neither alternative, and the analyst’s subsequent analytical 
approach. In this case, we will argue that opt-out should be preferred over neither in future 
DCE studies because using a neither alternative entails imputation of attribute values that 
are likely to be markedly different than those imagined by respondents. Our first research 
question is:
Research question 1: Does the inclusion of an “opt-out” instead of a “neither” alternative 
affect DCE results?
2.2 The inclusion of a status quo alternative
In markets where respondents have a SQ, an unforced choice is not necessarily ensured in 
a choice situation that includes an opt-out alternative [2, 25]. Respondents that prefer their 
current alternative to the hypothetical alternative(s) and the opt-out alternative do not have 
the opportunity to make this choice in choice situations where only an opt-out is included. 
For example, a DCE on patients’ preferences for their choice of dentist [7], included two 
hypothetical alternatives and an opt-out alternative. However, if respondents prefer their 
current dentist, they are forced to choose one out of three alternatives they would not 
have chosen in a real market setting, despite that an unforced choice experiment (in its 
traditional meaning) has been designed. Interestingly, the opt-out alternative is potentially a 
relevant option for patients who no longer wish to use their current alternative or any of the 
hypothetical alternatives, as historical decisions do not necessarily reflect future decisions 
(see e.g. [33] for a study on temporal stability in preferences). Including both an opt-out and 
a SQ alternative in a DCE has not been explicitly mentioned in the literature as a potential 
unforced choice format to use, and only a limited number of studies have included both 
an opt-out alternative and a SQ alternative in each choice set. The only study that we are 
aware of within health economics is a DCE on preferences for preventive asthma medication 
in which asthma patients were asked to choose between hypothetical medication, the 
medication they were currently using, and no medication [26, 27]. The authors argue that 
the opt-out was used together with the SQ to: “ensure that respondents were not forced to 
make a choice between two alternatives, when they might choose neither in practice”. For 
examples from other fields of economics where a SQ and an opt-out are also included see 
[28, 29]. 
In the second part of this study, we assess empirically whether the inclusion of a SQ in 
addition to an opt-out alternative affects the DCE results in markets where there is a SQ. 
We argue that if we find differences, this is indicative of the importance of also including a 
SQ alternative to ensure a truly unforced choice. In this case choice sets that include a SQ 
in addition to opt-out should be preferred to opt-out only in future DCE studies. Our second 
research question is: 
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Research question 2: Does the inclusion of a “status quo” alternative in addition to an “opt-
out” alternative affect DCE results in markets where there is a status quo?
3. METHODS
3.1 Case study details
A DCE on Dutch citizens’ preferences for personal health records (PHRs) served as our 
case. A PHR can be defined as: “An electronic application through which individuals can 
access, manage and share their health information, and that of others for whom they are 
authorized, in a private, secure, and confidential environment” [34]. PHRs are seen as a 
tool to empower patients [35], give patients more control over their health care process 
[35], and reduce administrative workload for health care practitioners. Unfortunately, many 
PHRs that are currently on the market are not based on patients’ needs [36], and uptake is 
limited. Insights in the value that consumers place on various PHR characteristics can help 
developers to improve their products, and advice policy makers on furthering conditions for 
the use of PHRs [37].
The case is appropriate for our methodological study since this is a market where some 
respondents do not have a SQ, while others do. Hence, we allocate respondents who do 
not have a PHR to DCE questions relating to research question 1, while those with a PHR are 
presented with DCE scenarios that are designed to answer research question 2.
3.2 Study design
The DCE included five attributes with two to six levels each (Table I). These attributes and 
levels were carefully selected based on a literature study, interviews with experts (policy 
makers and researchers; N=5), focus group discussions (N=4, with a total number of 25 
participants similar to the target group of the DCE), and brainstorm sessions with co-authors. 
By minimizing the D-efficiency criterion, a main-effects efficient Bayesian design based on 
best guess priors was generated using Ngene software (Choice Metrics, version 1.1.1.). 
These priors (small positive and negative values) were used to increase the efficiency of the 
design by avoiding dominant choice sets. We created a design with 12 choice sets to ensure 
enough degrees of freedom to estimate all main effects (assuming a non-categorical cost 
attribute), in which also level balance was achieved. 
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Table I | Attributes and corresponding levels included in the DCE.
Attributes Attribute levels Variable name
Facilitating party for storage of PHR data Commercial company Reference level
Independent organization or platform Stor1
Government Stor2
Health care providers or health facility Stor3
Level of connectivity Standalone Reference level
Tethered with your GP system Tech1
Tethered with your hospital system Tech2
Interconnected Tech3
Use of anonymized data by third parties No, never Reference level
Yes, after permission Data1
Option to upload the person’s own data 
into the PHR
No, not possible Reference level
Yes, possible Use1
The price you pay per year to make this 
PHR available to society
€0, €15, €30, €50, €70, €95 Cost
Abbreviations: GP general practitioner; PHR personal health record.
Choice sets consisted of two unlabelled hypothetical PHR alternatives, and one of the 
unforced choice formats. We used a split-sample design in which respondents were, given 
their PHR status, randomized to a certain split based on date of birth (Table II). The opt-out 
alternative was formulated as ‘no PHR’, neither was formulated as ‘none of these’, and the 
SQ alternative was formulated as ‘the PHR that I currently have’ (Additional file 1). The same 
choice sets were used across all splits. 
Table II | Overview of splits within the study.
Split PHR status1 Randomization2 Choice sets 1-12 Choice sets 12-24
Research 
question3
Split 1 PHR - 50% of PHR - a, b, opt-out N/A 1
Split 2 PHR - 50% of PHR - a, b, neither N/A 1
Split 3a PHR + 25% of PHR + a, b, opt-out a, b, SQ, opt-out 2
Split 3b PHR + 25% of PHR + a, b, SQ, opt-out a, b, opt-out 2
Abbreviations: PHR personal health record; SQ status quo; N/A not applicable.
Notes: 1The self-reported PHR status of a respondent; 2Respondents were, given their PHR status, randomized 
between splits based on their day of birth (odd or even). The data of 50% of respondents with a PHR was not 
used for the current study. 3For research question 1 we used between respondent comparisons, while for 
analysis of research question 2 we use within respondent comparison. The data of split 3a and split 3b was 
pooled to accommodate potential ordering effects. 
3.3 Survey instrument
The survey started with an introduction to the study and the topic. Next, respondents were 
screened for their PHR status and given this status subsequently randomized between splits 
based on their day of birth (odd or even). Those respondents that stated that they currently 
have a PHR were asked to select the attribute levels that they thought were closest to their 
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current PHR (the information was used in subsequent analyses). Hereafter, the included 
attributes and their corresponding levels, as well as the DCE task, were explained to 
respondents. Subsequently, respondents completed either 12 or 24 choice sets, depending 
on the split they were randomized to (Table II). The choice sets were followed by an open 
text question on what respondents had in mind for the neither alternative (split 2 only). 
All respondents were asked on perceived difficulty of the DCE questions, certainty in their 
answers to the DCE questions, and their perception of the number of DCE questions. 
These questions were followed by questions about sociodemographic characteristics. The 
draft survey was pilot tested using think aloud interviews (N=4) to test for respondent 
understanding and to improve the wording of the survey. Next, a formal pilot test was 
conducted (N=51). Pilot test data was analysed using multinomial logit models and estimates 
were used as priors for the final DCE design. 
3.4 Data collection
The survey was administered to Internet panel members of the Dutch Federation of Patient 
and Consumer Organizations (NPCF) in December 2015 and January 2016. All panel members 
(N=22,841) received an email with the URL to the online survey and were asked to complete 
it on a voluntary basis. Data-collection was terminated once the number of respondents 
completing the survey had decreased to a few respondents per day. Because of practical 
limitations at the NPCF, no reminders were sent out. Formal testing of the study protocol by 
a Medical Ethics Committee was not necessary, as a questionnaire study amongst healthy 
volunteers of an Internet panel does not fall within the scope of the Dutch Act on Medical 
Research Involving Human Subjects.
3.5 Data analysis
To answer our research questions we performed a number of tests across the relevant splits. 
In all cases we made comparisons on the number of respondents that always chose opt-out/
neither/SQ, respectively, and the total number of times the opt-out/neither/SQ alternative 
was chosen. Descriptive analyses were performed in SPSS version 22.
To estimate utilities, we used a random utility theory framework where the true but latent 
utility for alternative i of individual n can be written as: 
(1) Uin = Vin + εin
Vin represents the observable systematic component of utility, which is the explainable 
proportion of the choice of alternative i of individual n, and ein is the non-explainable 
proportion representing the unobservable and random treated component. Assuming a 
linear additive utility function, the observable component for individual n for alternative i 
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becomes Vin = βXin  where Xin = (X1, X2,....,Xr) is a vector of attributes. The linear predictor, V, 
of the applied models is shown below.
(2) Vn = αn + β1stor1n + β2stor2n + β3stor3n + β4tech1n 
+ β5tech2n + β6tech3n + β7data1n + β8use1n + β9cost n
Where α refers to the alternative specific constant (ASC) appropriate for that split. In the 
split where both a SQ and an opt-out are included, two ASCs were estimated. In that case, α 
is the sum of the estimates for the two constants. 
Assuming that the error terms are independent and identically distributed (iid) extreme 
value random variables, makes a logit model appropriate. Assuming that the coefficients 
vary over respondents with density 
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We compared model fit, signs and significance of utility parameters, relative importance of 
attributes (RI), and significance of error components between the relevant splits. In addition, 
we calculated marginal willingness-to-pay estimates (MWTP). T-tests were conducted to 
test for differences. We also calculated potential market shares to show how the different 
choice formats affect these. To take account of the random component in the error term, all 
probabilities were simulated (using 50,000 pseudo-random draws) based on the estimates 
from the error component models. 
3.5.1. Analyses specific to research question 1
In addition to the analyses described above, we compared sociodemographic variables 
between splits to test whether the randomisation was successful using chi2 tests and 
independent sample t-tests for equality of means. We also compared respondents’ median 
response times, answers to perceived difficulty of the DCE questions, certainty in their 
answers to the DCE questions, and their perception of the number of DCE questions. 
Moreover, we conducted log likelihood ratio tests as proposed by Swait & Louviere [40] 
to test for equality in utility parameters and scale across samples. Based on the open text 
question posed to respondents in split 2 regarding what they had in mind when choosing the 
neither alternative, responses were categorized by one researcher (e.g. as opt-out (no PHR), 
as a more ideal alternative, etc.), and when there was doubt another researcher verified it. 
We estimated two error component models for the neither split. In the first model, neither 
was coded as zeros for all respondents as is usual coding practice [23, 41]. This model was 
compared to the opt-out model. In the second model, we added interaction terms with the 
ASC based on the categorisation of respondents’ answers to what they had in mind when 
choosing neither. This allowed us to investigate the degree of heterogeneity in perceptions 
of the neither alternative.
4. RESULTS
4.1 Sample of respondents
The DCE was completed by 3404 panel members. Of those, 2986 (88%) had no PHR and 
were therefore randomized to split 1 or 2 (opt-out and neither split respectively, research 
question 1), while 418 (12%) had a PHR and were randomized to split 3a-3d. Only the data 
of respondents randomized to split 3a and 3bd (N=203) were used in the current study. 
Of these respondents 5% (N=11) had one or more missing current PHR values. Those 
respondents were excluded from the study. The Additional files 2 and 3 give an overview of 
number of respondents in the different splits, and their sociodemographic characteristics. 
Randomization was successful between the opt-out and neither splits on all observed 
variables (Additional file 3). 
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4.2 Research question 1 (Opt-out versus neither)
The median response time was slightly higher in the neither split compared to the opt-out 
split (Table III). The perceived difficulty, certainty in choices and quantity differed between 
the two splits. More respondents in the neither split found the choice tasks easy to answer, 
more were certain of their answers, and fewer perceived the number of choices as too 
high. Fewer respondents in the neither split always chose the neither alternative, while the 
neither alternative was chosen significantly more often than the opt-out alternative. 
4.2.1. Model 1: Opt-out versus neither
All marginal utilities were significantly different from zero for the two splits, and signs were 
the same across splits (Table III). The facilitating party for storage of PHR data was the most 
important attribute, while use of anonymized data by third parties was the least important 
attribute for both splits. For the rest of the attributes, rank orders differed between splits. 
The ASC for opt-out was relatively smaller than the ASC for neither. However, the standard 
error, as well as the standard deviation of the ASC, was larger for opt-out than for neither. 
Pseudo-R2, AIC and BIC indicated that the opt-out split had a much better model fit than the 
neither split. The Swait and Louviere log likelihood test showed that marginal utilities in the 
two models were not equal. MWTPs suggested significant differences between splits for 
the storage attribute as well as for tech2 (both higher in opt-out split), and the ASCs (higher 
in neither split). Calculation of potential market shares predicted that the PHR uptake for 
the best PHR (based on marginal utilities) would be 51% in the opt-out split and 43% in the 
neither split, whereas for a PHR with the worst attribute levels, uptake would be 35% in the 
opt-out split and only 14% in the neither split. 
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Table III | Descriptive statistics and estimation results for research question 1 (comparison between 
split 1 and split 2, N=2986).
Split 1: Opt-out (N=1,443) Split 2: Neither (N=1,543)
Median (IQR) Median (IQR) P-value
Response time in minutes 21 (16-28) 22 (17-30) 0.003
Survey perception N (%) N (%) P-value
Perceived difficulty
Very easy 44 (3.1) 81 (5.3) <0.001
Easy 257 (17.9) 346 (22.6)
Neutral 600 (41.9) 643 (42.0)
Hard 449 (31.3) 396 (25.9)
Very hard 83 (5.8) 64 (4.2)
Certainty in answers
Very certain 125 (8.7) 216 (14.1) <0.001
Certain 503 (35.0) 616 (40.3)
Neutral 547 (38.1) 499 (32.6)
Uncertain 224 (15.6) 178 (11.6)
Very uncertain 37 (2.6) 20 (1.3)
Quantity of choice sets
Too low 209 (14.6) 243 (15.9) 0.031
Exactly right 511 (35.6) 598 (39.1)
Too high 716 (49.9) 689 (45.0)
Choice behaviour
Respondents always choosing 
opt-out / neither
495 (34.3) 474 (30.7) 0.037
Choice sets in which opt-out / 
neither was chosen
9198 (53.1) 12212 (66.0) <0.001
Error component models1 Marginal utility (SE) RI (rank) Marginal utility (SE) RI (rank)
Stor1 0.880 (0.041)*** 0.31 (1) 0.858 (0.045)*** 0.39 (1)
Stor2 0.454 (0.048)*** 0.438 (0.050)***
Stor3 0.905 (0.048)*** 0.871 (0.049)***
Tech1 0.520 (0.046)*** 0.18 (3) 0.611 (0.047)*** 0.25 (2)
Tech2 0.381 (0.045)*** 0.351 (0.047)***
Tech3 0.363 (0.045)*** 0.390 (0.048)***
Data1 0.443 (0.025)*** 0.15 (4) 0.534 (0.028)*** 0.14 (3)
Use1 0.341 (0.024)*** 0.12 (5) 0.410 (0.028)*** 0.10 (5)
Cost -0.008 (0.000)*** 0.25 (2) -0.010 (0.000)*** 0.12 (4)
ASC opt-out / ASC neither 0.730 (0.210)*** N/A 1.734 (0.097)*** N/A
SD (SE) SD (SE)
ASC opt-out / ASC neither 7.073 (0.296)*** N/A  3.343 (0.104)*** N/A
Model fit
Observations 51948 55548
Respondents 1443 1543
Log Likelihood (0) -17078 -15709
Log Likelihood (Model) -10021 -11399
Pseudo-R2 0.413 0.274
AIC 20064 22820
BIC 20161 22918
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Swait and Louviere test
Equality in utility parameters
Easy 257 (17.9) 346 (22.6) 
Neutral 600 (41.9) 643 (42.0) 
Hard 449 (31.3) 396 (25.9) 
Very hard 83 (5.8) 64 (4.2) 
Certainty in answers    
Very certain 125 (8.7) 216 (14.1) <0.001 
Certain 503 (35.0) 616 (40.3) 
Neutral 547 (38.1) 499 (32.6) 
Uncertain 224 (15.6) 178 (11.6) 
Very uncertain 37 (2.6) 20 (1.3) 
Quantity of choice sets    
Too low 209 (14.6) 243 (15.9) 0.031 
Exactly right 511 (35.6) 598 (39.1) 
Too high 716 (49.9) 689 (45.0) 
Choice behaviour    
Respondents always choosing 
opt-out / neither 
495 (34.3) 474 (30.7) 0.037 
Choice sets in which opt-out / 
neither was chosen 
9198 (53.1) 12212 (66.0) <0.001 
Error component models1 Marginal utility (SE) RI (rank) Marginal utility (SE) RI (rank)  
Stor1 0.880 (0.041)*** 0.31 (1) 0.858 (0.045)*** 0.39 (1)  
Stor2 0.454 (0.048)*** 0.438 (0.050)***  
Stor3 0.905 (0.048)*** 0.871 (0.049)***  
Tech1 0.520 (0.046)*** 0.18 (3) 0.611 (0.047)*** 0.25 (2)  
Tech2 0.381 (0.045)*** 0.351 (0.047)***  
Tech3 0.363 (0.045)*** 0.390 (0.048)***  
Data1 0.443 (0.025)*** 0.15 (4) 0.534 (0.028)*** 0.14 (3)  
Use1 0.341 (0.024)*** 0.12 (5) 0.410 (0.028)*** 0.10 (5)  
Cost -0.008 (0.000)*** 0.25 (2) -0.010 (0.000)*** 0.12 (4)  
ASC opt-out / ASC neither 0.730 (0.210)*** N/A 1.734 (0.097)*** N/A  
 SD (SE)  SD (SE)   
ASC opt-out / ASC neither 7.073 (0.296)*** N/A  3.343 (0.104)*** N/A  
Model fit    
Observations 51948  55548  
Respondents 1443 1543  
Log Likelihood (0) -17078 -15709  
Log Likelihood (Model) -10021  -11399  
Pseudo-R2 0.413 0.274  
AIC 20064 22820  
BIC 20161 22918  
Swait and Louviere test    
Equality in utility parameters 03.21)12(205.0 =χ ; Statistical value = 252.97 
Parameter equality rejected, test stops 
 
Marginal willingness-to-pay MWTP (€) MWTP (€) P-value 
Stor1 114 84 0.001 
Stor2 59 43 0.047 
Stor3 117 86 0.001 
Tech1 67 60 0.357 
Tech2 49 35 0.038 
Tech3 47 38 0.247 
Data1 57 53 0.354 
Use1 44 40 0.442 
ASC opt-out / ASC neither 95 171 0.016 
Market shares Probability (Opt-out/PHR) Probability (Neither/PHR)  
Best PHR  49% / 51% 57% / 43%  
Worst PHR 65% / 35% 86% / 14%  
 
Abbreviations: IQR interquartile range; SE standard error; RI relative importance; N/A not applicable; ASC alternative specific constant; SD 
standard deviation; AIC Akaike Information Criterion; BIC Bayesian Information Criterion; MWTP marginal willingness-to-pay; PHR personal 
health record. 
(12) =21.03; Statistical value = 252.97
Parameter equality rej cted, test stops
Marginal willingness-to-pay MWTP (€) MWTP (€) P-value
Stor1 114 84 0.001
Stor2 59 43 0.047
Stor3 117 86 0.001
Tech1 67 60 0.357
Tech2 49 35 0.038
Tech3 47 38 0.247
Data1 57 53 0.354
Use1 44 40 0.442
ASC opt-out / ASC neither 95 171 0.016
Market shares Probability (Opt-out/PHR) Probability (Neither/PHR)
Best PHR 49% / 51% 57% / 43%
Worst PHR 65% / 35% 86% / 14%
Abbreviations: IQR interquartile range; SE standard error; RI relative importance; N/A not applicable; 
ASC alternative specific constant; SD standard deviation; AIC Akaike Information Criterion; BIC Bayesian 
Information Criterion; MWTP marginal willingness-to-pay; PHR personal health record.
Notes: 1 *** Statistically significant at the 0.01 level. 
4.2.2. Model 2: Interpretation of neither
Respondents interpreted neither in various ways (Table IV, and Additional file 4). Only 14.3% 
of respondents stated that they had ‘no PHR’ in mind, while 12.5% of the respondents stated 
to have another more ideal PHR in mind than the two hypothetical PHRs presented in the 
choice sets. Some respondents (0.9%) described that they did not think neither represented 
a real choice. These respondents never chose the neither alternative in any of the choice 
sets. 
The error component model showed significant interactions between the ASC and (most 
of) the categories of neither interpretation (Table IV). Respondents interpreting the neither 
as ‘no PHR’ had significantly more utility associated with choosing the neither alternative 
compared to those explaining neither as another more ideal alternative. Respondents 
belonging to the other categories had a significantly lower utility associated with choosing 
the neither compared to respondents thinking of an ideal PHR. 
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Table IV | Interpretation of neither alternative (split 2, N=1,543).
Interpretation of the neither alternative N (%)
Ideal PHR 193 (12.5)
Opt-out 220 (14.3)
Neither in their own words 147 (9.5)
Explanation of decision rule 600 (38.9)
Neither is not a real choice 14 (0.9)
Hard to make a choice between PHRs, neither is the easy 
option to choose
18 (1.2)
Blank or uninterpretable 351 (22.7)
Error component model 21 Utility (SE) SD (SE)
Stor1 0.858(0.045)***
Stor2 0.437(0.050)***
Stor3 0.871(0.049)***
Tech1 0.611(0.047)***
Tech2 0.350(0.047)***
Tech3 0.390(0.048)***
Data1 0.534(0.028)***
Use1 0.410(0.028)***
Cost -0.010 (0.000)***
ASC (reference: Ideal PHR) 2.613 (0.162)*** 1.678 (0.157)***
ASC No PHR 2.610 (0.598)*** 5.248 (0.650)***
ASC Neither in own words -0.976 (0.258)*** 1.318 (0.406)***
ASC Decision rule -0.735 (0.187)*** 0.927 (0.344)***
ASC Not a real choice2 -25.618 (4746.873) 0.726 (3932.678)
ASC Hard to make a decision -2.009 (0.913)** 3.185 (1.209)***
ASC Blank / uninterpretable -4.114 (0.378)*** 5.310 (0.451)***
Model fit
Observations 55548
Respondents 1543
Log Likelihood (0) -14442
Log Likelihood (Model) -11083
Pseudo-R2 0.2326
AIC 22211
BIC 22416
Abbreviations: PHR personal health record; SD standard deviation; SE standard error; ASC alternative specific 
constant; AIC Akaike Information Criterion; BIC Bayesian Information Criterion.
Notes: 1 *** Statistically significant at the 0.01 level, ** Statistically significant at the 0.05 level, * Statistically 
significant at the 0.1 level. 2This estimate is highly insignificant since none of these respondents (N=14) ever 
chose the neither alternative, hereby not contributing to the ASC.
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4.3 Research question 2 (The inclusion of a status quo alternative)
The opt-out alternative was chosen less frequently when a SQ alternative was also included 
in the choice sets, compared to when only opt-out was included (11.2% vs 30.6%, Table 
V). Moreover, the SQ alternative was chosen in 55.7% of the choice sets in which it was 
included. A similar pattern was seen for the proportion of respondents that always chose 
SQ or opt-out. 
All marginal utilities were significantly different from zero in the two splits, and signs were 
the same across splits (Table V). The relative importance and rank orders were comparable, 
although costs were slightly more important in the opt-out only model. The ASC for opt-
out was negative and significant in both splits, which indicates that respondents who are 
already on the PHR market, all else equal, prefer to have a PHR. The size of the ASC for opt-
out was relatively larger in the SQ and opt-out split. In the SQ and opt-out split, the ASC for 
the SQ was positive, which indicates that respondents, all else equal, prefer their current 
PHR to a new PHR. Pseudo-R2, AIC and BIC showed that the model fit was much better for 
the split in which the SQ was included in addition to the opt-out. MWTPs differed (some 
at the 10% level) and there were large differences in magnitude on some attributes. With 
respect to market shares an uptake of 75% (53%) for the best (worst) PHR was predicted 
in the DCE with opt-out only, while this prediction was 47% (8%) in the DCE with both the 
opt-out and the SQ. 
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Table V | Descriptive statistics research question 2 (within respondent comparison, N=192).
Split 3a and 3b: Opt-out only Split 3a and 3b: SQ and opt-out
Choice behaviour N (%) N (%) P-value
Respondents always choosing opt-out 24 (12.5) 11 (5.7) 0.021
Respondents always choosing SQ N/A 64 (33.3) <0.0011
Choice sets in which opt-out was chosen 705 (30.6) 258 (11.2) <0.001
Choice sets in which SQ was chosen N/A 1283 (55.7) <0.0011
Error component model2 Marginal utility (SE) RI (rank) Marginal utility (SE) RI (rank)
Stor1 0.881 (0.097)*** 0.31 (1) 0.640 (0.128)*** 0.38 (1)
Stor2 0.504 (0.113)*** 0.368 (0.145)**
Stor3 1.166 (0.117)*** 0.820 (0.143)***
Tech1 0.961 (0.111)*** 0.25 (2) 0.558 (0.140)*** 0.29 (2)
Tech2 0.891 (0.111)*** 0.513 (0.139)***
Tech3 0.798 (0.109)*** 0.377 (0.142)***
Data1 0.474 (0.057)*** 0.13 (4) 0.364 (0.079)*** 0.10 (5)
Use1 0.239 (0.056)*** 0.06 (5) 0.384 (0.079)*** 0.11 (4)
Cost -0.010 (0.001)*** 0.25 (3) -0.009 (0.001)*** 0.12 (3)
ASC opt-out -2.989 (0.557)*** N/A -5.602 (1.190)*** N/A
ASC SQ N/A N/A 1.371 (0.442)*** N/A
SD (SE) SD (SE)
ASC opt-out 5.797 (0.641)*** N/A 7.319 (0.860)*** N/A
ASC SQ N/A N/A 5.595 (0.593)*** N/A
Model fit
Observations 6912 9216
Respondents 192 192
Log Likelihood (0) -2382 -2649
Log Likelihood(Model) -1622 -1423
Pseudo-R2 0.319 0.463
AIC 3267 2872
BIC 3342 2964
Marginal willingness-to-pay MWTP (€) MWTP(€) P-value
Stor1 90 71 0.344
Stor2 51 41 0.583
Stor3 119 90 0.233
Tech1 98 62 0.080
Tech2 91 57 0.073
Tech3 81 42 0.043
Data1 48 40 0.496
Use1 24 42 0.128
ASC opt-out -304 -618 0.079
ASC SQ N/A 151 <0.0013
Market shares Probability (Opt-out/PHR) Probability (SQ/Opt-out/PHR)
Best PHR 25% / 75% 42% / 11% / 47%
Worst PHR 47% / 53% 71% / 21% / 8%
Abbreviations: SQ status quo; N/A not applicable; SE standard error; RI relative importance; ASC alternative 
specific constant; SD standard deviation; AIC Akaike Information Criterion; BIC Bayesian Information 
Criterion; MWTP marginal willingness-to-pay; PHR personal health record. 
Notes: 1 For the difference in proportions between the SQ and opt-out only. 2 *** Statistically significant at 
the 0.01 level, ** Statistically significant at the 0.05 level. 3 For the difference in WTP between the ASC opt-
out and ASC SQ. 
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5. DISCUSSION
5.1 Research question 1 (opt-out versus neither)
Completing choice sets that include neither seems to be easier for respondents than 
completing choice sets that include opt-out. This is most likely because respondents have 
the freedom to interpret the neither alternative in numerous different ways. Only a minority 
of the respondents’ interpret the neither alternative as it is coded by the analyst, namely 
as an opt-out alternative with zero attribute levels. We found that the marginal utilities and 
welfare estimates differ between the two splits, and that the model fit was much better for 
the opt-out split. Based on differences in results between the two splits, we recommend 
using opt-out instead of neither in future DCE studies, because the neither alternative 
entails imputation of attribute values (i.e. all zeroes) that are likely to be markedly different 
from those imagined by the respondents. 
5.2 Research question 2 (the inclusion of a status quo alternative)
Both the descriptive data and the error component model show that some respondents 
may have chosen the opt-out while they actually had their SQ in mind. When respondents 
are given the opportunity to choose either opt-out or SQ, a large majority of respondents 
chooses the SQ. In addition, the model fit was better for choice sets including both opt-out 
and SQ compared to the model with opt-out only. RIs, MWTPs, and market shares differ 
between the splits; hence, policy recommendations would be very different depending on 
which format to use. Based on these results, we recommend to include a SQ together with 
the opt-out in markets with a SQ to ensure a truly unforced choice. 
We have analysed the inclusion of SQ in addition to opt-out. However, one may question 
whether SQ may be a substitute for opt-out. In theory, we would argue for inclusion of both 
options in order to ensure the ideal unforced choice. Looking at our empirical results, the 
opt-out was chosen in 11.2% of the choice sets where SQ was also present. We believe that 
this result is a conservative estimate since PHRs are renewable goods, where consumers are 
not expected to change preferences on a daily or even monthly basis. If we had used a case 
of perishable goods, we would expect to observe an even larger rate of opt-out choices, as 
choices are more fluctuant. In other cases, for example in the case of lifesaving medication 
where opting out means not surviving, it can be argued that the opt-out alternative can 
be left out of the choice sets (hereby only including the SQ). To sum up, the relevance of 
including an opt-out alternative in addition to SQ may depend on the type of good or service 
(renewable/perishable) and the elasticity of demand (elastic/inelastic).
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5.3 Limitations
Our findings should be interpreted with the following limitations in mind. First, because of 
technical limitations at the NPCF, we were not able to present respondent specific SQ levels 
in the choice sets and to pivot the attribute levels of the hypothetical alternatives around 
the SQ (e.g. xx % more expensive than your SQ). Instead, the SQ alternative was framed as 
“My current PHR” (see Additional file 1). Our finding that SQ should be included in addition 
to opt-out might have been even more strongly supported if respondents could have seen 
their individual SQ levels. Second, we did not include a question on how respondents 
interpreted the opt-out alternative. Although we do not expect this alternative to be 
interpreted as heterogeneously as the neither alternative, future research could investigate 
if respondents indeed perceive the opt-out alternative as the option not to buy the good/
choose the service. Third, only 3,404 out of 22,841 panel members completed the survey 
(15%). We expect that the reason for the low completion rate is that panel members of 
NPCF are not used to this type of questions and that no reminders were sent. However, as 
we used a randomized design with a substantial number of respondents in each split, we do 
not expect this to influence our conclusions. 
5.4 Recommendations for future studies
Based on our findings we make two recommendations: 
•	 Use opt-out instead of neither, as neither represents an unspecified alternative 
that is interpreted differently by respondents, and seldomly as a true opt-out 
alternative.
•	 Include both an opt-out and a SQ alternative in markets with a SQ if this best mimics 
the real market situation. Given that DCE designs are increasingly web-based 
and interactive, initial SQ questions can easily feed into tailored DCE questions 
presented to the individual respondent.
We note that our study provides guidance particularly in those DCEs were it is unclear which 
format to use. We conclude that including either an opt-out option or a SQ option, does 
not necessarily ensure unforced choice. Hence, health economists engaged in preference 
elicitation tasks are urged to carefully consider how to design the unforced choice 
experiment. This study is the first to make a head-to-head comparison of the implications 
of including neither versus opt-out alternatives as well as the implications of including SQ in 
addition to opt-out. We show that choice of these design features of DCE matter, and should 
receive ample attention amongst researchers applying DCEs.
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ADDITIONAL FILE 1: CHOICE SET EXAMPLES
We used a dual response design in which respondents were forced to make a choice between 
two personal health record (PHR) alternatives first, and they were then asked to make an 
unforced choice. We believed that this approach was necessary given the low expected 
uptake of PHR. 
Opt-out:
 
A B
What do you prefer?
Personal Health Record A Personal Health Record B
Who facilitates data storage: Commercial company Government
Technical aspect of data storage: Standalone Tethered with your hospital 
Use of anonymized data to improve quality of Dutch health care system No, never Yes, after permission
Adding of own data possible: No Yes
PHR costs for society. The price you pay per year is: €15 €30
A B No PHR
What would you choose?
Neither:
 
A B
What do you prefer?
Personal Health Record A Personal Health Record B
Who facilitates data storage: Commercial company Government
Technical aspect of data storage: Standalone Tethered with your hospital 
Use of anonymized data to improve quality of Dutch health care system No, never Yes, after permission
Adding of own data possible: No Yes
PHR costs for society. The price you pay per year is: €15 €30
A B None of these
What would you choose?
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Status quo and opt-out:
 
A B
What do you prefer?
Personal Health Record A Personal Health Record B
Who facilitates data storage: Commercial company Government
Technical aspect of data storage: Standalone Tethered with your hospital 
Use of anonymized data to improve quality of Dutch health care system No, never Yes, after permission
Adding of own data possible: No Yes
PHR costs for society. The price you pay per year is: €15 €30
A B Current PHR No PHR
What would you choose?
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ADDITIONAL FILE 2: FLOWCHART
 
Invited to the survey 
N = 22,841 
Responses 
N = 3,404 
PHR- 
N = 2,986 
(Research question 1) 
Split 1: Opt-out 
N = 1,443 
Split 2: Neither 
N = 1,543 
PHR+ 
N = 418 
Split 3c and 3d: 
N = 215 
(not used in this study) 
Split 3a and 3b: 
N = 203 
N = 192 
(Research question 2) 
Excluded due to missing 
values in current PHR 
N = 11 
Non respondents  
N = 19,437 
Abbreviation: PHR personal health record.
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ADDITIONAL FILE 3: DESCRIPTIVE STATISTICS
Research question 1 Split 1: Opt-out
(N=1,443)
Split 2: Neither
(N=1,543)
Mean (SD) Mean (SD) P-value
Age 61.41 (11.26) 61.75 (11.00) 0.425
N (%) N (%)
Gender Female 698 (51.0) 736 (50.2) 0.677
Male 671 (49.0) 730 (49.8)
Education1 Low 254 (18.1) 309 (20.6) 0.213
Average 443 (31.6) 466 (31.1)
High 706 (50.3) 722 (48.2)
Work status Paid work 992 (70.0) 1090 (71.8) 0.297
No paid work 425 (30.0) 429 (28.2)
Income2 Low 370 (33.7) 436 (36.3) 0.360
Average 326 (29.7) 355 (29.5)
High 402 (36.6) 411 (34.2)
Health status Healthy 325 (22.5) 384 (24.9) 0.129
Chronically ill 1118 (77.5) 1159 (75.1)
Health literacy3 Low 29 (2.0) 36 (2.4) 0.535
Adequate 1395 (98.0) 1481 (97.6)
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Research question 2 Split 3a and 3b
(N=192)
Mean (SD)
Age In years 63.22 (10.65)
N (%)
Gender Female 82 (45.6)
Male 98 (54.4)
Education1 Low 54 (29.3)
Average 51 (27.7)
High 79 (42.9)
Work status Paid work 35 (18.5)
No paid work 154 (81.5)
Income2 Low 62 (40.5)
Average 45 (29.4)
High 46 (30.1)
Health status Healthy 26 (13.5)
Chronically ill 166 (86.5)
Health literacy3 Low 11 (5.7)
Adequate 181 (94.3)
Difficulty Very easy 5 (2.6)
Easy 40 (21.1)
Neutral 68 (35.8)
Hard 60 (31.6)
Very hard 17 (8.9)
Certainty Very certain 14 (7.3)
Certain 77 (40.3)
Neutral 62 (32.5)
Uncertain 33 (17.3)
Very uncertain 5 (2.6)
Quantity Too low 24 (12.8)
Exactly right 63 (33.5)
Too high 101 (53.7)
Median (IQR)
Response time In minutes 28 (21-37)
Abbreviations: SD standard deviation; IQR interquartile range. 
Notes: 1Educational level was categorized into three groups: low (primary education and lower secondary 
education), average (higher secondary education and intermediate vocational education), and high (tertiary 
education). 2Monthly nett income was categorized into three groups: low (less than €2000), average (€2000-
€3000), high (€3000 or more). 3Subjective health literacy was measured based on the validated Dutch 
questions of the Set of Brief Screening Questions (SBSQ-D) of Chew [1]. 
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ADDITIONAL FILE 4: QUOTES OF INTERPRETATION OF THE NEITHER 
ALTERNATIVE
“The elements that I preferred were mixed between PHR A and PHR B, so none of the 
alternatives offered exactly what I would want. So I thought of a combination where 
I myself could decide on the options.” [Respondent 1363: ideal PHR]
“That there was a better alternative” [Respondent 1815: ideal PHR]
“The combination of elements did not meet my preferences. I do want a PHR, but 
only one that has all my elements of choice.” [Respondent 3157: ideal PHR]
“No PHR” [Respondent 443: opt-out]
“Neither is not really a choice” [Respondent 1610: not a real choice]
“I like some elements of both PHR alternatives, so I could not make a clear choice” 
[Respondent 1003: hard to make a choice]
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ABSTRACT
Objectives: Electronic data-collection is increasingly used for discrete choice experiments 
(DCEs). We aimed to study whether paper or electronic administration results in 
measurement effects.
Methods: Respondents were drawn from the same sample frame (an Internet panel) and 
completed a nearly identical DCE survey either online or on paper during the same period. A 
DCE on preferences for basic health insurance served as a case study. We used panel mixed 
logit models for the analysis. 
Results: In total, 898 respondents completed the survey: 533 respondents completed the 
survey online, while 365 respondents returned the paper survey. There were no significant 
differences with respect to sociodemographic characteristics between the respondents in 
both samples. The median response time was shorter for the online sample compared to 
the paper sample, and a smaller proportion of respondents from the online sample was 
satisfied with the number of choice sets. In addition, a larger proportion of respondents 
from the online sample, compared to the paper sample, failed the monotonicity axiom. We 
found some significant between-sample differences in choice probabilities for the last five 
choice sets. Although some WTP estimates were higher for the online sample, the elicited 
preferences for basic health insurance characteristics were similar between both modes of 
administration.
Conclusions: We find no indication that online surveys yield inferior results compared to 
paper based surveys, while the price per respondent is lower for online surveys. However, 
researchers might want to include fewer choice sets per respondent when collecting DCE 
data online. More research is needed to support our findings. 
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INTRODUCTION
Discrete choice experiments (DCEs) can be administered in various manners, examples 
include paper surveys (either completed on site or distributed via mail) and electronic 
surveys (either on site using a laptop, or distributed via Internet) [1]. Although paper 
surveys were the most common DCE data-collection mode up to 2009, there has since then 
been a shift towards electronic administration [2]. Advantages of electronic data-collection 
over more traditional administration modes include a rapid collection of data, fewer errors 
in the process of data entry and, potentially, lower costs. Technical possibilities inherent 
to electronic nature of surveys offer additional benefits, such as being able to track the 
response time, to randomize or skip questions based on respondents’ previous answers and 
to force respondents to answer all questions. The main concerns regarding electronic data-
collection are the representativeness of samples, and reliability and validity of the obtained 
data. For a more extensive overview of advantages and disadvantages of electronic data-
collection, see for example Ekman & Litton [3], or Gelder et al. [4]. 
Choice of administration mode may affect the responses to a survey, even when the 
questions asked are identical [5, 6]. Administration mode effects can be divided into two 
broad effect categories [7], namely 1) sample composition, or representation effects, and 
2) measurement effects, which are the focus of this paper. Sample composition effects 
relate to who responds to the survey. Measurement effects on the other hand relate to the 
responses elicited, and include social desirability bias (e.g. in the case when an interviewer 
is present), and satisficing or a respondent’s failure to put in sufficient effort to answer the 
question. Measurement effects occur when the same respondent would provide different 
responses to identical worded questions between different survey modes [8]. Research 
within the field of DCEs has shown that changes in design of the survey, for example 
attribute framing [9], attribute ordering [10], and the presentation of attributes as either 
words or graphics [11], have unintended influences on obtained estimates, which might 
result in biased conclusions. In order to be able to assess the appropriateness of increased 
electronic data-collection, it is therefore essential to study whether mode of administration 
(paper versus online administration) also affects DCE results. 
In 2011, Lindhjem & Navrud reviewed studies that compared survey modes within 
environmental stated preference research including several studies that compared paper with 
online administration of DCEs [7]. The authors summarized that evidence of measurement 
effects was lacking, mainly because of the lack of experimental control and confounding 
of measurement and sample composition effects within the reviewed studies [7]. We are 
aware of one additional published study comparing paper with online DCE administration 
since this review. This study by Boyle et al., showed that Internet-based welfare estimates 
were 76% of the mail-based welfare estimates on average [12]. The health-related study 
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described in our paper is a novel contribution to the already existing literature since we 
study mode effects using a well-controlled design in which a large number of respondents 
drawn from the same sample frame (an Internet panel) completed a nearly identical survey 
either online or on paper during the same period. Additionally, almost all studies on this 
topic have been conducted in environmental economics. We found only two health-related 
stated preference studies comparing different administration modes, however not paper 
versus online. Pieterse et al. [13] used an adaptive conjoint analysis survey on rectal cancer 
treatment outcomes to study whether valuations differed between administration via 
a portable computer and administration through Internet; no mode effects were found. 
Mulhern et al. [14] studied whether mode (online versus computer-assisted personal 
interview) had an effect on health state valuations; no effect was found. 
We aimed to study whether the choice of DCE administration mode (paper versus online) 
results in measurement effects. 
METHODS
Case study details
Our study on administration mode was embedded in a DCE on choices of Dutch consumers 
with regard to basic health insurance. In the Netherlands, consumers have the chance to 
switch health insurance on a yearly basis. Within our healthcare system with managed 
competition, health insurers are supposed to act as prudent buyers of care on behalf of their 
customers. To fulfil this role adequately, understanding consumer preferences for health 
plan characteristics is of vital importance. For that reason, we conducted a DCE to quantify 
consumer trade-offs for basic health plan characteristics. We used this DCE application as a 
case for the current methodological study.
The DCE included four attributes: (1) level of choice of care provider, (2) the prime focus 
of insurers’ contracting practices, (3) service benefits provided by the insurer, and (4) 
monthly premium (Table 1). This selection was based on a literature study, interviews with 
experts in the field of health insurance (researchers, policy makers, and employees of a 
health insurance company, n=9) and focus group discussions (n=4) with a total number of 23 
participants. A subset of all possible choice sets was generated using best-guess fixed priors 
in Ngene design software (version 1.1.1.) by minimizing the D-efficiency criterion. These 
priors were based on the literature study and the expert interviews. In addition, experts 
suggested that it was unrealistic to include combinations of the lowest level of freedom 
of provider choice with the highest premium level and vice versa. These restrictions were 
therefore imposed upon the design. To assure level balance and to have enough power to 
estimate all the parameters, the final design consisted of 30 choice sets, blocked into two 
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versions. Each choice set consisted of two basic health plan alternatives: alternative A and 
alternative B. We choose not to include an opt-out alternative, as having a basic health 
insurance plan is obligatory in the Netherlands. 
Table 1 | Attributes and attribute levels included in the DCE.
Attributes Levels Explanation to respondents
Choice of care 
providers 
50% (ref) For fully reimbursed hospital care consumers can 
go to [level] of all hospitals. If consumers go to 
another hospital none (in the case of level 50%), 
75% (in the case of level 80%) or all (in the case 
of level 100%) of the health care costs will be 
reimbursed respectively
80%
100%
Primary focus 
of provider 
contracting
Price of care (ref) Health insurers contract care providers mainly 
focused on either the quality of the care provided, 
price of the care provided or based on social 
responsibility
Quality of care
Social responsibility
Level of service 
benefits
Negative ratings on consumer 
websites (ref)
Customer services include the friendliness and 
ease of contact with the health insurer and the 
accurate and prompt reimbursement of the claims 
of consumers
Positive ratings on consumer 
websites 
Premium €70 The monthly nominal premium for a basic health 
insurance that needs to be paid directly by the 
consumer to the health insurer
€85
€100
€115
Survey instrument
The survey contained two parts. Part one included an introduction, an example choice set, 
and either one of the blocks of 15 choice sets. In addition, we included two extra choice 
sets per respondent to test two important axioms underlying DCE methodology: (1) the 
number of respondents that chose the clearly dominant alternative (monotonicity axiom), 
and (2) the number of respondents that chose the same alternative in repeated choice sets 
(completeness axiom) were assessed [15-17]. It could be hypothesized that there might be 
differences in the number of respondents violating these axioms between administration 
modes. Thus, each respondent needed to complete 17 choice sets in total. Part two 
contained some additional questions (e.g. on respondents’ characteristics and on the survey 
perception). The draft paper survey was pilot tested using think aloud interviews (n=4) to 
test for respondents’ understanding. As a result, the wording of the survey was improved 
where necessary. Subsequently, a formal online pilot test (n=56) was conducted. The pilot 
test data was analysed using multinomial logit models and estimates were used as (fixed) 
priors of the final DCE design.
The survey instrument was kept as identical between the two modes as practically possible. 
However, the surveys differ on two points. First, the online survey forced respondents to 
answer before they could move on to the next question (standard practice in online surveys); 
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while in the paper survey there obviously was a possibility for item non-response. This also 
implies that the online survey is not scrollable, while respondents that completed the paper 
survey could flip through the whole survey. Second, we aimed to report response times 
for the two samples, because previous research shows a relation between response time 
and satisficing [18]. Respondents that completed the paper survey were therefore asked to 
write down the time when they started with the survey as well as to note the time when 
they finished the survey. This was done automatically for respondents who completed the 
survey online. 
Data-collection
We used the rule of thumb as suggested by Orme [19] to determine the minimum required 
sample size needed to answer our research question. We aimed to have at least n=900 
respondents completing the survey (n=450 per mode of administration). Afterwards, we 
used the parametric sample size calculation method as suggested by de Bekker-Grob et al. 
[20] to check whether the statistical power was sufficient, which it was. 
A Dutch research company (CG selections) was selected to collect the data for this study 
among their panel members. Ideally, panel members should have been randomly assigned 
to either one of the two survey modes. This was not possible however because panel 
members of this company are used to complete surveys online and not to complete paper 
surveys. Hence, it would have been unusual for panel members to receive a paper survey 
at home without a formal invitation to participate in the study. We therefore opted for the 
second best option, namely to first send a standard invitation email to panel members. 
When respondents clicked on the URL that was included in the email, they were first asked 
three questions on their age, gender and educational level, to ensure a representative 
distribution of the general adult population of The Netherlands in the sample. This was 
especially important since the aim of our study was to assess measurement effects between 
modes and not sample composition effects. Panel members who met the quotas for age, 
gender and educational level, were asked whether they would be willing to fill out a paper 
survey. Respondents that were willing to complete a paper survey were asked for their 
postal address and the research company sent the survey to them. Respondents were paid 
a small incentive once they had returned the completed survey to the research company. 
Another research company (Datadesk) entered answers given to the paper survey into 
SPSS. Those that were not willing to complete the paper survey were subsequently asked 
whether they would be willing to complete the survey online. Respondents that completed 
the survey online received a small incentive as well. When the target number of panel 
members that agreed to participate in the paper-based survey was reached, panel members 
were no longer asked whether they were willing to complete the paper survey, they instead 
were immediately asked to participate in the online study. The data was collected between 
December 17th, 2014 and January 14th, 2015. 
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Ethical statement
Formal testing of the study protocol by a Medical Ethics Committee was not necessary, as a 
survey study amongst healthy volunteers of an Internet panel does not fall within the scope 
of the Dutch Act on Medical Research Involving Human Subjects.
Analysis
First, we evaluated first whether respondents of both survey modes were comparable with 
respect to sociodemographic characteristics using independent t-tests and chi-squared tests 
in SPSS (version 22). 
Second, descriptive results were compared between administration modes. In addition, the 
number of respondents that fail the monotonicity axiom and completeness axiom were 
assessed. The number of missing responses in choice sets and the choice probabilities were 
also analysed. 
Third, Nlogit (version 5.0) was used to construct both panel latent class models (LC) and 
panel mixed logit models (MIXL). These models account for the panel nature of the data 
(i.e. each respondent completing a number of choice sets), as well as for preference 
heterogeneity between respondents [21]. A LC model with two classes, in which it was tested 
whether mode of administration was a significant class predictor, had a lower fit (based 
on AIC, pseudo-R2, and log likelihood) compared to the final MIXL model and is therefore 
not reported on in the rest of the paper. In the MIXL models, all attributes (except for the 
premium attribute) were effects coded. In order to be able to calculate the willingness-to-
pay (WTP), the premium attribute was included as a fixed parameter, while it was assumed 
that all other attribute level estimates were random and follow a normal distribution. An 
alternative specific constant (ASC) was included in the model to account for the possibility of 
left-to-right bias. A positive significant constant indicates that respondents were more likely 
to select the first alternative they read when answering the choice sets (first column, i.e. 
‘health insurance A’). The final analysis included two models. In the MIXL model on pooled 
data, it was tested whether the mode of administration interacted with all attribute levels. 
Because of potential between-sample differences in scale of the (unobserved) variance of 
the error term, we estimated the same MIXL (except for the interactions) in the two samples 
separately. The coefficients are still not directly comparable between these two models; 
however, coefficient significance, as well as signs, relative importance and WTP estimates 
can be compared. Mean marginal monthly WTP estimates were calculated by taking the 
ratio of the change in the attribute level of interest over the negative coefficient of the 
premium attribute. By doing this, the scale factor becomes redundant in the equation. The 
95% confidence levels around the mean WTP estimates were approximated using the Delta 
method [22].
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RESULTS
The URL in the email was clicked on by 1313 panel members. Of those 1313 members, 329 
(25%) did not meet the quotas for age, gender and/or educational level, and these members 
were therefore directly excluded from participation. A large majority of the target number 
of 450 panel members that agreed to participate in the paper survey (n=365, 81%) returned 
the completed paper survey to the research company. Of the 534 panel members that were 
asked to participate in the online survey, 533 participated. Thus, a total of 898 respondents 
completed the survey. As sample completion was steered by quotas based on socio-
demographic characteristics, there were no significant differences in sociodemographic 
characteristics between the respondents of both samples (Table 2). 
Table 2 | Demographic characteristics of study population, stratified by administration mode.
Total 
sample
(n=898)
Online 
sample 
(n=533)
Paper
sample1 
(n=365)
P-value2 
Age in years Mean ± SD 
(range)
47.7 ± 15.0 
(19-74)
47.0 ± 14.9 
(19-70)
48.7 ± 14.9 
(19-74)
0.12
Age groups 18-29 years (%) 17.8 18.8 16.5 0.40
30-44 years (%) 24.1 25.3 22.3
45-59 years (%) 27.8 27.6 28.2
60+ years (%) 30.2 28.3 33.0
Gender Female (%) 49.7 50.7 48.2 0.47
Educational level3 Low (%) 23.8 24.0 23.4 0.76
Average (%) 41.3 42.0 40.2
High (%) 34.9 34.0 36.4
Gross income per 
month4
Low (%) 33.3 34.1 32.0 0.72
Average (%) 20.4 19.9 21.3
High (%) 27.9 27.4 28.7
Does not know, or does not 
want to tell (%)
18.3 18.6 18.0
Working status Paid, full or part-time (%) 53.1 54.4 51.2 0.35
Number of chronic 
diseases5
Mean ± SD 
(range)
1.23 ± 1.49 
(0-9)
1.21 ± 1.54 
(0-9)
1.27 ± 1.41 
(0-6)
0.52
None (%) 41.7 44.7 37.3 0.06
1 disease (%) 25.4 24.2 27.1
2 diseases (%) 16.5 14.1 20.2
3 diseases (%) 8.3 8.3 8.3
> 3 diseases (%) 8.1 8.8 7.2
Subjective health 
literacy6
Low health literacy (%) 3.7 4.5 2.5 0.11
Abbreviation: SD standard deviation. 
Notes: 1Contains missing data: age and age groups (n=7), gender (n=2), educational level (n=2), income 
(n=3), number of chronic diseases (n=3); 2P-value for online vs. paper sample; 3Educational level was 
subdivided into three groups: low (primary education and lower secondary education, average (higher 
secondary education and intermediate vocational education), and high (tertiary education); 4Gross income 
was measured on a categorical scale. Respondents’ answers were subdivided into four groups: low (less than 
€2000), average (between €2000 and €3000), high (€3000 or more), and does not know, or does not want 
to tell; 5Respondents were asked to select from a predefined list which chronic disease(s) they suffered. 
6Subjective health literacy was measured using the Set of Brief Screening Questions (SBSQ-D) of Chew [23].
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Descriptive statistics
The logged response time was significantly shorter in the online sample compared to the 
reported response time of the paper sample (median, 14.0 vs. 24.5 minutes, Table 3). The 
majority of respondents of both samples (65 to 69%) found the survey easy or very easy 
to complete. The number of choice sets was perceived differently between the samples. 
Significantly more respondents from the online sample found the number of choice sets too 
high, compared to respondents from the paper sample (24.0% vs. 13.0%). Almost half of the 
paper sample (46.6%) was indifferent when asked (after the survey) whether they preferred 
to complete DCE surveys either online or on paper, and more than one-third (38.6%) stated 
to prefer paper over online. The majority of the online sample stated that they prefer to 
complete DCE surveys online (68.5%). A small number of respondents of both samples 
searched for information during the survey. Of those who did, respondents from the paper 
sample stated to having discussed the survey with others, while those who completed the 
survey online stated to having searched for information online. Slightly more respondents 
of the paper sample, compared to the online sample, chose the dominant alternative in the 
choice set with a clearly dominant alternative (99.2% vs 97.0%). There was no difference 
between samples with respect to the completeness axiom. Because answering the choice 
sets was mandatory in the online sample, there was no missing choice data, while 21 choice 
observations (0.4%, from n=7 respondents) were missing from the paper sample. The choice 
probabilities for individual choice sets differ between administration modes, especially in 
choice sets 10-15 (Figure 1).
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Figure 1 | Choice probabilities.
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Mixed logit model results
Mode of administration significantly interacted with two out of four attributes, i.e. the 
attribute ‘primary focus of provider contracting’ and the ‘monthly premium’ (Table 4, 
column total sample), indicating that the mean estimates differ significantly between the 
two samples. The interactions between mode and the other attributes, as well as the 
interaction between mode and the ASC, were not significant. 
The separate models of the two samples show that all attribute level mean estimates were 
statistically significant and had identical signs (Table 4, online sample & paper sample). 
However, the mean estimate of the ASC was statistically significant in the paper sample 
only (indicating left-to-right bias), while standard deviations of the ASC were not significant 
in both samples. The statistically significant attribute level estimates of the standard 
deviations are an indication of preference heterogeneity, except for the attribute level 
‘social responsibility’. The model fit was slightly better for the online sample. 
The rank order of importance of attributes and importance scores were similar across both 
samples. Choice of care provider was considered most important, followed by premium 
per month, level of service benefits, and the primary focus of provider contracting. The 
importance scores differed slightly between the samples: choice of care providers was 
slightly more important in the online sample, compared to the paper sample, while premium 
was more important in the paper sample.
WTP estimates of the choice of care provider attribute were significantly higher in the online 
sample compared to the paper sample (ratio 1.32) and the level of service benefits (ratio 
1.16, Table 5). No significant differences in WTP estimates were found for the attribute 
levels of primary focus of provider contracting.
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Table 5 | Average marginal WTP estimates in euros per month.
Online sample (n=533) Paper sample (n=365) Ratio
Attributes Attribute levels WTP (€) 95% CI1 WTP (€) 95% CI1
Choice of care providers 50 à 80% 76 69;84 58 52;63 1.32
50 à 100% 142 125;159 104 90;117 1.36
Primary focus of 
provider contracting
Price à quality 14 13;14 14 13;15 0.98
Price à SR 2 0.88;4 3 2;5 0.63
Level of service benefits Negative à positive 29 27;32 25 23;27 1.16
Abbreviations: WTP willingness-to-pay; CI confidence interval; SR social responsibility.
Notes: 195% confidence intervals were approximated using the Delta method [22].
DISCUSSION
The median response time was shorter for the online sample, compared to the paper 
sample, and a smaller proportion of respondents from the online sample was satisfied with 
the number of choice sets. In addition, a larger proportion of respondents from the online 
sample, compared to the paper sample, failed the monotonicity axiom. Although we found 
that some WTP estimates were higher for the online sample, the elicited preferences for 
basic health insurance characteristics were similar between both modes of administration.
In previous studies, Windle & Rolfe [24] found that Internet respondents were more 
confident that they made the correct choices and that they found the choice sets less 
confusing. Olsen [25] showed that although Internet respondents reported to be more 
certain of their choices, the estimation precision and reliability in choices was higher in the 
mail sample. Findings of these studies, as well as our findings could be explained by the 
fact that Internet panel members are experienced in completing online surveys, possibly 
resulting in less well considered choices. Savage et al. [26] compared respondents’ learning 
and fatigue between mail and online DCE administration. They found that online respondents 
who completed the DCE suffered from fatigue or boredom, while mail respondents did not 
and where therefore more consistent in their answers [26]. We found some significant 
between-sample differences in choice probabilities for the last five choice sets, which 
supports the recommendation of Savage et al. that researchers might need to include fewer 
choice sets per respondents when collecting DCE data online, compared to when collecting 
DCE data using paper surveys. In order to collect the same number of choice observations, 
researchers might want to increase the number of respondents that participate in the online 
DCE. This may be feasible since the costs for online data-collection are usually lower. The 
price per completed online survey in our study was €4 excluding taxes, while the price per 
completed paper survey was €14. Previous studies also found that conducting a DCE on 
paper was more expensive than conducting a DCE online [24, 25]. For instance, Windle & 
Rolfe reported $70 per paper survey and $15 per online survey [24]. In contrast to previous 
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studies in which lower (average ratio 0.76) [12] and similar WTP estimates were found [24, 
25] for online responders versus paper responders, we found some of the WTP estimates 
in our study to be slightly higher for online respondents compared to paper respondents, 
while other WTP estimates were equal between the samples.
This study is subject to limitations. First, as opposed to previous studies with a similar aim, 
our findings are less prone to bias stemming from differences in respondent characteristics 
between samples. We successfully controlled for well-known confounders that may 
distort the comparison of paper survey and online responses [27, 28] and indeed found 
no significant differences in respondent characteristics. Unfortunately, we were not able 
to randomize respondents to either one of the administration modes, nor did we use a 
crossover design in which respondents answered the choice sets both online and on paper, 
and there might therefore be differences in unobserved respondent characteristics that 
could have biased our results. Second, since we aimed to study measurement effects, not 
sample composition effects, we conducted our study using the same sample frame for both 
administration modes. The sample frame we used might have affected our results because 
Internet panel members are experienced to completing surveys online, not on paper. In 
addition, these Internet panel members have actively signed-up to complete surveys. Results 
might have shown more differences between administration modes if we would have used 
other samples of respondents, e.g. random digit dialling versus an Internet panel. Third, 
we used a DCE on health insurance preferences as a case for this methodological study. 
This DCE was administered among a sample representative of the general adult population 
of the Netherlands. The generalizability of our findings to other respondent groups (e.g. 
elderly) or other topics may be limited. 
Our study also provides directions for future research. Due to its technical possibilities, 
electronic data-collection offers additional benefits over paper data-collection. For 
example, explanations using video might improve the survey understanding of lower literate 
respondents [29]. It would be worthwhile if future DCE studies test whether such features 
aid in the understanding of the DCE. Electronic data-collection also provides more control 
and flexibility over the information that is presented in a survey [30] compared to paper 
data-collection and can therefore more easily facilitate methodologic DCE studies that 
incorporate split samples with different presentation formats, e.g. when studying ordering 
effects [10]. Previous research shows no mode effects between a mobile app and computer 
web survey administration [31]. Although we did not receive any negative feedback hereof 
in the current study, it can be questioned whether the choice sets of a DCE are fully visible 
on the relatively small smartphone screens. Future studies might therefore want to focus 
on the effects of completing a DCE on different digital devices, such as laptops, tablets, and 
smartphones.
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In conclusion, we find no indication that online surveys yield inferior results compared to 
paper based surveys, while the price per respondent is lower for online surveys. However, 
researchers might want to include fewer choice sets per respondent when collecting DCE 
data online. More research is needed to support our findings. 
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ABSTRACT
Background: To be able to make valid inferences on stated preference data from a Discrete 
Choice Experiment (DCE) it is essential that researchers know if participants were actively 
involved, understood and interpreted the provided information correctly and whether they 
used complex decision strategies to make their choices and thereby acted in accordance 
with the continuity axiom. 
Methods: During structured interviews, we explored how 70 participants evaluated and 
completed four discrete choice tasks aloud. Hereafter, additional questions were asked 
to further explore if participants understood the information that was provided to them 
and whether they used complex decision strategies (continuity axiom) when making their 
choices. Two existing DCE questionnaires on rotavirus vaccination and prostate cancer-
screening served as case studies.
Results: A large proportion of the participants was not able to repeat the exact definition of 
the risk attributes as explained to them in the introduction of the questionnaire. The majority 
of the participants preferred more optimal over less optimal risk attribute levels. Most 
participants (66%) mentioned three or more attributes when motivating their decisions, 
thereby acting in accordance with the continuity axiom. However, 16 out of 70 participants 
continuously mentioned less than three attributes when motivating their decision. Lower 
educated and less literate participants tended to mention less than three attributes when 
motivating their decision and used trading off between attributes less often as a decision-
making strategy. 
Conclusion: The majority of the participants seemed to have understood the provided 
information about the choice tasks, the attributes, and the levels. They used complex 
decision strategies (continuity axiom) and are therefore capable to adequately complete 
a DCE. However, based on the participants’ age, educational level and health literacy 
additional, actions should be undertaken to ensure that participants understand the choice 
tasks and complete the DCE as presumed.
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INTRODUCTION 
A Discrete Choice Experiment (DCE) is a stated preference method in which individuals are 
asked to choose between two or more scenarios. Each scenario consists of several attributes 
with systematically varying levels that describe the product or service at hand. By monitoring 
individuals’ choices over a series of choice tasks, their preferences are elicited. DCEs are 
increasingly being used to make inferences on individuals’ preferences for a wide range of 
products or services within a health care context [1, 2].
DCE results are analysed according to economic theory like Lancaster’s theory of demand 
[3], random utility theory [4, 5] or random regret minimization [6, 7]. These methodologies 
use a multi-attribute approach [8, 9]. It might be that individuals do not understand all the 
information that was provided to them and do not weigh all attributes when making their 
choices, especially not if risk information is included [10-12]. Therefore, this methodological 
approach may result in invalid conclusions regarding the attribute level estimates and the 
estimated potential uptake rates of goods or services. This in turn may lead to sub-optimal 
concordance between stated and revealed preferences. For these reasons, it is essential that 
researchers know how participants interpret the attributes and the levels, and ultimately 
make their decision.
Theoretical assumptions
Conducting, analysing and interpreting DCEs is based on several implicit and explicit 
assumptions regarding respondents’ decision-making, among which the ones listed next 
[13-15]. It is assumed that respondents are actively involved in completing the choice tasks. 
Additionally, respondents are expected to understand and interpret the information that 
they are provided with, as intended by the researcher [16, 17]. Finally, respondents are 
assumed to use complex decision strategies by considering all attributes and making their 
choice based on trade-offs between all attributes (continuity axiom) [7, 18, 19]. 
Theoretical assumptions in practice
Both within and outside the health care setting, mainly quantitative research showed that 
these assumptions do not always hold. First, health-related DCEs often contain risk attributes. 
Research showed that respondents often misinterpret risk information [20, 21]. For example, 
respondents often interpret numerical values (ratio scales) as categorical information (for 
instance respondents recode a risk of 10%, 30% or 50% to a low-medium-high risk) in DCEs 
[22-24]. In addition, respondents might apply simplified decision strategies such as choosing 
a scenario based on one attribute only [25]. Such simplifying strategies may especially be 
used by lower educated and less health literate respondents [8]. Second, completing choice 
tasks can be a cognitive challenge [26, 27]. Cognitively demanding decisions induce the use 
of simplified heuristics [28-31], which is not in accordance with the assumption that people 
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use complex decision strategies; hence, people do not act in accordance with the continuity 
axiom. Additional research on this latter axiom showed that participants with dominant 
preferences base their decisions on one high priority attribute [32]. Such non-compensatory 
decision-making could either reflect a true strong preference for one specific attribute or it 
may be a way to avoid complex decision-making [33, 34]. Moreover, different quantitative 
studies show that up to 45% of the participants have dominant preferences [33, 35, 36] and 
that lower educated participants more often base their decisions on dominant preferences 
[33]. Other studies showed that participants may disregard certain attributes and base their 
decision on some, but not on all attributes (attribute-non-attendance) [24, 32, 34, 37-42], 
thereby violating the continuity axiom. 
Aims
This study explored in depth how respondents complete choice tasks in a DCE, whether 
participants were actively involved, understood and interpreted the provided information 
correctly and whether they used complex decision strategies to make their choices and 
thereby acted in accordance with the continuity axiom. It was tested whether results 
differed by respondents’ educational level and health literacy. In contrast to other 
published qualitative studies that used a retrospective ‘top-down’ approach in relatively 
small samples to determine if and why respondents violate theoretical axioms, this paper 
uses a prospective ‘bottom-up’ approach in a large sample, and specifically focusses on 
respondents’ understanding and interpretation of risk information, and their use of complex 
decision-making strategies.
 
MATERIALS AND METHODS
Discrete Choice Experiments
Two previously administered Dutch DCE questionnaires, that used a state-of-the-art approach 
by designing their experiment according to the latest guidelines for DCEs [13, 15], were used 
as case studies for the current study [43, 44]. One DCE reported on parental preferences 
for rotavirus vaccination while the other DCE reported on men’s preferences for prostate 
cancer-screening. Both DCEs selected their attributes and designed the survey based on 
formal literature review, interviews with experts, focus group discussions with participants, 
a pilot study and a think-aloud pilot study. Additionally, both DCEs contained several risk 
attributes, namely: vaccine effectiveness & frequency of severe side effects (rotavirus DCE) 
and proportion of unnecessary biopsies & proportion of unnecessary treatment (prostate 
cancer-screening DCE). Detailed descriptions of both studies are reported elsewhere [43, 
44]. Since DCEs often cover very specific health topics, and thereby have very selective study 
samples, we included two DCEs to increase participant heterogeneity regarding demographic 
characteristics. A sample of the respondents of the case studies was re-contacted after 
Chapter 10  |  239 
previously indicating that they were willing to participate in further research. Participants 
completed the initial DCE at least 6 months before the interview. See additional file 1 for a 
description of both studies, Table 1 and 2 for a description of the included attributes and 
levels, and additional file 2 for examples of choice tasks of both case studies.
Table 1 | Attributes and levels for rotavirus DCE.
Attributes Explanation Levels
Vaccine effectiveness The percentage of children that will be protected 
against a rotavirus infection when vaccinated
55%
75%
95%
Frequency of severe side 
effects 
The number of vaccinated children that will 
suffer from intussusception due to vaccination1 
1 in 10,000
1 in 100,000
1 in 1,000,000
Protection duration The number of years that the vaccine protects 
against a rotavirus infection [47]
1 year
3 years
6 years
Healthcare facility of 
vaccine administration 
Child welfare centre
General practitioner
Out-of-pocket costs €0
€30
€140
Note: 1Intussusception is an acute condition in which part of the bowel telescopes into another adjacent 
part of the bowel, resulting in obstruction.
Participants
In total, we included 70 participants for the current study; 35 from the rotavirus DCE and 35 
from the prostate cancer-screening DCE. To study potential differences in decision-making 
strategies between lower and higher educated respondents, we purposively sampled equal 
proportions of lower and higher educated individuals from the participants of the previously 
performed DCE’s who had indicated to be willing to participate in future research. If subjects 
agreed to participate in the current study, they received a package with materials by 
mail. The Dutch National Ethics Board (Central Committee on Research involving Human 
Subjects) concluded that formal testing by a medical ethical committee was not necessary 
as participants only completed one non-invasive questionnaire on voluntary basis. Results 
were not analysed or reported at the individual level, which is in accordance with the 
guidelines laid down in the Declaration of Helsinki.
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Interviews
Both face-to-face (N=5 per cohort) and telephone interviews (N=30 per cohort) were 
scheduled. Interview guides were developed for both DCEs. During a consensus meeting 
with all authors the categorization of answers was discussed. Although the topic of the 
two DCEs differed, both guides described a similar interview protocol to make the results 
of both groups comparable. The structured interviews were pilot tested (N=7) to optimize 
the interview guide, to test the duration of an interview and to ensure both interviewers 
conducted the interviews in the same manner. This resulted in minimal adaptations to the 
interview guides. The final interview outline is described in Table 3. All interviews started 
with a short introduction to the current study. Next, participants were given some time to 
read the introduction of the DCE questionnaire. To get familiar with the DCE and the think 
aloud method, participants were asked to complete one choice task as a warm up exercise. 
The core of the interview consisted of three parts. During part one (think aloud part), 
participants completed four choice tasks from the original DCE (Table 3). We instructed the 
participants to think aloud when reading and completing the choice tasks. Part one of the 
interview took place without any specific guidance by the interviewers in order to mimic 
non-lab questionnaire completion situations as much as possible. However, if a participant 
was quiet for some time, the interviewer reminded him/her to keep thinking aloud and to 
report his/her thoughts. During part two of the interview (interview part), specific questions 
were asked to test the interpretation of the risk attributes, the understanding of the risk 
attributes, the decision strategy and the continuity axiom (Table 3). Finally, in part three 
of the interview, health literacy was measured both by means of a subjective self-reported 
questionnaire [45] and a validated objective measurement [45] (see additional file 3). 
Results will be reported in the following order: choice task reading, interpretation of the 
risk attributes, understanding of the risk attributes, decision strategy and continuity axiom 
and differences by educational level and health literacy (stratified by the rotavirus and the 
prostate cancer-screening cohort).
Two researchers (JV and DD) conducted the interviews. The interviewers used a predefined 
form to categorize reading and decision-making behaviour in part one (this for instance 
entailed monitoring and marking how individuals read the choice tasks), as well as the 
answers the participants provided in part two and three of the interview (see Table 3). They 
also made notes and wrote down specific observations during each interview. Interviews 
were audio taped. Whenever there was doubt about participants’ behaviour (in part one) 
or their answers (in part two), the two interviewers discussed and jointly listened to the 
audiotaped interview and completed the predefined form. As a result of this use of objective 
and pre-specified categories in the interviews, data could be analysed with SPSS.
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RESULTS
Table 4 describes the demographic characteristics of the participants who were interviewed. 
The average duration of the interviews in the rotavirus cohort was 27 minutes, while the 
average duration of the interviews in the prostate cancer-screening cohort was 41 minutes.
Table 4 | Demographics of participants in both cohorts.
Rotavirus 
cohort (n=35)
Prostate cancer-screening 
cohort (n=35)
Mean (SD) Mean (SD)
Age in years 30.4 (4.5) 67.6 (5.5)
Proportion (%) Proportion (%)
Gender Female 94.3 0
Education1 Lower 45.7 48.6
Higher 54.3 51.4
Health literacy2 High subjective score 100 100
High objective score 100 55.9
Notes: 1Educational level was dichotomized into a higher and a lower educational level, whereby a Bachelor’s 
and/or Master’s degree were defined as a higher educational level and all other educational levels were 
defined as a lower educational level. 2High subjective score includes participants with a score >2 on the 
SBSQ-D. High objective score includes participants with a score of 4-6 on the NVS-D. 
Choice task reading
a. Think aloud part 
Within both cohorts, the majority of the participants (60.7% for the rotavirus cohort, and 
56.4% for the prostate cancer-screening cohort) read the choice tasks attribute-wise, starting 
from the top and moving to the bottom. In the rotavirus cohort, two other frequently used 
strategies for reading the choice tasks were 1) reading scenario-wise (15.0%), and 2) directly 
motivating which of the two scenarios was preferred based on the attribute levels (14.3%). 
This latter strategy was also often applied in the prostate cancer-screening cohort (18.6%). 
Additionally, a considerable number of participants used different reading strategies 
(12.1%); only reading attributes that were of personal importance, only reading attributes 
that differed between the two scenarios, and reading choice tasks (completely) in a random 
manner. The prostate cancer-screening choice tasks included an opt-out option (i.e. no 
screening), that was specifically read aloud by 42.9% of the participants in choice task one, 
by 25.7% in choice task two, 20.0% in choice task three and 8.6% of the participants in 
choice task four. 
Interpretation of the risk attributes 
a. Think aloud part
With respect to the risk attributes, on average over all four choice tasks, 56.6% of the 
participants of the rotavirus cohort mentioned the actual values of the attribute levels 
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for vaccine effectiveness while completing the choice task and 45.9% mentioned this for 
frequency of severe side effects. For the attribute ‘vaccine effectiveness’, on average over 
the four choice tasks, 17.5% of the participants described the levels on an ordinal scale and 
20.6% combined reading with interpretation, like: ‘In total 75 out of every 100 children are 
protected against a rotavirus infection, or three-quarters of the children do not become ill’. 
With respect to the frequency of severe side effects, these percentages were 23.7% and 
20.6% respectively. 
In the prostate cancer-screening cohort, 52.2% of the participants mentioned the actual 
values of both of these attributes when reading the choice tasks. Additionally, 12.9% of the 
participants interpreted the number of unnecessary biopsies and 14.3% of the participants 
interpreted the number of unnecessary treatments when reading the choice tasks, for 
example: ‘If I have to choose between 200 or 800 unnecessary biopsies/treatments, the 
likelihood of me having an unnecessary biopsies/treatment is four times as high in scenario 
two’. Others did not mention these attributes while reading the choice tasks (30.7% for the 
number of unnecessary biopsies and 29.3% for the number of unnecessary treatments). 
Many of the participants experienced difficulties interpreting these two attributes. Some 
participants who experienced such difficulties did not understand the difference between 
biopsies and treatment, and some even thought they were similar or at least had similar 
side effects. For instance, participants stated: ‘An unnecessary biopsy is an unnecessary 
treatment’ or ‘Biopsy causes urine incontinence’. Some participants stated that they 
ignored these attributes when reading the choice tasks for those reasons, while others 
misinterpreted the numbers.
b. Interview part
Twenty percent of the participants of the rotavirus cohort was able to repeat the definition 
of vaccine effectiveness as described in the introduction section of the questionnaire. 
Another 57.1% described vaccine effectiveness as ‘how well a vaccine works’ and 22.9% 
provided a completely different definition. When asked about the meaning of the attribute 
side effects, the definition of side effects as provided in the questionnaire was mentioned by 
37.1% of the participants, 54.1% interpreted side effects correctly but mentioned additional 
side effects that were not mentioned in the explanation of the attribute, such as a high 
temperature, feeling sick or dying, while 11.4% provided a completely different definition. 
In the prostate cancer-screening cohort, only 17.1% of the participants was able to give the 
definition of the unnecessary treatment attribute as described in the attribute explanation 
section of the questionnaire.
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Understanding of the risk attributes
a. Interview part
All participants of the rotavirus cohort chose the vaccine with the highest effectiveness 
within both choice tasks when they were asked to choose based on this one attribute. On 
average over two choice tasks, all but three (4.3%) participants chose the scenario with the 
lowest frequency of severe side effects. 77.1% of the participants gave the correct answer to 
the control question for vaccine effectiveness, and 94.3% of the participants gave the right 
answer to the control question for frequency of severe side effects. These results indicate 
that most participants were able to interpret percentages and frequencies correctly. 
Within the prostate cancer-screening cohort, 83% chose the screening option with the lowest 
level of unnecessary treatments. Although the concepts might not have been completely 
clear to some participants, 88.6% answered the control question correctly, indicating that 
the participants were able to interpret the numbers of unnecessary treatment correctly.
Decision strategy and continuity axiom
a. Think aloud part
In both cohorts, most participants mentioned the majority of the included attributes while 
motivating their choice for a scenario, which is in accordance with the continuity axiom 
(Table 5). In both cohorts, the majority also traded off between the levels of those attributes 
when motivating their decision, which again is in accordance with the continuity axiom. 
Within the rotavirus cohort, 20.0% mentioned two attributes and 7.2% only mentioned one 
attribute when motivating their decisions. In the prostate cancer-screening cohort 16.4% 
mentioned two attributes, 17.9% only mentioned one attribute and 5.7% did not mention 
any of the attributes but chose to opt-out. 
b. Interview part
A total number of 16 participants (one in the rotavirus cohort and 15 in the prostate cancer-
screening cohort) continuously traded off less than three attributes when completing the 
choice tasks. Nine out of those 16 participants stated that they traded off so few attributes 
because only those attributes were important to them, the other seven mentioned that 
they did so because they found it hard to trade off more attributes at once or because 
they did not understand the meaning of certain attributes. This latter category of seven 
participants comprised of participants for whom it is questionable whether they grasped 
the questions and understood the hypothetical nature of the choice tasks at all. The finding 
that some participants might not have understood the DCE at all is reflected in the fact that 
they decided per attribute which scenario they preferred, without making one final decision 
for one scenario. They also mentioned things such as: ‘What is the difference between this 
question and the previous one?’ or ‘Can I switch between scenarios within one question?’
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Table 5 | Continuity axiom and decision strategy.
Average over all four 
choice tasks (%)
Rotavirus 
cohort (n=35)
Motivating decision (continuity axiom)1
Motivation based on one attribute 7.2
Motivation based on two attributes 20.0
Motivation based on three or more attributes 72.9
Decision strategy for those who acted in accordance with 
the continuity axiom
Traded off attribute levels between each other 85.6
One attribute was most decisive 11.5
Otherwise 2.9
Prostate 
cancer-
screening 
cohort (n=35)
Motivating decision (continuity axiom)1,2
Motivation based on one attribute 17.9
Motivation based on two attributes 16.4
Motivation based on three or more attributes 60.0
Decision strategy for those who acted in accordance with 
the continuity axiom
Traded off attribute levels between each other 60.0
One attribute was most decisive 26.4
Otherwise 13.6
Notes: 1Participants were marked as acting in accordance with the continuity axiom, only if they motivated 
their decision based on three or more attributes. 2These numbers do not add up to 100% because some men 
did not mention any of the attributes when motivating which scenario they preferred; they chose opt-out 
(5.7%).
Differences by educational level and health literacy
Overall, there is a trend showing that more educated and literate participants included 
three or more attributes when motivating their decision and that they traded off between 
attributes more often compared to participants with a lower educational level or lower 
health literacy score (Table 6). Additionally, higher educated and literate participants more 
often correctly explained the risk attributes and more often answered the risk attribute 
control question correctly (Table 6). Finally, lower educated and less literate participants 
who based their decision on two attributes or less, more often stated that they found it 
difficult to compare all attributes. 
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DISCUSSION 
The majority of the participants preferred more optimal over less optimal attribute levels 
and answered the control question(s) regarding their understanding of the numerical values 
of the risk attributes correctly. At the same time, a large proportion of the participants 
was not able to repeat the exact definition of the risk attributes as explained to them in 
the introduction of the questionnaire. While the majority of the participants based their 
decision on three or more attributes by trading them against each other, which implies 
complex decision strategies and is in accordance with the continuity axiom, about a third of 
the participants used simplifying strategies such as basing their decision on less than three 
attributes. 
Acting in contrast with the continuity axiom does not seem to be a problem per se. In 
real life, individuals might also not include all product characteristics when making their 
decision. However, within a DCE analysis, this may result in invalid conclusions regarding the 
attribute level estimates and estimated potential uptake rates of goods or services, since a 
multi-attribute approach is undertaken to analyse the data [8, 9]. This in turn may lead to 
sub-optimal concordance between stated and revealed preferences. This is also reflected by 
previous studies that indicated different DCE outcomes and significant influences on marginal 
rates of substitution depending on attribute-non-attendance being taken into account in 
DCE analyses [32, 39-41]. Previous research described that this non-compensatory decision-
making behaviour might have different causes; participants might actually have dominant 
preferences, it might be that the attribute levels are too similar, or that the participants lack 
understanding of certain attribute levels [18]. This latter was shown in the current study. In 
the rotavirus cohort for instance, 54% of the participants mentioned that they had other and 
sometimes far more serious side effects in mind when completing the choice tasks. This will 
probably cause an overestimation of the relative importance of the side effects attribute, 
which affects the WTP estimate. Additionally, in the prostate cancer-screening cohort, a 
majority of the participants indicated that they did not understand one or more attributes 
(mostly the risk attributes). Studies state that a lack of understanding of certain attribute 
(levels) might be due to a lower educational level, older age and a lower health literacy [8, 
21, 23, 45, 46]. The current study indeed showed that the number of attributes included in 
decision-making, decision strategy, interpretation of the risk attributes and understanding of 
the risk attributes differed between participants with different educational levels and health 
literacy scores. This might also be reflected by the fact that the mean interview duration of 
the less literate and older prostate cancer-screening group was almost 15 minutes longer 
compared to the rotavirus cohort. Besides educational level and health literacy scores, the 
topic of the DCEs and the included attributes and attribute levels may have added to the 
differences that were found between the two cohorts. 
250  |  Chapter 10
This study was subject to some limitations. Firstly, the two DCEs that we used as case 
studies for this study were quite complex, because each included two risk attributes. It is 
commonly known that the interpretation of such attributes is perceived as more difficult 
by participants than for instance qualitative attributes [20, 48]. Difficulties in interpreting 
attribute levels and making decisions might therefore be more pronounced in this study 
compared to DCEs that include no or less risk-related attributes. However, since most 
health-related decisions include risk information, the case studies used for this study may 
be representative for many DCEs within a healthcare context. Secondly, this study focused 
on participants’ understanding of the provided information on risk attributes, their use of 
complex decision strategies and the continuity axiom. Other assumptions underlying the DCE 
methodology, namely the rationality assumption (which does not describe the psychological 
assumption of rationality, but merely represents the completeness and transitivity axioms) 
and the monotonicity axiom, were not tested. Thirdly, although this study used the well-
recognized think aloud method for the interviews, additional methods such as eye-tracking 
might provide even more insight into how and what participants read. Such research could 
focus on visual attention sequences and underlying decision processes, as well as reading 
strategies regarding for instance the opt-out option. The current study showed a decrease 
in the percentage of respondents reading the opt-out option, which might reflect that 
participants assume this option to be fixed (attribute levels are not changing). Additionally, 
eye-tracking research will also provide insight in the potential discrepancy between the 
way participants complete a DCE with or without thinking aloud. Future research could 
incorporate such methods when investigating participants’ behaviour when completing a 
DCE questionnaire. Fourthly, although efforts were made to mimic non-lab choice situations, 
the fact that the interviewers were present during DCE completion might have influenced 
how participants completed the choice tasks. Participants therefore might have been more 
committed to completing the DCE. As a result, we might have overestimated the number of 
participants that acts in accordance with the tested assumptions. Fifthly, the sample size of 
70 is relatively large for an interview study, at the same time, this sample size is too small 
to draw any conclusions based on statistical testing. However, the trends in the findings and 
the agreement of the current findings with the existing literature related to educational 
level and health literacy (non-DCE studies) provide face validity for the current study results. 
Confirmation of our findings is needed, e.g. from new DCEs including (preferably objective) 
health literacy measurements as well as axiom testing questions in their study.
The results of our study indicate that respondents have difficulties understanding all the 
information that is provided to them, they do not always use complex decision strategies to 
make their choices and therefore do not always act in accordance to the continuity axiom. 
This was most prominent in respondents with a lower educational level, higher age and 
lower health literacy status. We therefore recommend to conduct DCE questionnaires among 
older and/or less health literate populations in, for instance, mini-labs, where participants 
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complete DCEs in the presence of a researcher. Researchers have the opportunity to explain 
how to complete a DCE, including the hypothetical nature of the questionnaire and to 
answer questions that arise during the completion of the questionnaire, e.g. concerning the 
attributes and attribute levels. This is important especially among older target populations 
as participants in the prostate cancer-screening cohort sometimes indicated that they had 
difficulties interpreting the questions (e.g., ‘In real life, I have a blood test to check my PSA 
levels every year, so I can only choose a scenario with that frequency of blood testing’). 
This is in line with the findings of previous studies [37, 38]. Moreover, when conducting 
online research, the understanding of attribute levels among participants with a lower 
educational level and/or health literacy can be enlarged by providing the option to include 
an explanation of the attributes by audio or other technical solutions, e.g. pop-ups when 
clicking on attributes or levels. In addition, the option to listen to the explanation again while 
completing the choice tasks could be offered. Another recommendation is that a thorough 
pilot testing phase is necessary while developing a DCE, which includes think aloud testing 
to a priori identify possible problematic issues with the completion of the questionnaire. 
Finally, age, educational level and health literacy should be standard measures to include in 
every DCE questionnaire as well as in the analysis of DCE data. Until options to correct DCE 
responses for possible differences in demographic characteristics become common practice, 
researchers should at least describe these measures in their population and explain the 
possible effects on the results retrieved. 
CONCLUSION
In conclusion, the majority of the participants seemed to have understood the provided 
information about the choice tasks, the attributes, and the levels. They used complex 
decision strategies (continuity axiom) and are therefore capable to adequately complete 
a DCE. However, based on the participants’ age, educational level and health literacy 
additional actions should be undertaken to ensure that participants understands the choice 
tasks and complete the DCE as presumed.
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ADDITIONAL FILE 1: DESCRIPTION OF BOTH STUDIES
Rotavirus DCE
Between January and March 2013, Veldwijk et al. [1] conducted a DCE on parental 
preferences for rotavirus vaccination of new-borns in the Netherlands. A random sample 
of 2500 parents with new-borns was selected from the Praeventis database (a national 
vaccination register in which the vaccination status of all Dutch new-borns is registered) to 
participate in this study. The DCE questionnaire consisted of nine choice tasks. In the choice 
tasks, participants were asked to choose between two different rotavirus vaccine scenarios 
to protect their child from an infection. Each choice task was constructed based on five 
attributes with either two or three levels (Table 1a). In total, 959 participants completed the 
questionnaire, of which 202 gave permission to be re-contacted for further research.
Prostate cancer-screening DCE
To investigate men’s preferences and trade-offs for prostate cancer screening, de Bekker-
Grob et al. [2] conducted a DCE between January and May 2011 among a population-based 
random sample of 1000 men aged 55 to 75, living in the Rijnmond region of the Netherlands. 
The DCE questionnaire comprised 16 choice tasks, in which participants were asked to 
choose between a no screening scenario (opt-out) and two prostate cancer-screening 
scenarios. Each scenario consisted of five attributes, with each four levels (Table 1b). In 
total, 459 men responded to the questionnaire and 373 gave permission to be contacted 
again for additional questions.
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ADDITIONAL FILE 2: EXAMPLE OF CHOICE TASKS
Rotavirus DCE [1]
Imagine that a vaccine against rotavirus infections would become available within the 
Netherlands. In what situation would you prefer to vaccinate your new-born, situation 1 or 
situation 2?
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Prostate cancer-screening DCE [2]
Thirty-five out of every 1000 deaths among men are caused by prostate cancer. Which 
alternative do you prefer to reduce your risk of dying from prostate cancer: no screening, 
screening program 1, or screening program 2? (please, tick one box)
  
No screening 
 
Program 1 
 
 
Program 2 
 
Amount of men per 1.000 men who 
will die from prostate cancer  
 
35 deaths 
 
 
(0 deaths prevented) 
 
25 deaths 
 
 
(10 deaths prevented) 
 
18 deaths 
 
 
(17 deaths prevented) 
 
 
Frequency of a blood test 
 
 
No blood test 
 
 
Every 4 years a blood test 
 
Every 3 years a blood test 
 
Amount of men per 1,000 men with 
an increased PSA who receive an 
unnecessary biopsy  
 
(= no cancer detected, although the 
blood test suggested that a blood 
test was necessary) 
 
Not applicable 
 
 
 
 
 
400 unnecessary biopsies 
 
 
(600 correct biopsies) 
 
 
800 unnecessary biopsies 
 
 
(200 correct biopsies) 
 
Amount of men per 1,000 treated 
men who receive an unnecessary 
treatment 
 
(= no increase in life expectancy, but 
there is a risk of urine incontinence 
and erection problems due to 
treatment) 
 
Not applicable 
 
 
 
 
0 unnecessary treatments 
 
 
(1,000 correct treatments) 
 
 
500 unnecessary treatments 
 
 
(500 correct treatments) 
 
Out of pocket cost per year during 
the period of the screening program 
 
 
0 euro per year 
 
 
100 euro per year 
 
 
 
 
50 euro per year 
 
 
 
Which alternative would you 
choose? 
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ADDITIONAL FILE 3: DESCRIPTION OF THE HEALTH LITERACY MEASURES
The prostate cancer-screening cohort was asked to complete the three validated Dutch 
questions of the Set of Brief Screening Questions (SBSQ-D) of Chew [1] to measure their 
subjective health literacy. This instrument was already included in the initial rotavirus DCE, 
these questions were therefore not repeated in the current study. The SBSQ-D contains 
questions on how often participants need help to read letters from their GP/specialist, how 
sure participants are that they complete medical forms correctly and how often participants 
find it difficult to find information about their health. Participants scored these questions 
on a 5-point Likert scale, from zero to four. An average score of ≤2 indicates inadequate 
health literacy, while an average score >2 indicates adequate health literacy [1]. The Dutch 
version of the Newest Vital Sign (NVS-D) was included as an objective measure of health 
literacy [1] for both groups. To measure the participants’ health literacy status, they were 
asked six questions about an ice cream nutrition label. Participants scored one point for 
each correctly answered question, with a maximum of 6 points. A score of 4-6 indicates 
adequate health literacy [1]. 
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The objective of this dissertation was to contribute to the growing field of health-related 
stated-preference research by addressing research questions that relate to the past 
(research question 1), the present (research questions 2a-2c) and the future (research 
questions 3a-3c) of the discrete choice experiment (DCE) methodology. In this final chapter, 
the main findings are described first. The methodological considerations are described next, 
followed by the interpretation of the main findings and directions for further research. This 
chapter concludes with recommendations for health policy and recommendations for DCE 
researchers. 
MAIN FINDINGS
Part I: The past - review of the literature
1. What are recent practices and trends, including progress in methodology, in applications 
of health-related DCEs?
The systematic literature review of health-related DCE studies published between 2009 
and 2012 (Chapter 2) shows that the use of DCEs continues to grow, as does the scope of 
applications across an expanding range of countries. We found that qualitative methods are 
less often used to inform attribute selection, compared to the period 2001-2008. The trend 
towards the use of D-efficient designs and the use of more flexible econometric methods, 
including mixed logit and latent class models, continued. There has been a shift from paper 
DCE surveys towards computer-administered surveys and the use of Internet panels. 
Part II: The present - three state of the art applications
2a. What are preferences of European citizens for vaccination programmes during future 
pandemics?
The qualitative exploration of public opinion and attitudes in three European countries (The 
Netherlands, Sweden and Poland; Chapter 3) showed that participants would base their 
vaccination decision on trade-offs between perceived benefits and barriers of the vaccine 
also taking into account the seriousness of the new outbreak. Except for those having chronic 
diseases, participants expected a low infection risk. Participants displayed concerns about 
vaccine safety due to the limited available time to produce and test vaccines in the acute 
situation of a new pandemic. Important differences between respondents from different 
countries stood out, such as previous vaccination experiences, the degree of adherence 
to social norms, and the degree of trust in health authorities. The findings of this study 
served as input for the attribute and level selection of the DCE on preferences for pandemic 
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vaccinations. Chapter 4 describes this DCE application on pandemic vaccinations that was 
conducted in four European countries (The Netherlands, Spain, Sweden and Poland). In 
the case of a severe pandemic scenario, vaccine effectiveness was the most important 
characteristic determining vaccination preferences in all four countries, followed by the 
body that advises the vaccine. In Sweden, the advice of family and/or friends and the advice 
of physicians strongly affect vaccine preferences, in contrast to Poland and Spain, where 
the advice of (international) health authorities was more decisive. Irrespective of pandemic 
scenario or vaccination programme characteristics, the predicted vaccination uptakes were 
lowest in Sweden, and highest in Poland. 
The DCE data of the Netherlands was further used to study within country differences in 
preferences for pandemic vaccinations (Chapter 5). Substantial preference heterogeneity 
was found. Females and individuals who stated that they were never in favour of vaccination 
made different trade-offs than males and individuals who stated that they were (possibly) 
willing to get vaccinated. 
2b. What trade-offs do consumers make between basic health plan characteristics in the 
Dutch health insurance market?
Chapter 6 describes the DCE application on basic health plans. Being able to choose a 
care provider freely (and associated reimbursement level) was by far the most decisive 
characteristic for respondents aged over 45, those with chronic conditions, and those 
with a gross income over €3000/month. Although choice of care provider (and associated 
reimbursement level) was also an important characteristic for those younger, healthier, and 
with a lower income, monthly premium was their most important determinant of choice. 
Health insurers with a focus on contracting high quality providers were preferred over health 
insurers with a focus on lower-priced providers, although WTP estimates were generally 
low. Half of the sample would never choose health plans with restricted provider choice. 
However, a premium discount up to €15/month by restricted health plans might motivate 
especially younger, healthier, and less wealthy consumers to choose these plans.
2c. What are personal health records preferences of potential users?
Chapter 7 describes the DCE application on personal health records (PHRs). Three latent 
classes with different preference structures were identified: “refusers”, “eager adopters” 
and “reluctant adopters”. Those with one or more chronic diseases were significantly more 
likely to belong to the eager adopter’s class. The uptake of the reluctant adopters varied 
between 4% and 68% depending on PHR characteristics as varied in our DCE, while the 
uptake of the refusers was always below 9% and the uptake of the eager adopters was 
always above 91%. The facilitating party for storage of PHR was the most decisive aspect for 
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the eager and the reluctant adopters, while the costs were most decisive for the refusers. 
Across all classes, care providers and independent organisations were the most preferred 
facilitators of data storage. 
Part III: The future - methodological studies
3a. Does the inclusion of an “opt-out” instead of a “neither” alternative affect DCE results? 
Does the inclusion of a “status quo” alternative in addition to an “opt-out” alternative 
affect DCE results in markets where there is a status quo?
The methodological study described in Chapter 8 shows that the use of different unforced 
choice formats affects marginal utilities and welfare estimates and hence the conclusions 
that will be drawn from the DCE. Only a minority of respondents stated that they interpreted 
the neither alternative as analysts normally code it (zero option). 
3b. Does the choice of DCE administration mode (paper versus online) affect the result of 
a DCE?
The methodological study described in Chapter 9 shows that the median response time 
was shorter for the online sample compared to the paper sample, and that a smaller 
proportion of respondents from the online sample was satisfied with the number of choice 
sets. In addition, a larger proportion of respondents from the online sample, compared 
to the paper sample, failed the monotonicity axiom. We found some significant between-
sample differences in choice probabilities for the last five choice sets. Although some WTP 
estimates were higher for the online sample, the elicited preferences for basic health plan 
characteristics were similar between both modes of administration. We found no indication 
that online surveys yield inferior results compared to paper based surveys, while the price 
per respondent is generally lower for online surveys. 
3c. How do respondents complete the choice sets in a DCE?
The interview study described in Chapter 10 revealed that the majority of the participants 
preferred better over worse risk attribute levels and answered the control questions 
regarding their understanding of the numerical values of the risk attributes correctly. At 
the same time, a large proportion of the participants was not able to repeat the exact 
definition of the risk attributes as explained to them in the introduction of the survey. The 
majority of the participants based their decision on three or more attributes by trading 
them against each other, which implies complex decision strategies and is in accordance 
with the continuity axiom. However, lower educated and less literate participants tended 
to mention less than three attributes when motivating their decision and used trading off 
between attributes less often as a decision-making strategy. 
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METHODOLOGICAL CONSIDERATIONS
Similar to all research methods, DCEs have specific benefits, and some restrictions. In the 
following sections, methodological considerations of the studies in this dissertation will be 
discussed. 
Part I: The past - review of the literature
In the interests of ensuring comparability with data from the earlier review that included 
studies published between 2001-2008 [1], the searches to identify the health-related DCEs 
published between 2009 and 2012 were restricted to PubMed only (Chapter 2).
Part II: The present - three state of the art applications
Conclusions drawn from the focus group study (Chapter 3) should be considered with some 
caution as the findings are based on a small number of individuals, and may therefore not be 
generalizable to populations at large. However, this qualitative research served as important 
input for the selection of attributes and levels of the DCE. In addition, it contributed to the 
interpretation of the DCE results. 
Four important issues need to be considered when interpreting the findings from the three 
DCE applications included in this dissertation: 
First, because a discrete choice model depends completely on the attributes that are 
included in the DCE, exclusion of important attributes might lead to biased part-worth 
utilities and inaccurate welfare measures [2-4]. For all the applications in this dissertation, 
we aimed to select the most important attributes and corresponding levels by carefully 
studying the literature, interviewing experts, conducting focus group discussions with the 
target population of the DCE and pilot testing of the DCE. However, we cannot exclude the 
option that we missed an attribute or a level that would have affected our findings. 
Second, in all three applications, we used Internet panels to collect the DCE data. It might 
be that those panel members that were not interested in the topic did not start the survey, 
which in turn might have affected estimated preferences. Responder bias can thus not be 
excluded. We used commercial panels in Chapter 4, 5, 6 and 9, and participation rates 
were comparable to the average rate of the Internet panels we used. We do expect our 
results to be generalizable since age, gender, level of education and region of our sample 
are comparable to that of the general population of the Netherlands. The NPCF Internet 
panel was used to collect the DCE data of Chapter 7 and 8. The study sample may not be 
fully representative for the Dutch general adult population. Respondents were older, more 
highly educated, and more often had chronic diseases.
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Third, another issue is the complexity of the discrete choice task. Due to both the number 
and the type of attributes and levels that respondents needed to take into account when 
completing the choice sets (especially due to inclusion of probabilities as attributes in 
Chapter 4, 5, 6, 9, and 10) it can be expected that respondents might have experienced 
difficulties completing the DCE, which might have influenced the results. In Chapter 4 and 
5, we were advised by experts in the field of risk communication on how to present the 
choice sets, we included graphs to demonstrate percentages and rates, and used realistic 
presentation of attributes (i.e. integers when discussing rates that included humans). Piloting 
and think-a-loud interviews in the preparation phase, as well as questions that assessed 
the experienced difficulty of the survey showed that the majority of respondents had no 
problems with completing the choice sets. Additionally, the signs of the coefficients were 
generally consistent with our a priori hypothesis, e.g. a higher vaccine effectiveness would 
have a positive effect on vaccination, which confirms the theoretical validity of the DCE [3].
Fourth, preferences in DCEs are stated and based on hypothetical scenarios. An advantage 
of stated over revealed preference data is that the uptake of new products with new 
attributes can be modelled within a controlled experiment [5], see for example Chapter 
4 in which we were able to estimate preferences for and uptake of vaccinations in future 
pandemics. The DCE-based predicted uptake could be used in economic evaluations [6]. 
However, respondents face no direct consequences of their choices in a DCE [7] and might 
have given socially desirable responses. DCEs could therefore suffer from hypothetical bias, 
for example, the WTP estimates and/or predicted uptake rates might differ from real life 
situations. The external validity of the DCE method has been studied in some other health 
related contexts, and results are encouraging with respect to prediction of preferences on 
an aggregate level [8-10]. However, the external validity of DCEs is an under-researched 
topic, and one of the reasons that has been stated for this is the lack of available revealed-
preference data [11]. The DCE on health plan preferences described in Chapter 6 might be a 
suitable application to test the external validity of DCEs, given that respondent’s choices for 
a certain health plan can easily be reported by respondents. 
Part III: The future - methodological studies
Because of data-collection software limitations, we were not able to present respondent 
specific status quo (SQ) levels in the choice sets and to pivot the attribute levels of the 
hypothetical alternatives around the SQ (e.g. xx % more expensive than your SQ). Our finding 
that SQ should be included in addition to opt-out (Chapter 8) might have been even more 
pronounced if respondents could have seen their individual SQ levels in the choice sets.
Although we successfully controlled for well-known confounders that may distort the 
comparison of paper survey and online responses [12, 13] in Chapter 9, there might still 
be differences in unobserved respondent characteristics that could have biased our results. 
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The sample frame we used (Internet), might have affected our results because Internet 
panel members are experienced to completing surveys online, not on paper. In addition, 
these Internet panel members have actively signed-up to complete surveys. Results might 
have shown more differences between administration modes if we would have used 
other samples of respondents, e.g. random digit dialling versus an Internet panel. The 
generalizability of our findings to other respondent groups (e.g. elderly) or other topics may 
be limited. More research on the generalizability of the findings to other topics and target 
groups is thus needed.
The two DCEs that we used as case studies for the study in Chapter 10 were quite complex, 
because each included two risk attributes. It is commonly known that participants perceive 
the interpretation of such risk attributes as more difficult than qualitative attributes [14, 
15]. Difficulties in interpreting attribute levels and making decisions might therefore 
be more pronounced in this study compared to DCEs that include no or less risk-related 
attributes. However, since most health-related decisions include risk information, the case 
studies used for this study may be representative for many DCEs within a healthcare context. 
Although efforts were made to mimic non-lab choice situations during these interviews, 
the fact that the interviewers were present during DCE completion might have influenced 
how participants completed the choice sets. Participants therefore might have been more 
committed to completing the DCE. As a result, we might have overestimated the number 
of participants that acts in accordance with the tested assumptions. The sample size of 70 
is relatively large for an interview study, at the same time; this sample size is too small to 
draw any conclusions based on statistical testing. However, the trends in the findings and 
the agreement of the current findings with the existing literature related to educational 
level and health literacy (non-DCE studies) provide face validity for the current study results. 
INTERPRETATION OF EMPIRICAL FINDINGS AND DIRECTIONS FOR 
FURTHER RESEARCH (PART II - THE PRESENT)
Preferences for pandemic vaccinations
The studies described in Chapter 3, 4 and 5 show that seriousness of a pandemic influences 
vaccination uptake dramatically. In order to increase pandemic vaccination coverage, it is 
essential that susceptible people feel susceptible and perceive the pandemic as a serious 
threat. This can be achieved, for example, by avoiding conflicting messages and information 
overload [16-18]. To increase attention to information that is being communicated in 
pandemics it is important to acknowledge any uncertainty about this pandemic information, 
and to highlight that this uncertainty is common during almost all pandemics. Visualize risk 
using a heat map when communicating the number of cases and deaths in each country, and 
use a label that is connected to the animal vector (e.g. Swine flu) or that sounds unusual, to 
increase interest in more information [19]. 
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The vaccination program attributes that can be influenced by policy makers directly are 
out-of-pocket costs and how/what to communicate. As our results show that by whom a 
vaccine is advised had a different effect on uptake in the included countries, it is important 
that during future pandemics the responsible authorities align with other important 
stakeholders in the country and communicate in a coordinated manner. In addition, it is 
important to build trust in the pre-outbreak phase, maintain trust during outbreaks and, if 
necessary, restore or further develop trust after the pandemic ends [20, 21]. 
Swedish participants indicated that their experiences during the Influenza A/H1N1 2009 
pandemic would reduce their tendency to accept future vaccination advice (Chapter 3). 
These discussions may be rooted in the Swedish government having signed a contract with 
a pharmaceutical company to buy pandemic Influenza A/H1N1 vaccines years before the 
outbreak [22] and the high incidence rates of narcolepsy following the Influenza A/H1N1 
2009 pandemic, suggesting an association with vaccination [23, 24]. The seasonal Influenza 
vaccination coverage in Sweden decreased since the Influenza A/H1N1 2009 pandemic; it 
was 65.8% in 2008-2009 but decreased to 44.3% in 2012-2013 [25]. Combined with the 
Polish participants being proud that their Minister of Health had not bought vaccines during 
the Influenza A/H1N1 2009 pandemic, these findings confirm what Börjesson et al concluded 
in 2013 [26]; previous experiences with outbreak situations play a crucial role in public 
opinions and future behaviour. The focus group study highlights that outbreak experiences 
differ between countries in many dimensions: with regard to cultural differences, with regard 
to government policies, and with regard to vaccination side effects (narcolepsy in Sweden). 
These differences stress the need to adapt communication strategies to local circumstances.
Given potential differences in cultures, government policies, trust in health authorities, and/
or previous experiences with outbreaks, it may be expected that preferences also differ 
between countries within the same European region. It might therefore be useful to conduct 
the same DCE in other European countries within the same European region as well. Future 
research could use the available DCE data to study differences in preferences within Spain, 
Sweden and Poland as well. Additionally, future research could focus on subgroups of the 
population, such as healthcare workers or under-vaccinated groups. 
Our studies show that the availability of an effective pandemic vaccine is of paramount 
importance in order to reach certain coverage levels. Unfortunately, such a highly effective 
vaccine might not be available due to the crisis-situation that is inherent to a pandemic, or 
proof that the vaccine is effective might be lacking, as time is usually limited and because 
it is not known in advance which virus will cause a next pandemic [27]. In addition, due 
to contracts or limited availability of vaccines, there are usually only one or two different 
vaccines available for policymakers to choose from. Therefore, other preventive measures 
such as quarantine, and antiviral drugs might be helpful to limit the spread of the virus during 
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the first phase of an influenza pandemic [28]. Further research into preferences for other 
preventive measures, and differences herein across European countries is recommended.
Preferences for basic health insurance
A possible explanation for the dominance of the choice of care providers (and associated 
reimbursement level) attribute that we found in Chapter 6 might be that respondents 
prefer to choose healthcare providers regardless of financial considerations. In addition, 
the dominance might partly be related to an objection to the government proposal allowing 
insurers to set a lower level of reimbursement of care by non-contracted providers. At the 
time of data-collection, this proposal was heavily disputed by the medical profession and 
widely covered by the media. 
Our results indicate that consumers do not value the focus of insurers on quality of care 
highly. This might indicate that consumers do not expect insurers to play an important role 
as purchasing agents of high quality care. Instead, consumers seem to rely on their general 
practitioner to select which are the best care providers to go to [29]. If insurers are able to 
provide objective quality information of the contracted providers that is easy to understand, 
consumers might make more well considered insurance choices that do include quality of 
contracted care. As a result, consumers might be more willing to accept less freedom of 
provider choice. Recently, the Dutch Minister of Health advised the insurers to be more 
transparent about their contracting practices [30]. 
Given that characteristics of supplementary health insurance affect the choice for basic 
health insurance of the majority of the respondents much or very much (Chapter 6), it is 
important that future research explores the trade-offs that respondents make between 
basic and supplementary health insurance. We showed in Chapter 8 that if a DCE concerns 
a market where a SQ exists, the choice sets of a DCE should include a SQ alternative in 
addition to opt-out. As the health insurance market is such a market where respondents 
have a SQ, i.e. their current health plan, future DCEs on health plan preferences might want 
to consider to include a SQ alternative, especially if the aim is to predict uptake rates. 
Preferences for personal health records 
The study described in Chapter 7 showed that it is of importance that information campaigns 
of policy makers as well as of PHR producers are targeted to chronically ill people given our 
finding that those respondents had a higher probability to belong to the eager adopters. 
This large class of respondents showed to have great interest in PHRs, irrespective of its 
characteristics. Given that our sample consisted of people that currently do not have a PHR, 
they might be willing to have a PHR, but they might not know how to get one, or the PHRs 
that are currently on the market are not interesting to them. The reasons for this might be 
an area for further research. Further research may also want to focus on preferences of 
current PHR users and how their preferences differ from potential PHR users. 
Chapter 11  |  271 
It appears to be extremely difficult to increase the uptake of PHRs by creating a better 
product given our finding that the PHR uptake of only 20% of respondents was influenced 
by the characteristics of a PHR. The ideal PHR of this group would be a PHR which is 
facilitated by the care provider and tethered with the GP system. The data would be used 
for other purposes after permission only and adding own data would be possible at zero 
costs to the user. Policymakers who aim to expand the use of PHRs will be most successful 
when healthcare providers and health facilities, or independent organizations facilitate the 
storage of PHR data, while refraining to include market parties in storage of the data. Low 
costs, some form of connection with other systems, and the option to upload own data are 
valued positively by potential users, but these aspects will affect the uptake to a smaller 
extent. Producers of PHRs need to convince the potential users that they secure the privacy 
of the PHR data.
INTERPRETATION OF THEORETICAL FINDINGS (PART I - THE PAST & 
PART III - THE FUTURE)
The decline in the use of qualitative methods to inform attribute selection (Chapter 2) is 
of concern. If the selection of attributes is not properly grounded in qualitative research, 
important attributes might not be identified, resulting in a less usable and less valid design 
[4]. If qualitative methods have been used they are usually reported without much detail 
[31], and it is often not clear how exactly attributes and attributes levels were selected 
[32]. The process of how certain attributes and levels are selected based on the qualitative 
research performed is often a black box that involves numerous decisions of the researchers. 
Coast et al. called for “rigorous and transparent” reporting of the attribute selection process 
[32]. This might even result in writing a separate paper on the process of attribute and 
level development. A good example of such practice is a paper by Abiiro et al. in which the 
systematic process of developing attributes and attribute levels for a DCE on micro health 
insurance is reported [33]. 
Based on the methodological study presented in Chapter 8, health economists engaged 
in preference elicitation tasks are urged to carefully consider how to design the unforced 
choice experiment. We recommend to use opt-out instead of neither, as neither represents 
an unspecified alternative that is interpreted differently by respondents, and seldom as 
a true opt-out alternative. We further recommend to include both an opt-out and a SQ 
alternative in markets with a SQ if this best mimics the real market situation. Given that 
DCE designs are increasingly web-based and interactive, initial SQ questions can easily feed 
into tailored DCE questions presented to the individual respondent. The standard argument 
for not including respondents’ own SQ levels is that such products are often marketed as 
non-differentiated products, and that consumers’ current products are therefore hard to 
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identify. Further, collecting information on the SQ alternative requires that consumers can 
correctly identify which attribute levels describe their usual product [34].
DCE data is increasingly being collected online (Chapter 2). We find no indication that 
online surveys yield inferior results compared to paper based surveys, while the price per 
respondent is generally lower for online surveys (Chapter 9). Savage et al. [35] compared 
respondents’ learning and fatigue between mail and online DCE administration. They found 
that online respondents who completed the DCE suffered from fatigue or boredom, while 
mail respondents did not and where therefore more consistent in their answers [35]. Hess 
et al. found more evidence of learning (in terms of utility scale) than fatigue in a number 
of DCE applications, while no relation between results and mode of administration was 
found (computer aided personal interviews versus online) [36]. We found some significant 
between-sample differences in choice probabilities for the last five choice sets, which 
supports the recommendation of Savage et al. that researchers might need to include fewer 
choice sets per respondents when collecting DCE data online, compared to when collecting 
DCE data using paper surveys. In order to collect the same number of choice observations, 
researchers might want to increase the number of respondents that participate in the online 
DCE. This may be feasible since the costs for online data-collection are usually lower. The 
majority of the DCEs published between 2009-2012 included 9 to 16 choice sets (Chapter 
2). However, there is no consensus on the ‘right’ number of choice sets in the DCE literature. 
Watson et al. found mixed effects of the number of choice sets on response rates in a meta-
regression analysis on postal DCE surveys: response rates are higher when a DCE includes 
3-7 or more than 8 choice sets, compared to 8 choice sets [37]. 
Results of the interview study described in Chapter 10 indicate that some respondents have 
difficulties understanding all the information that is provided to them in the DCE, that they 
do not always use complex decision strategies to make their choice and therefore do not 
always act in accordance to the continuity axiom. This was most prominent in respondents 
with a lower educational level, higher age and lower health literacy status. Additional actions 
should therefore be undertaken to ensure that participants understand the choice task and 
complete the DCE as presumed. For example, DCE surveys among older and/or less literate 
populations could be conducted in mini-labs, where participants complete the DCE in the 
presence of a researcher. Recent research shows that allowing for attribute non-attendance 
(ANA, ignoring one or more attributes) in the choice models, for example by using latent 
class models, positively affects the model fit [38, 39]. Another study recommended to also 
take attribute-level non-attendance into account when modelling choice data because 
respondents process each level differently [40]. Attribute level overlap was identified as an 
effective strategy to improve attribute attendance and reduce task complexity in DCEs [41].
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In order to exploit the full potential that DCEs yield, it is essential that policy makers pick up 
the generated evidence. However, the use of available evidence on patient preferences in, 
for example clinical practice guidelines development and coverage decisions [42], is currently 
limited. It might therefore be worthwhile to increase interactions between researchers 
and policy makers [43], by already involving policy makers - or other end users of the DCE 
results – when designing the DCE. In addition, researchers need to actively approach policy 
makers to present their research findings and to discuss the implications for health policy. To 
increase societal impact, researchers might also want to consider publishing the DCE results 
in journals that are easily accessible for policy makers, in addition to scientific journals. 
DIRECTIONS FOR FURTHER METHODOLOGICAL DCE RESEARCH (PART 
I - THE PAST & PART III - THE FUTURE)
The review of published health-related DCE studies (Chapter 2) needs to be updated to 
the most recent years to continuously monitor current practices and to identify areas for 
methodological research. When doing so, searches should not be restricted to PubMed 
only. In addition, it is important to follow progress in methodology in other fields that 
have a longer tradition of using DCEs than health economics, for example transport and 
environmental economics [44], closely and to adapt and apply their best practices to the 
health economics field. 
The study in Chapter 8 is the first in health that examines the use of different choice 
formats in DCEs. In addition, it is the first study in the field of discrete choice modelling that 
compared opt-out with neither, and explored the effects of including a SQ in addition to an 
opt-out. More research is clearly needed to test the replicability of the findings. In addition, 
future research could investigate if respondents indeed perceive the opt-out alternative as 
the option not to buy the good or not to choose the service.
Previous research shows no mode effects between a mobile app and computer web survey 
administration [45]. Although we did not receive any negative feedback hereof in the study 
presented in Chapter 9, it can be questioned whether the choice sets of a DCE are fully 
visible on the relatively small smartphone screens. Future studies might therefore want 
to focus on the effects of completing a DCE on different digital devices, such as laptops, 
tablets, and smartphones. Due to its technical possibilities, electronic data-collection 
offers additional benefits over paper data-collection. For example, explanations using 
video might improve the survey understanding of lower literate respondents [46]. It would 
be worthwhile if future DCE studies test whether such features aid in the understanding 
of the DCE. Electronic data-collection also provides more control and flexibility over the 
information that is presented in a survey [47] compared to paper data-collection and can 
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therefore more easily facilitate methodologic DCE studies that incorporate split samples 
with different presentation formats, e.g. when studying ordering effects [48]. An additional 
benefit of collecting data online is that response times can be logged. Earlier work shows 
that the time respondents take when answering the choice sets can be seen as a proxy for 
respondent engagement, and needs to be taken into account when modelling choice data, 
as it influences the mean and the variances of random parameter distributions [49].
We used the think aloud method to study how respondents complete a DCE in Chapter 10. 
Future research could use eye-tracking to explore visual attention sequences and underlying 
decision processes, as well as reading strategies regarding for instance the opt-out option. 
Additionally, eye-tracking research will also provide insights in the potential discrepancy 
between the way respondents complete a DCE with or without thinking aloud. Eye-tracking 
seems to be a promising method to investigate respondents’ behaviour when completing a 
DCE, see for example [50, 51]. 
RECOMMENDATIONS FOR HEALTH POLICY
1. During future pandemics, responsible authorities should align with important 
stakeholders in a country and communicate in a coordinated manner.
2. Adapt pandemic preparedness plans and communication strategies to local 
circumstances.
3. A premium discount of up to €15/month on restricted health plans might motivate 
especially younger, healthier and less wealthy consumers to choose these plans.
4. Policymakers who aim to expand the use of personal health records (PHRs) in the 
Netherlands will be most successful when healthcare providers or independent 
organizations facilitate the storage of PHR data, while refraining from including market 
parties in the storage of such data. 
5. Target PHR information campaigns to chronically ill people.
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RECOMMENDATIONS FOR DCE RESEARCHERS
1. Use qualitative methods (such as focus group discussions) to inform attribute and level 
selection, and report more details on this selection process.
2. Follow progress in methodology in research fields that have a longer tradition of using 
the DCE methodology. 
3. Involve policy makers, or other end users of the DCE results, when designing the DCE. 
In addition, approach policy makers actively to present research findings and to discuss 
the implications for health policy. Consider publishing the DCE results in journals that 
are easily accessible for policy makers.
4. Use “opt-out” instead of “neither” in unforced DCEs.
5. Include a “status quo” alternative in addition to “opt-out” in markets where a status 
quo exists.
6. We find no indication that online surveys yield inferior results compared to paper 
based surveys. However, especially in online DCEs, researchers might want to include 
fewer choice sets per respondent to avoid fatigue or boredom of respondents.
7. Include age, education and health literacy measures in the DCE survey as well as in the 
analysis of DCE data. Until options to correct DCE responses for possible differences 
in demographic characteristics become common practice, researchers should at least 
describe these measures in their population and explain their possible effects on the 
results. 
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SUMMARY
Patient-centeredness, patient empowerment, shared decision-making and self-management 
are fundamental elements of current health policy in the Netherlands. The involvement of 
consumers in health policy decision-making is being encouraged more and more. By involving 
the public, health policies will better reflect public preferences. Preferences can have an 
impact on the acceptance of and satisfaction with products, services or interventions, as 
well as on outcomes.
Although numerous research techniques are available to elicit public preferences for health-
related topics, this dissertation focuses specifically on the discrete choice experiment (DCE) 
methodology to quantify public preferences. A DCE is a survey-based stated-preference 
elicitation technique: respondents are asked to state their preference for a product, 
service, or intervention in hypothetical choice situations (called choice sets). A DCE survey 
typically consists of a series of choice sets, each concerning a discrete choice between two 
or more alternatives. The word ‘discrete’ indicates that respondents can only choose one 
of the alternatives. The presented alternatives are decomposed into characteristics (called 
attributes). Alternatives are distinguished from one-another by the systematic variation in 
values of the characteristics (called attribute levels). In the introductory chapter (Chapter 1) 
relevant concepts for DCE are introduced.
DCEs originate from mathematical psychology and are standard practice in the field of 
marketing, transportation and environmental economics. Since the first DCE in health 
economics was published in 1990 the body of scientific literature is increasing rapidly. This 
dissertation aimed to contribute to the growing field of health-related stated-preference 
research by addressing research questions that relate to the past, the present and the future 
of the DCE methodology. The research questions as well as the outline of this dissertation 
are also described in Chapter 1.
Part I: The past - review of the literature
Chapter 2 gives an overview of recent health-related DCE practices, including progress in 
methodology since two previously published reviews (covering the periods 1990-2000 and 
2001-2008). We identified 179 health-related DCEs that were published between 2009 and 
2012. A review of these studies shows that qualitative methods (such as focus groups) are 
less often used to inform attribute selection. There has been a growing trend towards the 
use of D-efficient designs and the use of more flexible econometric methods, including 
mixed logit and latent class models. Additionally, there has been a shift from paper DCE 
surveys towards computer-administered surveys and the use of Internet panels.
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Part II: The present - three state of the art applications
The second part of this dissertation includes a qualitative study and three DCE applications 
on: pandemic vaccinations, health insurance and personal health records.
The first three chapters of this part pertain to studies carried out in the context of the 
project ‘Effective Communication in Outbreak Management: development of an evidence-
based tool for Europe (ECOM)’. Chapter 3 describes a qualitative exploration of public 
opinions and attitudes on pandemics and vaccinations across three European countries 
(The Netherlands, Sweden and Poland). In each country, two focus group discussions were 
conducted with 6-9 participants per discussion. We found that participants would base 
their vaccination decisions on trade-offs between perceived benefits and downsides to 
getting the vaccine (such as side effects), also taking into account the seriousness of the 
new outbreak. Except for participants with chronic diseases, participants expected a low 
infection risk. However, overall participants displayed concerns about vaccine safety due 
to the limited time available to produce and test vaccines in the acute situation of a new 
pandemic. Important differences between participants from different countries were seen 
based on previous vaccination experience, the degree of adherence to social norms and 
the degree of trust in health authorities. The findings from this study served as input for 
the attribute and level selection of the first DCE application on preferences for pandemic 
vaccinations described in Chapter 4 and 5. A comparison of pandemic vaccinations 
preferences between four European countries (The Netherlands, Spain, Sweden and 
Poland) is presented in Chapter 4. Internet panel members, nationally representative in 
terms of age, sex, educational level and region (N=2,068) completed an online DCE survey 
in 2013. In the case of a severe pandemic scenario, vaccine effectiveness was the most 
important characteristic that determined vaccination preferences in all four countries, 
followed by the body that advised on the vaccine. In Sweden, the advice of family and/or 
friends and the advice of physicians strongly affected vaccine preferences, in contrast to 
Poland and Spain, where the advice of (international) health authorities was more decisive. 
Irrespective of pandemic scenario or vaccination programme characteristics, the predicted 
vaccination uptakes were lowest in Sweden, and highest in Poland. The DCE data of Chapter 
4 was further used to study differences in preferences for pandemic vaccinations within 
the Netherlands (Chapter 5). Females and individuals who stated that they were never in 
favour of vaccination made different trade-offs when deciding on whether they would get 
vaccinated in case of a pandemic than males and individuals who stated that they were 
(possibly) willing to get vaccinated. 
Chapter 6 presents the second DCE application of this part, in which consumer trade-offs in 
health insurance plan characteristics in the Netherlands were explored. Potential differences 
in these trade-offs on the basis of age, health status and income were also explored. A 
representative sample (N=533) of the Dutch adult population completed the online DCE 
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survey during the 2015 annual period in which persons can select a new health plan. We 
found that being able to choose a care provider freely (and associated reimbursement 
level) was by far the most decisive characteristic for health plan choices for respondents 
aged over 45, those with chronic conditions, and those with a gross income over €3000/
month. Although choice of care provider (and associated reimbursement level) was also 
an important characteristic for those younger, healthier and with a lower income, monthly 
premium was the most important determinant in their choice. Health insurers with a focus 
on contracting high quality providers were preferred over insurers with a focus on lower-
priced providers, although willingness-to-pay estimates were generally low. Half of the 
sample would never choose health plans with restricted provider choice and lower level 
of reimbursement of healthcare costs. However, a premium discount of up to €15/month 
on restricted health plans might motivate especially younger, healthier and less wealthy 
consumers to choose these plans. 
Chapter 7 concerns the third DCE application on potential user preferences for personal 
health records (PHRs). A PHR is an electronic application through which health information 
can be accessed, managed and shared. Opposed to the clinician’s medical record, PHRs 
are managed by patients. The DCE survey was completed in December 2015 and January 
2016 by 1,443 Internet panel members of the Dutch Federation of Patients and Consumer 
Organizations (NPCF). Three subgroups with different preference structures were identified: 
“eager adopters”, “reluctant adopters” and “refusers”. Those with one or more chronic 
disease were significantly more likely to belong to the eager adopter class. The facilitating 
party for storage of PHR was the most decisive aspect for the eager and the reluctant adopters, 
while the costs were most decisive for the refusers. Across all classes, care providers and 
independent organisations were the most preferred facilitators of data storage. The uptake 
of the eager adopters was always above 91%, the uptake of the reluctant adopters varied 
between 4% and 68% depending on PHR characteristics, and the uptake of the refusers was 
always below 9%.
Part III: The future - methodological studies
The third part of the dissertation describes three methodological DCE studies.
DCEs often include unforced choice situations in which respondents are allowed not to 
choose any of the hypothetical alternatives through inclusion of an “opt-out” (choose not 
to buy the good or not to choose the service), “neither” (choose neither of the alternatives) 
and/or “status quo” alternative (choose your current alternative over the hypothetical 
alternatives). In the study presented in Chapter 8, we aimed to investigate the implications 
of using different unforced choice formats in different settings. The DCE application on 
personal health records (Chapter 7) served as our case. We show that the choice in these 
design features of a DCE matters, and should receive ample attention amongst researchers 
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applying DCEs. We recommend to use opt-out instead of neither, as neither represents an 
unspecified alternative that is interpreted differently by respondents, and seldom as a true 
opt-out alternative. We further recommend to include both an opt-out and a status quo 
alternative in contexts with a status quo if this best mimics the real situation.
It is increasingly common to collect DCE data via computers, and more particularly, online. 
In the study presented in Chapter 9 we assessed whether the mode of DCE administration 
(either via pen-and-paper or online) affects the outcomes of the DCE. The DCE application 
on basic health insurance served as our case (Chapter 6). We found no indication that 
online surveys yield inferior results compared to paper based surveys, while the price per 
respondent is generally lower for online surveys.
In order to make valid inferences about individuals’ preferences, it is essential that 
researchers understand how participants complete the choice sets in a DCE. During 
structured interviews, we explored how 70 participants evaluated and completed four choice 
sets aloud. Hereafter, additional questions were asked to further explore if participants 
understood the information that was provided to them and whether they used complex 
decision strategies (considering all attributes and making their choice based on trade-offs 
between all attributes) when making their choices. The majority of the participants seemed 
to have understood the provided information about the choice tasks, the attributes and 
the levels. They used complex decision strategies and are therefore capable of adequately 
completing a DCE. However, based on participants’ age, educational level and health literacy, 
additional actions should be undertaken to ensure understanding of the choice tasks and 
completing the DCE as presumed. This third methodological study is described in Chapter 
10.
In the general discussion (Chapter 11), the main findings of the previous chapters are 
integrated and further discussed alongside the methodological considerations. Directions for 
future research are formulated. The chapter concludes with the following recommendations:
RECOMMENDATIONS FOR HEALTH POLICY
1. During future pandemics, responsible authorities should align with important 
stakeholders in a country and communicate in a coordinated manner.
2. Adapt pandemic preparedness plans and communication strategies to local 
circumstances.
3. A premium discount of up to €15/month on restricted health plans might motivate 
especially younger, healthier and less wealthy consumers to choose these plans. 
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4. Policymakers who aim to expand the use of personal health records (PHRs) in the 
Netherlands will be most successful when healthcare providers or independent 
organizations facilitate the storage of PHR data, while refraining from including market 
parties in the storage of such data. 
5. Target PHR information campaigns to chronically ill people.
RECOMMENDATIONS FOR DCE RESEARCHERS
1. Use qualitative methods (such as focus group discussions) to inform attribute and level 
selection, and report more details on this selection process.
2. Follow progress in methodology in research fields that have a longer tradition of using 
the DCE methodology. 
3. Involve policy makers, or other end users of the DCE results, when designing the DCE. 
In addition, approach policy makers actively to present research findings and to discuss 
the implications for health policy. Consider publishing the DCE results in journals that 
are easily accessible for policy makers.
4. Use “opt-out” instead of “neither” in unforced DCEs.
5. Include a “status quo” alternative in addition to “opt-out” in markets where a status 
quo exists.
6. We find no indication that online surveys yield inferior results compared to paper based 
surveys. However, especially in online DCEs, researchers might want to include fewer 
choice sets per respondent to avoid fatigue or boredom of respondents.
7. Include age, education and health literacy measures in the DCE survey as well as in the 
analysis of DCE data. Until options to correct DCE responses for possible differences 
in demographic characteristics become common practice, researchers should at least 
describe these measures in their population and explain their possible effects on the 
results. 
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SAMENVATTING
Patiëntgerichtheid, gedeelde besluitvorming en zelfmanagement zijn fundamentele 
elementen van het huidige gezondheidsbeleid in Nederland. De betrokkenheid van burgers 
bij besluitvorming over gezondheidsbeleid wordt steeds meer gestimuleerd. Door het 
publiek te betrekken zal het beleid beter afgestemd zijn op publieke voorkeuren. Voorkeuren 
kunnen een impact hebben op de acceptatie, tevredenheid en uitkomsten van producten, 
diensten of interventies.
Hoewel tal van onderzoekstechnieken beschikbaar zijn om publieke voorkeuren voor 
gezondheid-gerelateerde onderwerpen te meten, gaat dit proefschrift specifiek over 
discrete keuze experimenten (DCE’s). In een DCE vragenlijst krijgen respondenten een serie 
hypothetische keuzesituaties (ook wel keuzesets genoemd) voorgelegd, die elk bestaan 
uit twee of meer alternatieven van een product, dienst of interventie. De alternatieven 
worden beschreven aan de hand van hun kenmerken (ook wel attributen genoemd). De 
gepresenteerde alternatieven verschillen van elkaar door een systematische variatie in de 
niveaus van deze kenmerken (ook wel attribuut levels genoemd). Het woord ‘discrete’ geeft 
aan dat de respondenten slechts kunnen kiezen voor een van de alternatieven. De keuzes 
die respondenten maken worden geanalyseerd en geven inzicht in welke kenmerken het 
belangrijkst zijn en welke afwegingen gemaakt worden. Ook kan de deelnamebereidheid 
of het marktaandeel geschat worden. In het inleidende hoofdstuk (Hoofdstuk 1) worden 
relevante DCE begrippen geïntroduceerd.
DCE’s zijn afkomstig uit de wiskundige psychologie en worden standaard toegepast in 
de marketing, en de transport- en milieueconomie. In 1990 werd de eerste DCE in de 
gezondheidseconomie gepubliceerd, en sindsdien neemt de hoeveelheid wetenschappelijke 
literatuur snel toe. Het doel van dit proefschrift is een bijdrage te leveren aan dit groeiende 
onderzoeksgebied, door onderzoeksvragen te beantwoorden die betrekking hebben op het 
verleden (deel I), het heden (deel II) en de toekomst (deel III) van de DCE methodologie. De 
onderzoeksvragen en de inhoud van dit proefschrift worden beschreven in Hoofdstuk 1.
Deel I: Het verleden - review van de literatuur
Hoofdstuk 2 geeft een overzicht van de tussen 2009 en 2012 gepubliceerde gezondheid-
gerelateerde DCE’s. Ook worden methodologische ontwikkelingen sinds twee eerder 
gepubliceerde reviews (over de periodes 1990-2000 en 2001-2008) beschreven in dit 
hoofdstuk. We identificeerden 179 gezondheid-gerelateerde DCE’s in PubMed (een 
database met referenties van wetenschappelijke artikelen). We vonden dat kwalitatieve 
methoden (zoals focusgroepen) minder vaak werden gebruikt om attributen te selecteren in 
vergelijking met de vorige periodes. Daarnaast vonden we een toename in het gebruik van 
zogenaamde ‘D-efficient’ designs en meer flexibele econometrische methoden, waaronder 
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‘mixed logit’ en ‘latent class’ modellen. DCE data wordt in toenemende mate digitaal en/of 
via Internet panels verzameld.
Deel II: Het heden - drie state-of-the-art toepassingen
Het tweede deel van dit proefschrift beschrijft een kwalitatieve studie en drie DCE toepassingen 
(pandemische vaccinaties, zorgverzekeringen en persoonlijk gezondheidsdossiers).
De eerste drie hoofstukken van dit deel van het proefschrift zijn geschreven naar 
aanleiding van het project ‘Effective Communication in Outbreak Management: 
development of an evidence-based tool for Europe (ECOM)’. Hoofdstuk 3 beschrijft een 
kwalitatieve verkenning van publieke opinies en attitudes over toekomstige pandemieën 
en vaccinaties in drie Europese landen (Nederland, Zweden en Polen). In elk land werden 
twee focusgroepen met 6-9 deelnemers per focusgroep gehouden. Deelnemers gaven 
aan hun vaccinatiebeslissingen te baseren op afwegingen tussen de verwachte voor- en 
nadelen van een vaccin (zoals werkzaamheid en bijwerkingen). In die beslissing wegen zij 
ook de ernst van de nieuwe pandemie mee. Behalve degenen met één of meer chronische 
ziekten, verwachten deelnemers niet dat zij snel ziek zullen worden tijdens een toekomstige 
pandemie. Alle deelnemers gaven aan bezorgd te zijn over de veiligheid van de vaccins, 
vanwege de beperkte tijd om vaccines te produceren en te testen in de acute situatie 
van een pandemie. Belangrijke verschillen tussen de deelnemers uit verschillende landen 
werden gevonden voor eerdere vaccinatie ervaringen, de invloed van sociale normen op 
gedrag en het vertrouwen in de gezondheidsautoriteiten. De bevindingen van deze studie 
dienden als input voor de selectie van de attributen en attribuut levels voor de eerste DCE 
toepassing over voorkeuren voor pandemische vaccinaties beschreven in Hoofdstuk 4 en 
5. Een vergelijking van voorkeuren voor pandemische vaccinaties tussen vier Europese 
landen (Nederland, Spanje, Zweden en Polen) wordt beschreven in Hoofdstuk 4. Leden van 
Internet panels, landelijk representatief op basis van leeftijd, geslacht, opleidingsniveau en 
regio (N=2068) vulden in 2013 een online DCE vragenlijst. In het geval van een ernstige 
toekomstige pandemie was de werkzaamheid van een vaccin het belangrijkste kenmerk dat 
vaccinatie voorkeuren in vier landen bepaald. Dit werd gevolgd door het advies over het 
vaccin. Het advies van familie en/of vrienden en het advies van artsen beïnvloedde vaccinatie 
voorkeuren van Zweedse respondenten het meeste. Voor Poolse en Spaanse respondenten 
was vooral het advies van de (internationale) gezondheidsinstanties van belang. Ongeacht 
het pandemische scenario of de kenmerken van een vaccinatieprogramma was de geschatte 
vaccinatiegraad het laagst in Zweden en het hoogst in Polen. De DCE data van Hoofdstuk 
4 werd verder gebruikt om verschillen in voorkeuren voor pandemische vaccinaties binnen 
Nederland (Hoofdstuk 5) te bestuderen. Vrouwen en respondenten die verklaren nooit vóór 
vaccinatie te zijn, maakten andere afwegingen bij de beslissing of zij zich al dan niet zouden 
laten vaccineren in het geval van een pandemie dan manen en respondenten die verklaren 
dat zij (mogelijk) bereid zijn zich te laten vaccineren.
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Hoofdstuk 6 heeft betrekking op de tweede DCE toepassing van dit proefschrift, waarin 
de afwegingen die consumenten maken als zij kiezen voor de basiszorgverzekering in kaart 
werden gebracht. Ook werd onderzocht of, en welke verschillen er zijn in afwegingen op 
basis van leeftijd, gezondheidstoestand en inkomen. Een representatieve steekproef (N=533) 
van de Nederlandse volwassen bevolking voltooide de online DCE vragenlijst tijdens de 
tweemaandelijkse periode waarin van zorgverzekering gewisseld kon worden voor het jaar 
2015. Het hebben van vrije artsenkeuze (en de bijbehorende vergoeding van zorgkosten) 
was veruit het meest beslissende kenmerk voor de keuze voor een zorgverzekering voor 
respondenten ouder dan 45 jaar, respondenten met één of meer chronische aandoeningen 
en respondenten met een bruto inkomen van meer dan €3000 per maand. Hoewel de vrije 
artsenkeuze (en bijbehorende vergoeding van zorgkosten) ook een belangrijk kenmerk was 
voor jongere en gezondere respondenten en respondenten met een lager inkomen, was 
de maandelijkse premie voor hen het belangrijkste voor hun keuze. Zorgverzekeringen van 
zorgverzekeraars die bij het inkopen van zorg focussen op kwaliteit van zorg werden verkozen 
boven verzekeringen van zorgverzekeraars met een focus op goedkopere aanbieders, hoewel 
de betalingsbereidheid laag was. De helft van de steekproef zou nooit kiezen voor een polis 
met een beperkte keuzevrijheid. Echter een premiekorting van maximaal €15 per maand 
op polissen met beperkt keuzevrijheid zal vooral jongere, gezondere en minder welvarende 
consumenten motiveren om zo een polis te kiezen.
Hoofdstuk 7 heeft betrekking op de derde DCE toepassing over voorkeuren voor 
persoonlijke gezondheidsdossiers (PGDs). Deze studie richt zich specifiek op personen die 
op dit moment geen PGD hebben. Een PGD is een digitaal hulpmiddel voor patiënten waarin 
informatie over gezondheid en ziekte kan worden verzameld, beheerd en gedeeld. De DCE 
vragenlijst werd in december 2015 en januari 2016 ingevuld door 1443 Internet panel leden 
van de Patiëntenfederatie NPCF. We identificeerden drie subgroepen met verschillende 
voorkeuren tussen de groepen: zij die gretig zijn, zij die terughoudend zijn en zij die 
weigeren. Respondenten met één of meer chronische ziekten hadden een hogere kans om 
tot de gretige subgroep te behoren. De faciliterende partij voor de opslag van PGD data was 
het meest doorslaggevende kenmerk voor zowel de gretige als de terughoudende subgroep, 
terwijl de kosten het meest bepalend waren voor de weigeraars. In alle drie de groepen 
waren zorgverleners en onafhankelijke organisaties de meest geprefereerde facilitators van 
dataopslag. De geschatte deelnamebereidheid van de gretige subgroep was altijd boven de 
91%, de deelnamebereidheid van de terughoudende subgroep varieerde tussen de 4% en 
68% en was afhankelijk van PHR kenmerken, en de deelnamebereidheid van de weigeraars 
was altijd onder de 9%.
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Deel III: De toekomst - methodologische studies
Het derde deel van dit proefschrift beschrijft drie methodologische DCE studies.
In keuzesets wordt, naast de hypothetische alternatieven van producten, diensten of 
interventies, vaak een “opt-out” optie geboden. Dit betekent dat als je voor deze optie 
kiest, je het product niet wilt kopen in de gegeven situatie, of geen gebruik wilt maken van 
de interventie of dienst. Minder vaak wordt gekozen voor de optie “geen van beiden” (de 
optie om geen van beide alternatieven te kiezen) en een “status quo” alternatief (de optie 
om te kiezen voor het huidige alternatief in plaats van de hypothetische alternatieven). 
In Hoofdstuk 8 hebben we de implicaties van het gebruik van deze verschillende formats 
getest. Deze methodologische studie was onderdeel van de DCE over het persoonlijk 
gezondheidsdossiers (Hoofdstuk 7). We toonden aan dat de keuze voor een bepaald format 
van invloed is op de resultaten en dat dit meer aandacht zou moeten krijgen van DCE 
onderzoekers. Wij adviseren om “opt-out” te gebruiken in plaats van “geen van beiden”, 
omdat “geen van beiden” multi-interpretabel is voor respondenten. “Geen van beiden” 
wordt slechts zelden geïnterpreteerd als een echte “opt-out”, terwijl dit door onderzoekers 
wel zo gemodelleerd wordt. Daarnaast adviseren wij om zowel een “opt-out” als een status 
quo op te nemen in keuzesets voor markten waarin een status quo bestaat.
DCE data wordt steeds vaker verzameld via digitale vragenlijsten en/of Internet panels. In 
de studie beschreven in Hoofdstuk 9 onderzochten we of de manier van dataverzameling 
(via papier of online) van invloed is op de uitkomsten van een DCE. Deze methodologische 
studie was onderdeel van de DCE over zorgverzekeringen (Hoofdstuk 6). We vonden geen 
aanwijzingen dat dataverzameling via online vragenlijsten minder goede resultaten zou 
opleveren dan papieren vragenlijsten, terwijl de prijs per respondent over het algemeen 
lager is voor online vragenlijsten.
Om de juiste conclusies te trekken op basis van DCE data, is het essentieel dat onderzoekers 
begrijpen hoe deelnemers de keuzesets in een DCE invullen. Om dit te onderzoeken hebben 
we 70 gestructureerde interviews gehouden. Deelnemers werden eerst gevraagd om vier 
keuzesets hardop in te vullen. Vervolgens werden aanvullende vragen gesteld om verder 
te verkennen of de deelnemers de verstrekte informatie begrepen en of ze alle attributen 
tegen elkaar afwogen bij het maken van hun keuzes. De meerderheid van de deelnemers leek 
de verstrekte informatie over de keuzesets, de attributen en de attribuutlevels te hebben 
begrepen en woog de meerderheid van de attributen tegen elkaar af. Echter, op basis van 
leeftijd, opleidingsniveau en gezondheidsvaardigheden zullen aanvullende maatregelen 
genomen moeten worden om te zorgen dat keuzesets worden ingevuld zoals verondersteld 
wordt door onderzoekers. Deze derde methodologische studie is beschreven in Hoofdstuk 
10.
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In het laatste hoofdstuk van dit proefschrift (Hoofdstuk 11) worden de belangrijkste 
bevindingen van de voorgaande hoofdstukken geïntegreerd en verder bediscussieerd. 
Methodologische overwegingen en aanknopingspunten voor toekomstig onderzoek worden 
benoemd. Het hoofdstuk sluit af met de volgende aanbevelingen:
AANBEVELINGEN VOOR GEZONDHEIDSBELEID
1. Tijdens toekomstige pandemieën is het wenselijk dat verantwoordelijke autoriteiten 
samenwerken met belangrijke stakeholders in een land, en op een gecoördineerde 
manier communiceren.
2. Pas pandemiedraaiboeken en communicatiestrategieën aan nationale omstandigheden 
aan.
3. Een premiekorting van maximaal €15 per maand op polissen met beperkt keuzevrijheid 
zal vooral jongere, gezondere en minder welvarende consumenten motiveren om zo 
een polis te kiezen.
4. Beleidsmakers die als doel hebben om het gebruik van persoonlijke gezondheidsdossiers 
(PGD) in Nederland te vergroten zullen het meest succesvol zijn als zorgverleners 
of onafhankelijke organisaties de dataopslag van PGDs faciliteren, in plaats van 
commerciële bedrijven.
5. Focus in PGD voorlichtingscampagnes op chronisch zieken.
AANBEVELINGEN VOOR ONDERZOEKERS DIE DE DCE METHODOLOGIE 
GEBRUIKEN
1. Gebruik kwalitatieve technieken (bijvoorbeeld focusgroepen) om attributen en 
attribuut levels te selecteren en rapporteer meer details over dit selectieproces.
2. Volg de vooruitgang in de methodologie in onderzoeksvelden die de DCE methodologie 
al langer gebruiken.
3. Betrek beleidsmakers en andere eindgebruikers van de DCE resultaten bij het opzetten 
van de DCE. Benader daarnaast actief beleidsmakers om onderzoeksresultaten te 
presenteren en de gevolgen voor beleid te bespreken. Overweeg de DCE resultaten te 
publiceren in tijdschriften die gemakkelijk toegankelijk zijn voor beleidsmakers.
4. Gebruik een “opt-out” optie in plaats van een “geen van beiden” optie.
5. Neem een  “status quo” alternatief als aanvulling op de “opt-out” optie op in keuzesets 
voor markten waarin een status quo bestaat.
6. We vinden geen aanwijzingen dat online vragenlijsten minder goede resultaten 
opleveren in vergelijking met papieren vragenlijsten. Echter, vooral als DCE data online 
wordt verzameld, zouden onderzoekers kunnen overwegen om minder keuzesets per 
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respondent in de DCE op te nemen om vermoeidheid of verveling van de respondenten 
te voorkomen.
7. Neem vragen op over leeftijd, opleiding en gezondheidsvaardigheden in de DCE 
vragenlijst en in de analyse van de DCE data. Tot mogelijkheden om DCE antwoorden 
te corrigeren voor mogelijke verschillen in demografische kenmerken standaard 
toegepast worden, moeten de onderzoekers in ieder geval de antwoorden op deze 
vragen rapporteren en de mogelijke effecten op de resultaten beschrijven. 
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DANKWOORD
Ruim vier jaar geleden stond ik voor de (discrete) keuze: kies ik voor dit promotieonderzoek, 
of toch voor iets anders? Degenen die mij kennen weten dat ik niet altijd een ster ben in het 
maken van keuzes - het liefst wil en doe ik alles. Achteraf gezien paste dit promotieonderzoek 
daarom ook zo goed bij mij: de afgelopen vier jaar waren afwisselend, leerzaam en vol met 
mooie kansen. Op deze plaats wil ik graag iedereen bedanken die, ieder op zijn of haar eigen 
manier, heeft bijgedragen aan de totstandkoming van dit proefschrift.
Mijn promotor en copromotoren: Ewout Steyerberg, Esther de Bekker-Grob en Mattijs 
Lambooij. Ewout, bedankt voor je snelle reacties, je kritische blik en je toegankelijkheid. 
Tijdens onze afspraken kwam onze gedeelde passie voor hardlopen altijd eerst aan bod. 
De inhoudelijke en wetenschappelijke discussies die daarna volgden hebben absoluut 
bijgedragen aan mijn wetenschappelijke ontwikkeling. Esther, ik waardeer het vertrouwen 
dat je in mij had en de zelfstandigheid die je mij gaf. Ik wens je alvast een plezierige en nuttige 
tijd in Australië toe. Mattijs, bedankt voor je betrokkenheid, je ideeën en je creativiteit. Ik 
heb met plezier met je samengewerkt.
Ardine de Wit en Ida Korfage, ondanks dat jullie niet officieel als copromotoren in dit 
proefschrift genoemd mochten worden, zie ik jullie weldegelijk als copromotor. Ardine, 
altijd waren je reacties op mijn stukken opbouwend en zeer waardevol, zowel inhoudelijk 
als tekstueel. Ik hoop in een latere fase van mijn carrière op een vergelijkbare manier te 
kunnen bijdragen aan artikelen. Ida, je ving mij op mijn eerste werkdag op en ook daarna 
was je er altijd voor me. Onze samenwerking voelde als vanzelfsprekend. Bedankt voor je 
oprechte geïnteresseerdheid, zowel werkinhoudelijk als privé.
Ik wil de leden van de kleine en grote promotiecommissie bedanken voor de tijd die aan 
mijn proefschrift is besteed en voor het opponeren tijdens de verdediging. 
De artikelen in dit proefschrift zouden er niet gekomen zijn zonder samenwerking met 
andere onderzoekers binnen én buiten Nederland. Ik wil alle coauteurs bedanken voor 
hun waardevolle inbreng. Graag noem ik een aantal mensen in het bijzonder: Jan Hendrik 
Richardus en Helene Voeten, bedankt voor jullie inzet om het ECOM project tot een succesvol 
einde te brengen. Helene, ik zal je altijd dankbaar blijven voor de beste boekentip ooit! 
Thanks also to all other ECOM project members; it was a pleasure to be part of this very 
interesting project. I really enjoyed working with all of you. Michiel Bliemer, Bas Donkers en 
Marcel Jonker, bedankt dat we indien nodig een beroep op jullie DCE expertise konden doen. 
Erik Schut, Marco Varkevisser en Arthur Hayen, jullie input betreffende de zorgverzekeringen 
DCE was zeer waardevol. Line Pedersen og Dorte Gyrd-Hansen, tak for muligheden for at 
komme til jeres universitet. Tak også for den tid I har investeret i mig og i projektet. Jeg har 
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virkelig lært en masse af jer. Det var en berigelse af min PhD! Jeg håber, at vi vil samarbejde 
igen i fremtiden. Line, jeg takker dig og Martin også for jeres gæstfrihed og hyggelig tid i 
Odense: jeg er glad for jeg mødte dig. De artikelen in dit proefschrift zouden er ook niet zijn 
gekomen zonder de deelnemers aan de interviews, focusgroepen en vragenlijsten. Bedankt! 
Het was een voorrecht om zowel bij het Erasmus MC als het RIVM werkzaam te zijn 
en dus ook dubbel zoveel fijne collega’s te hebben. Ik wil jullie allemaal, maar in het 
bijzonder mijn (buur-, en flex-) kamergenoten, NIHES maatjes, JVO’ers, CMB’ers, KZG’ers, 
en lunchwandelaars, bedanken voor de samenwerking en collegialiteit. Ik wil de dames 
van beide secretariaten en de ICT’ers bedanken voor hun hulp en ondersteuning. Ik wens 
iedereen die nog met een promotieonderzoek bezig is succes met het vervolg hiervan. Esther 
H., ik ga onze Spotify-sessies missen! Yesim, het was fijn om onze ervaringen met elkaar te 
kunnen delen. Overigens ben ik blij voor je dat je het naar je zin hebt in de dermatologie. 
Jorien, ik denk met plezier terug aan onze tijd samen op het RIVM. Wat hebben we gelachen 
tijdens het schrijven van ons artikel. Juist door onze verschillende manieren van werken 
vulden we elkaar goed aan. 
Fenna, Kerstin, en Rienke, we zijn ondertussen geen collega’s meer, en daarom is dit zo’n 
mooie overgang naar de vrienden alinea. Ik ben zo blij dat we elkaar hebben leren kennen. 
Met jullie is het altijd gezellig waar we ook zijn en wat we ook doen: in de trein van 7.17u, 
tijdens onze hardlooprondjes, als we koffiedrinken met lekkere baksels (ik ben een bofkont!) 
en ook tijdens het kaarten. Bedankt voor jullie vriendschap. Ik wil ook mijn andere vrienden 
en vriendinnen bedanken voor hun betrokkenheid, waarvan vier in het bijzonder. Anne, 
het briefje “Veel plezier en succes op je eerste werkdag. Wel drie treinen eerder nemen 
hè?’ dat je schreef heb ik nog steeds! Het was leuk dat we huisgenoten waren in die tijd 
en onze eerste werkervaringen met elkaar konden delen, hoe anders die ervaringen ook 
waren. Willemien, mede-ranger! Takk voor de afleiding en gezelligheid die onze reizen altijd 
boden. Binnenkort maar weer eens een reisje plannen? Marjolein, ik was altijd welkom om 
bij jullie te eten als ik in Rotterdam had gewerkt. Dat was leuk, thanks. Het werd iets minder 
praktisch sinds jullie zijn verhuisd, maar ook nu weet ik dat ik altijd welkom ben. Marlies, 
ik vind het zo fijn dat we al zo lang vriendinnen zijn en hoop dat we dat nog véél langer 
blijven. Ik voel mij ontzettend op mijn gemak bij jou en ik ben daarom ook heel blij dat je 
mijn paranimf wilt zijn. Dit is dan weer een mooie overgang naar de familie alinea, want je 
zult altijd ‘La Viana’ blijven, ook al ben je al weer een paar jaar ‘La de Vrij’. 
Lieve familie en schoonfamilie: bedankt voor jullie interesse de afgelopen jaren. Oma John 
& John, leuk dat jullie mijn artikelen lezen! Jammer dat opa Kippen niet meer met ons mee 
kan vieren dat mijn ‘studie’ klaar is en ik een ‘echte’ baan heb. Lieve Laszlo en Samantha: ja 
nu ben ik dan eindelijk PhDomino! Ook door jullie mede mogelijk gemaakt; tusentakk voor 
jullie input. Ik word er echt heel blij van hoe gezellig we het met z’n vieren hebben. Fijn dat 
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je mijn paranimf wilt zijn lieve broer. Lieve Mam en Tino, wat leven jullie altijd met mij mee. 
Mam, dat doe jij op belangrijke momenten, maar juist ook zomaar, wanneer je mij een fijne 
werkdag wenst als je weet (of denkt, of hoopt ;)) dat ik in de trein zit of net op m’n werk ben 
aangekomen. Dat doet mij goed. Tekenend voor je betrokkenheid is ook dat je inmiddels 
regelmatig allerlei vragenlijsten invult (en de mijne dan, natuurlijk, toch vaak beter in elkaar 
vindt zitten). Lieve Pepz, wat was het fijn om allebei in Rotterdam te werken! Altijd maak 
je tijd voor mij vrij om te lunchen of om onder het genot van een troebel appelsapje in de 
Rotterdamse Schouwburg de dag te bespreken. Gelukkig is mijn nieuwe baan ook weer een 
beetje bij jou in de buurt. Bedankt ook voor je originele ideeën over de voorkant van mijn 
proefschrift. 
Lieve Len, de laatste woorden zijn voor jou. Thanks voor je support en het aanhoren van 
al mijn verhalen. Ik kan nog veel van jouw positiviteit en geduld leren. Ik kijk uit naar onze 
toekomst samen: we zijn een goed duo!
Domino
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Summary of PhD training and teaching
Name:  Domino Determann
Erasmus MC department:  Public Health
Research school:  Netherlands Institute for Health Sciences (NIHES)
PhD period: 2012-2016
Promotor: Prof. Dr. EW Steyerberg
Copromotors: Dr. EW de Bekker-Grob (Erasmus MC), Dr. MS Lambooij (RIVM)
Year Workload 
(ECTS)
1. PhD Training
General academic skills
- Research integrity for PhD students, Erasmus MC 2014 0.3
- Time and project management course for PhD students, Erasmus MC 2012 0.6
In-depth courses
- Health economics introductory course, RIVM 2015 2.0
- Master of Science in Health Sciences: specialization clinical 
epidemiology, NIHES
2012-2015 70
Discrete choice experiment courses
- Choice modelling course, Institute for Transport Studies, University of 
Leeds, United Kingdom
2014 1.5 
- Workshop ‘Using discrete choice experiments in health economics; 
theoretical and practical issues’, Health Economics Research Unit 
(HERU), University of Aberdeen, United Kingdom
2013 0.9
National and international conferences
- European Scientific Conference on Applied Infectious Disease 
Epidemiology (ESCAIDE), Stockholm, Sweden: poster and oral 
presentation
2015 0.9
- Annual European Congress of the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR), Amsterdam: 
poster presentation
2014 0.9
- International Academy of Health Preferences Research (IAHPR), 
Amsterdam
2014 0.3
- Lowlands Health Economics Study Group conference (LolaHESG), 
Oostvoorne
2014 0.6
- Biennial European Conference of the Society of Medical Decision 
Making (SMDM), Antwerp, Belgium: oral presentation
2014 0.6
- European Congress of Clinical Microbiology and Infectious Diseases 
(ECCMID), Barcelona, Spain: oral presentation
2014 1.2
- Nederlands Congres voor Volksgezondheid (NCVGZ), Rotterdam: poster 
presentation 
2014 0.6
- Lowlands Health Economics Study Group conference (LolaHESG), 
Nunspeet
2013 0.6
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Seminars and workshops
- ‘A free lunch’ health economics meetings, RIVM 2014-2016 1.0
- Seminars department of Public Health, Erasmus MC 2012-2016 1.0
- Meetings Medical Decision Making, department of Public Health, 
Erasmus MC
2012-2016 1.0
- Pre-ESCAIDE final symposium ECOM project, Stockholm, Sweden: oral 
presentation
2015 0.3
- Using stated preference methods in health and public health, RIVM: oral 
presentation
2015 0.6
- Minisymposium ‘Risicocommunicatie bij opkomende infectieziekten’, 
Erasmus MC
2014 0.2
Other presentations
- Oral presentations within department of Public Health, Erasmus MC 2013-2016 0.6
- Oral presentation at Epidemiology meeting, RIVM 2015 0.2
- Oral presentation at brown-bag seminar, COHERE, Odense, Denmark 2015 0.2
- Oral presentation at internal seminar applied economics, COHERE, 
Odense, Denmark
2015 0.2
- ‘Eenduidige boodschap cruciaal in strijd tegen toekomstige pandemieën’ 
(2014) and ’NL-er wil bij elke arts terecht kunnen; kwaliteit van zorg is 
ondergeschikt in keuze voor zorgverzekering’ (2015), oral presentations 
(‘half tientjes’), RIVM
2014-2015 0.2
- Oral presentations at ECOM project meetings in Munster (2013), 
Rotterdam (2014), London (2014), Hamburg (2015)
2013-2015 5.0
Didactic skills
- ‘Teach the teachers’ didactic training Erasmus MC, part-qualification 
teaching
2015 0.6
- ‘VO Lifestyle counselling and primary prevention’ didactic training 
Erasmus MC, part-qualification teaching
2013 0.2
2. Teaching activities
- Lecturer ‘Patient preferences in the delivery of healthcare’, Master 
HEPL, EUR
2016 0.3
- Lecturer VO Vaccination training (theme 3.C.3) 2015-2016 1.0
- Correcting QALY exam question (theme 3.C.1) 2015 0.3
- Correcting Bachelor essays (3rd year medical students) 2014 2.0
- Correcting discourses (Medical Research and Society module, 2nd year 
medical students) 
2014 1.0
- Assistant teacher ‘Patient preferences in the delivery of healthcare’, 
Master HEPL, EUR
2014 0.3
- Wetenschapsknooppunt EUR: introduction to science at primary and 
secondary schools
2013-2014 0.3
- Supervisor Community projects (theme 3.C.4) 2012-2014 2.0
- Lecturer VO Lifestyle counselling and primary prevention (theme 3.C.2) 2013 0.6
3. Other activities
- Peer reviewer for scientific journals (BMC Health Services Research, 
Health Policy and Planning, BMJ Open)
2014-2016 N/A
- Member of the junior representatives consultation, department of 
Public Health, Erasmus MC
2013-2016 N/A
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- Visiting PhD student, Centre of Health Economics Research (COHERE), 
University of Southern Denmark, Odense, Denmark
2015 N/A
- Advisory board ‘MMRV medical education communication strategy and 
curriculum development’, Glaxo Smith Kline, London, United Kingdom
2014 0.9
- Career orientation training, Erasmus MC 2014 0.6
- PhD day, Erasmus MC 2012 0.3
4. Awards
- Epiet Alumni Network (EAN) prize for best poster presentation at 
ESCAIDE 2015
2015 N/A
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